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To all children with diabetes; 
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Introduction 
 
1.1 BACKGROUND 
Diabetes mellitus is one of the most frequent chronic diseases in children and 
adolescents (Sperling, 1996). It is not a single disease but a group of metabolic disorders 
characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin 
action, or both (Ize-Ludlow et al, 2005). Until recently, childhood diabetes has not been 
considered a diagnostic specialty, as patients were almost undoubtedly considered to 
have type 1 diabetes. However, this assumption is no longer correct. Although insulin-
deficient diabetes is by far the commonest subtype of diabetes in childhood and 
autoimmune type 1 diabetes accounts for the vast majority of cases (>95%), an 
increasing body of evidence demonstrates that several other types of diabetes can 
manifest during the first two decades of life (Porter et al, 2004). This fact has important 
implications for clinical practice, as non-type 1 diabetes differs from type 1 diabetes not 
only in its cause, but also in its prognosis and associated conditions, and the cause of 
diabetes may even guide the most appropriate treatment. This has proved to be true 
especially for certain subtypes of monogenic diabetes, which represents 1-2% of all 
diabetes cases. 
 
 
1.2 GENETICS OF DIABETES MELLITUS 
Genes play an important role in the development of diabetes, whichever type is 
considered. From a genetic point of view, diabetes can be classified as being polygenic 
or monogenic. Overall, polygenic diabetes accounts for the vast majority of cases both in 
children and in adults. The study of the genetics of polygenic diabetes is fraught with 
difficulty because there are multiple predisposing polymorphisms, each having a small 
effect, while environmental factors also play a large role (Gill-Carey et al, 2007). In 
contrast, monogenic diabetes is rare and results from the presence of one or more 
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mutations in a single gene. Almost all cases of monogenic diabetes in children and 
adolescents result from mutations in genes causing β-cell loss or β-cell dysfunction and 
hence affect insulin synthesis, packaging, glucose sensing or insulin secretion, although 
diabetes can rarely occur from mutations resulting in very severe insulin resistance 
(Hattersley et al, 2009). 
 
 
1.3 POLYGENIC DIABETES 
In most western countries, type 1 diabetes accounts for more than 95% of 
childhood and adolescence diabetes (Thunander et al, 2008). Type 2 diabetes is 
becoming more common and, although rare in unselected pediatric diabetic patients as a 
whole, it accounts for a significant proportion of youth-onset diabetes in certain at-risk 
populations (Shaw, 2007). 
 
1.3.1 Type 1 diabetes 
Type 1 diabetes results from selective destruction of the pancreatic insulin-
producing β-cells, which occurs at a variable rate and becomes clinically symptomatic 
when approximately 90% of β-cells has been destroyed (Gillespie, 2006). The β-cells are 
destroyed by an autoimmune response mediated by T cells that react specifically to one 
or more β-cell proteins. Serological markers of the autoimmune process, including islet 
cell (ICA), glutamic acid decarboxylase (GADA), islet antigen-2 (IA2A), or insulin 
autoantibodies (IAA), are present in 85–90% of affected children when fasting 
hyperglycemia is detected (Sabbah et al, 1996). However, whether they participate in the 
pathogenic mechanism of the disease remains to be fully understood. When the clinical 
presentation is typical of type 1 diabetes, often associated with diabetic ketoacidosis 
18 
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(Roche et al, 2005), but antibodies are absent, then the diabetes is classified as type 1b 
or idiopathic (Tiberti et al, 2000). The environmental triggers that initiate pancreatic β-cell 
destruction remain largely unknown, but the process usually begins months to years 
before the manifestation of clinical symptoms. 
Familial aggregation of type 1 diabetes has been recognized for a long time, and 
∼10–13% of newly diagnosed children have an affected first-degree relative, this 
proportion being higher for siblings of affected patients than for offspring or parents. The 
risk of diabetes mellitus to an identical twin of a patient with type 1 diabetes is about 36% 
and for a sibling the risk is approximately 4% by the age of 20 years and 9.6% by the age 
of 60 years, compared with 0.5% for the general population. The younger the proband is 
at diagnosis, the higher the risk for siblings. Type 1 diabetes is two to three times more 
common in the offspring of diabetic men (3.6–8.5%) compared with diabetic women (1.3–
3.6%) (Marcovecchio et al, 2007). 
Despite this familial clustering, there is no recognizable pattern of inheritance of 
the disease. Instead, association studies exploiting unbiased genome-wide analyses 
have identified over 40 regions in the human genome that are linked to type 1 diabetes, 
but most make only a minor contribution overall to the genetic susceptibility to this 
disease (Barrett et al, 2009; Concannon et al, 2009). The most significant susceptibility 
locus (IDDM1 locus) is the HLA class II region in the major histocompatibility complex on 
chromosome 6p21.3, as allelic variation within this locus contributes about 50% of the 
inherited risk for type 1 diabetes. The disease susceptibility conferred by HLA represents 
the combined effect of several genes within the region, DRB1 and DQB1 genes being the 
major determinants of HLA-encoded susceptibility to type 1 diabetes. Whereas several 
HLA genotypes confer increased risk, other genotypes confer protection. In Caucasians, 
type 1 diabetes is strongly associated with HLA DR3-DQ2 and DR4-DQ8 haplotypes, and 
recent studies from different European countries have confirmed that the HLA DR3-
DQ2/DR4-DQ8 genotype is associated with the highest diabetes risk. This genotype is 
found in 20–30% of type 1 diabetic patients and in almost 50% of patients diagnosed in 
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early childhood. In contrast, genotypes containing the HLA DQ6 haplotype confer 
dominant protection from type 1 diabetes. Several other disease susceptibility loci have 
been clearly demonstrated based on their direct effect on risk. However, a large 
proportion of type 1 diabetes clustering remains unexplained (Bartsocas et al, 2006). 
More than half of individuals with type 1 diabetes are diagnosed before the age of 
15 years. A well documented rise in the incidence of approximately 3% per year has been 
noted in many countries (DIAMOND Project Group, 2006), and in some reports, there has 
been a disproportionately greater increase in those less than 5 years. As a rule of thumb, 
the earlier the onset of the disease, the stronger the HLA-defined genetic susceptibility 
and the more frequent an autoantibody response is detected (Komulainen et al, 1999). 
Nevertheless, among those type 1 diabetes patients diagnosed during childhood, less 
than 5% present clinically within the first 2 years of life. Moreover, because months or 
even years can elapse between the beginning of the autoimmune response and the 
clinical appearance of type 1 diabetes, the onset of diabetes very early in life might not be 
consistent with the time required for an autoimmune response to result in overt diabetes, 
even if the autoimmune disease begins in the fetal period (Lindberg et al, 1999; 
Achenbach et al, 2005). Thus, clinical presentation of type 1 diabetes in infancy is rare, 
especially within the first 6 months of life. Children diagnosed after the sixth month of life 
have an HLA-DQA1 and DQB1 genotype distribution similar to older classic type 1 
diabetic patients, whereas “early onset” diabetic children are similar to control subjects 
(Figure 1.1) (Iafusco et al, 2002; Edghill et al, 2006). These data are even more relevant 
if we consider that type 1 diabetic patients diagnosed in childhood are more likely than 
adults to carry HLA alleles associated with disease susceptibility and, in addition, in very 
young children diabetes appears to be associated with a higher-risk genotype than in 
older children. Individuals diagnosed before 6 months of age are therefore unlikely to 
have polygenic autoimmune type 1 diabetes. However, it is difficult to be certain of an 
absolute cut-off at 6 months. The fact that the prevalence of high-risk HLA is slightly 
lower in those diagnosed between 6 and 12 months of age compared with those between 
20 
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12 and 24 months of age indicates that there may be a few patients with non-autoimmune 
diabetes in the 6- to 12-month age range (Figure 1.1) (Edghill et al, 2006).  
 
Figure 1.1.  Prevalence of high-risk HLA class II genotypes (DR4-DQ8/DR3-DQ2, DR4-DQ8/X, and 
DR3-DQ2/X, where X is not DR2-DQ6) in subjects diagnosed with diabetes under 24 months of 
age, compared to patients with adult-onset type 1 diabetes and normal controls (modified with 
permission from Edghill et al, 2006).  
 
1.3.2 Type 2 diabetes 
Type 2 diabetes is often considered a polygenic disorder with multiple genes 
located on different chromosomes being associated with this condition. This is further 
complicated by numerous environmental factors that also contribute to the clinical 
manifestation of the disorder in genetically predisposed persons (Porter et al, 2007). 
Once considered almost restricted to adults, the incidence of type 2 diabetes is 
increasing among pediatric patients (Shaw, 2007). The rapid increase in the population 
prevalence of type 2 diabetes in youth can only be explained by changes in lifestyle, as it 
parallels the increasing incidence of childhood obesity worldwide. However, even in 
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sedentary western culture, only a small minority of obese children develops type 2 
diabetes. Genetic factors are important in determining the children who become obese 
and also the obese children who develop type 2 diabetes (Gill-Carey et al, 2007). Support 
for the role of genetic factors comes from epidemiological evidence that type 2 diabetes 
in youth is most common in individuals from racial groups with a high prevalence of 
diabetes and in subjects with a strong family history. TCF7L2 has recently been 
discovered as the gene with the greatest impact on the risk of type 2 diabetes at least in 
the European populations (Grant et al, 2006; Groves et al, 2006; Scott et al, 2006; Florez 
et al, 2006; Cauchi et al, 2006; van Vliet-Ostaptchouk et al, 2007). However, systematic 
population screening for type 2 diabetes cannot be justified in most countries because of 
the low prevalence. Nevertheless, targeted screening is recommended if youths are 
overweight and have any two risk factor listed in Table 1.1, starting at 10 years or at 
onset of puberty, whichever is earlier, and every 2 years thereafter (American Diabetes 
Association, 2000). 
 
Table 1.1.  Risk factors for type 2 diabetes in children and adolescents.
22 
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1.4 MONOGENIC DIABETES 
A familial form of diabetes presenting during adolescence or in early adulthood 
(usually before the age of 25 years) was first described in the early 70’s (Tattersall, 
1974). Even though diabetes presented in young patients, the disease clinically 
resembled elderly-onset non-insulin dependent diabetes and the newly recognized 
subtype of familial diabetes became known by the acronym MODY (maturity-onset 
diabetes of the young). As MODY patients seemed to pass on the disease to their 
offspring following an autosomal dominant pattern, it was quickly suspected that it might 
be a monogenic disorder. However, the first causative genes were not identified until two 
decades later. MODY is both clinically and genetically heterogeneous. All currently known 
subtypes of MODY are caused by dominantly acting heterozygous mutations in genes 
important for the development or function of β-cells (Fajans et al, 2001). 
In recent years, several forms of monogenic diabetes clinically different from 
MODY have been identified. Indeed, some of them show an autosomal recessive or X-
linked recessive inheritance. In addition, patients with monogenic diabetes may have 
dominant mutations arising de novo (not inherited from parents), so there is no positive 
family history suggesting a monogenic condition. All these circumstances, along with the 
widespread lack of awareness, hinder clinical diagnosis. Since the vast majority of 
patients with genetically proven monogenic diabetes are initially incorrectly diagnosed as 
having type 1 or type 2 diabetes (Table 1.2), specific recommendations have been 
published to facilitate identification of patients with monogenic diabetes (Hattersley et al, 
2009). These recommendations are based on the presence of certain clinical features or 
laboratory findings unusual in type 1 or type 2 diabetes (Table 1.3). None of these 
features is pathognomonic and therefore should be considered together rather than form 
individual (Hattersley et al, 2009).  
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Table 1.2. Clinical characteristics of the different types of diabetes in children and adolescents 
(from Craig et al, 2009). 
 
From a practical standpoint, monogenic diabetes can be categorized into five 
distinct groups; the first four subtypes are primarily due to ß-cell failure (Murphy et al, 
2008; Hattersley et al, 2009):  
1. Neonatal diabetes and diabetes diagnosed in early infancy.  
2. Autosomal dominant familial diabetes. 
3. Familial, mild fasting hyperglycemia. 
4. Diabetes mellitus associated with extrapancreatic features. 
5. Monogenic insulin resistance syndromes. 
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Table 1.3. Features in children initially thought to have type 1 or type 2 diabetes that might suggest 
a monogenic subtype of diabetes (modified from Hattersley et al, 2009). 
 
1.5 NEONATAL DIABETES AND DIABETES DIAGNOSED IN EARLY 
INFANCY 
All cases of diabetes diagnosed before 6 months of age are likely to be 
monogenic and not classic autoimmune type 1 diabetes (Iafusco et al, 2002; Edghill et al, 
2006). Neonatal diabetes is a rare and clinically heterogeneous disorder with an 
estimated prevalence of 1 case in 100,000 live births (Sperling, 2006). Many of these 
patients are born small for gestational age, which reflects a prenatal deficiency of insulin 
secretion as insulin exerts potent growth-promoting effects during intrauterine 
development (Gicquel et al, 2006). Diabetes resolves in approximately half of the patients 
(transient neonatal diabetes, TNDM), most often during the first year of life. The 
remaining patients continue to need treatment for life (permanent neonatal diabetes, 
PNDM) (von Muhlendahl et al, 1995). In both cases, diabetes can present isolated or 
associated with other clinical manifestations. At least 14 different loci for neonatal 
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diabetes have been described so far (Table 1.4). No clinical or laboratory features can 
help distinguish transient from permanent forms in patients with isolated neonatal 
diabetes. However, associated clinical features can be used to guide molecular testing 
when present (Hattersley at al, 2009). 
 
Table 1.4. Known genetic subtypes of neonatal diabetes (TNDM: transient neonatal diabetes; 
PNDM: permanent neonatal diabetes; DEND: developmental delay, epilepsy and neonatal 
diabetes; IPEX: immunodysregulation, polyendocrinopathy, enteropathy, X-linked). 
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1.5.1 Transient neonatal diabetes 
A genetic diagnosis is now possible for most patients diagnosed with TNDM 
(Flanagan et al, 2007). The majority of cases (~70%) are linked to several abnormalities 
in an imprinted region on chromosome 6q24. Activating mutations in either of the genes 
encoding the two subunits of the ATP-sensitive potassium channel (KATP) of the β-cell 
membrane (KCNJ11 or ABCC8) account for most of the remaining cases (~25%) (See 
below). Patients with 6q24 abnormalities show a more severe intrauterine growth 
retardation and are diagnosed earlier than patients with KATP channel mutations, 
indicating a more severe insulin deficiency during the last months of intrauterine 
development and at the time birth in the former. Furthermore, diabetes usually remits 
sooner and relapses later (Table 1.5). 
 
Table 1.5. Clinical characteristics of probands with TNDM grouped by genetic etiology (adapted 
from Flanagan et al, 2007). 
 
A. TNDM due to abnormalities on chromosome 6q24. 
This is the single most frequent genetic cause of neonatal diabetes (Temple et al, 
2000). The 6q24 region, where the candidate gene ZAC or PLAGL1 maps to, is 
an imprinted region. Normally, the maternal allele is silenced and only the allele 
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inherited from the father is expressed. TNDM is ultimately associated with the 
overexpression of the gene (Ma et al, 2004). To date, three different molecular 
mechanisms leading to this overexpression have been reported: paternal 
uniparental disomy of chromosome 6 (either complete or partial; it accounts for 
50% of sporadic TNDM cases), unbalanced paternal duplication of 6q24 (found in 
most familial cases), and abnormal methylation of the maternal allele (found in 
some sporadic cases) (Temple et al, 2002). Methylation defects may affect only 
the 6q24 locus or may arise in the context of a generalized hypomethylation 
syndrome along with other clinical features including congenital heart defects, 
brain malformations, etc. (Mackay et al, 2006). Some cases of TNDM secondary 
to multiple methylation defects are caused by recessively acting mutations in 
ZFP57, a gene on chromosome 6p involved in the regulation of DNA methylation 
(Mackay et al, 2008). 
Patients with 6q24 abnormalities are born with intrauterine growth retardation 
(average weight: 1,930 g) and develop severe but non-ketotic hyperglycemia very 
early on, usually during the first week of life (Temple et al, 2002). Despite the 
severity of the initial presentation, the insulin dose can be tapered quickly so that 
the majority of patients do not require any treatment by a median age of 12 
weeks. One third of patients show macroglossia and, more rarely, an umbilical 
hernia is present. During remission, transient hyperglycemia may occur during 
intercurrent illnesses (Shield et al, 2004). Over time diabetes relapses in at least 
50-60% of patients, usually around puberty, although recurrences have been 
reported since age 4 years. Relapse clinically resembles early-onset type 2 
diabetes and is characterized by a loss of the first-phase insulin secretion. Insulin 
therapy is not always necessary (there is usually some response to oral 
sulfonylureas) and, if needed, doses required tend to be lower than in patients 
with type 1 diabetes. 
The phases described above do not present irremediably in every patient. 
Interestingly, some mutation carrier relatives develop type 2 diabetes or 
28 
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gestational diabetes in adulthood without any evidences of having had neonatal 
diabetes, suggesting that other genetic or epigenetic factors may influence the 
clinical expression alterations of chromosome 6q24 (Temple et al, 2000). 
Genetic counseling depends on the underlying molecular mechanism. 
Uniparental disomy of chromosome 6 is generally sporadic and therefore the risk 
of recurrence in siblings and offspring is low. When paternal duplication of the 
6q24 region is found, males have a 50% chance of transmitting the mutation and 
the disease to their children. In contrast, females will pass on the duplication but 
their children will not develop the disease. In this case, TNDM may recur in the 
next generation as their asymptomatic sons pass on the molecular defect to their 
own children. Some methylation defects (ZFP57 mutations) show an autosomal 
recessive inheritance and hence the recurrence risk is 25% for siblings and 
almost negligible for the offspring of a patient. 
 
1.5.2 Permanent neonatal diabetes 
In contrast to TNDM, the genetic basis of PNDM can be identified in about 60% of 
probands (Edghill et al, 2008). Most of them will have isolated PNDM as a result of 
mutations in one of four different genes (KCNJ11, ABCC8, INS, and GCK) (Figure 1.2). 
Only 10% of cases of diabetes is associated with pancreatic aplasia/hypoplasia or other 
extrapancreatic features (Table 1.4). 
A. Neonatal diabetes due to activating mutations in the KATP channel. 
The KATP channels are hetero-octameric complexes formed by four pore-forming 
Kir6.2 subunits and four SUR1 regulatory subunits, encoded by the genes 
KCNJ11 and ABCC8, respectively (Miki et al, 2005). These channels regulate 
insulin secretion by linking intracellular metabolic state to the β-cell membrane 
electrical activity. In addition to pancreatic β-cells, they can be found in other cell 
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types, including neurons and muscle cells (Ashcroft, 2005). Any increase in the 
intracellular metabolic activity induces an increase in the ATP/ADP ratio within 
the cell, which makes the KATP channels close. This leads to the cell membrane 
depolarization that ultimately triggers insulin secretion (Ashcroft, 2005). Mutations 
in KCNJ11 or ABCC8 are found in nearly half of PNDM patients (~35% KCNJ11, 
~13% ABCC8) (Flanagan et al, 2006; Ellard et al, 2007). These mutations 
prevent KATP channel closure, and hence insulin secretion, in response to 
hyperglycemia. 
 
Figure 1.2. Schematic representation of the pancreatic β-cell, illustrating the role of glucokinase 
and the ATP-sensitive potassium (KATP) channel in insulin secretion. Glucose enters the β-cell by 
way of the GLUT2 glucose transporter. Once inside the cell, glucose is phophorylated by 
glucokinase and metabolized, leading to changes in the intracellular concentration of adenine 
nucleotides that cause KATP channel closure. The KATP channel consists of four sulfonylurea-
receptor (SUR1) subunits and four Kir6.2 subunits in an octomeric structure. Channel closure leads 
to membrane depolarization, which subsequently activates voltage-dependent calcium (Ca2+) 
channels, leading in turn to an increase in intracellular Ca2+, which triggers insulin exocytosis. 
Sulfonylureas initiate secretion by directly binding to the SUR1 subunits of KATP channels and 
causing channel closure (reproduced from Gloyn et al, 2004). 
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Mutations in either of the KATP channel genes can produce both TNDM and 
PNDM. Most patients with mutations in KCNJ11 have isolated diabetes and the 
majority has PNDM (~90%) rather than TNDM (~10%). In contrast, mutations in 
ABCC8 cause TNDM more frequently (~66%). There are no significant 
differences between the two subtypes of neonatal diabetes regarding the severity 
of intrauterine growth retardation or the age at diagnosis of diabetes (Tables 1.5 
and 1.6). Approximately 30% of patients present in diabetic ketoacidosis. In 
keeping with the expression of KATP channels in brain and skeletal muscles, about 
20% of probands with KCNJ11 mutations present with associated neurological 
symptoms (Hattersley et al, 2005). The most severe defect includes marked 
developmental delay and early-onset epilepsy, and has been called DEND 
syndrome (Gloyn et al, 2006). An intermediate DEND syndrome characterized by 
neonatal diabetes and less severe developmental delay without epilepsy is more 
common. Neurological features are less frequent and usually milder (language 
delay and dyspraxia, mainly) in patients with mutations in ABCC8 (Babenko et al, 
2006; Ellard et al, 2007).  
 
Table 6. Clinical characteristics of the three commonest subtypes of PNDM (modified from Edghill 
et al, 2008). 
Approximately 90% of patients with activating mutations in the KATP channel 
genes can be transferred from insulin onto sulfonylurea tablets (Pearson et al, 
2006; Rafiq et al, 2008). Transfer usually improves glycemic control without 
increasing the risk of hypoglycemia. The required doses are typically higher than 
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those used in type 2 diabetes, although somewhat lower in patients with ABCC8 
mutations than in patients with mutations in KCNJ11. The only side effects 
reported to date are transient diarrhea and staining of the teeth (Codner et al, 
2005; Kumaruguru et al, 2009). Preliminary data also suggest that glibenclamide 
can partially improve some of the neurological symptoms (Slingerland et al, 2006; 
Gurgel et al, 2007). 
Activating mutations in KCNJ11 causing neonatal diabetes are always 
heterozygous. Since about 90% of these mutations arise de novo, there is usually 
no family history of neonatal diabetes (Edghill et al, 2007). Familial cases show 
an autosomal dominant inheritance. Anyway, recurrence risk for the offspring is 
50%. This is also true for most patients with activating mutations in ABCC8. 
However, some patients are homozygous or compound heterozygous for two 
different mutations and neonatal diabetes is recessively inherited (Ellard et al, 
2007). In this case, the risk of neonatal diabetes for future siblings is 25% but 
almost inexistent for the offspring. Germline mosaicism (mutations present in the 
gonads but not detectable in blood) has been reported in several families (Gloyn 
et al, 2004; Edghill et al, 2007) and hence unaffected parents of a child with an 
apparently de novo mutation should be advised that the recurrence risk in 
siblings is low but not negligible. 
B. PNDM due to mutations in the proinsulin gene. 
Approximately 12% of patients with isolated PNDM have a heterozygous coding 
mutation in the preproinsulin gene (INS) (Støy et al, 2007; Edghill et al, 2008, 
Polak et al, 2008; Colombo et al, 2008). The mutation usually results in a 
misfolded proinsulin molecule that is trapped and accumulated in the 
endoplasmic reticulum, leading to endoplasmic reticulum stress and β-cell 
apoptosis (Eizirik et al, 2008). 
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The severity of intrauterine growth retardation in patients with INS mutations is 
similar to that of patients with KATP channel mutations. In contrast, diabetes 
presents at a slightly later age although the ranges overlap greatly (Table 6). 
Since there is a progressive β-cell death, insulin is the only treatment available.  
The majority of INS mutations are sporadic de novo mutations. Only 20% of 
probands have a positive family history of autosomal dominant neonatal diabetes 
(Edghill et al, 2008).  
Occasionally, INS mutations cause permanent diabetes after 6 months of age. 
Genetic testing should be considered in certain situations, especially in patients 
with antibody-negative type 1 diabetes (Polak et al, 2008; Molven et al, 2008).  
C. PNDM due to mutations in the glucokinase gene. 
The enzyme glucokinase is considered the glucose sensor of the β-cells, as it 
catalyzes the rate-limiting step of glucose phosphorylation and therefore enables 
the β-cell to respond appropriately to the degree of glycemia (Matschinsky, 
2005). 
Heterozygous mutations in the GCK gene produce familial mild non-progressive 
hyperglycemia (see below). However, complete glucokinase deficiency 
secondary to mutations in both alleles (either homozygous or compound 
heterozygous) prevents the β-cells from secreting insulin in response to 
hyperglycemia (Njølstad et al, 2001; Njølstad et al, 2003). For this reason, 
patients present with severe intrauterine growth retardation (mean birth: 1,700 g), 
are usually diagnosed with diabetes during the first few days of life, and require 
exogenous insulin therapy. Apart from diabetes, patients do not show any 
relevant extrapancreatic features.  
GCK is responsible for not more than 2-3% of cases of PNDM. This type of 
PNDM is inherited in a recessive manner so the recurrence risk for future siblings 
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is 25%. This diagnosis should be strongly considered in probands born to 
consanguineous families, especially if both parents have mild hyperglycemia. 
However, the later is usually asymptomatic and measuring fasting blood glucose 
in the parents of any child with neonatal diabetes, even when there is no known 
family history of diabetes, is often recommended. 
D. Other subtypes of PNDM. 
The remaining known genetic causes of neonatal diabetes are rare (Table 1.3). 
Associated clinical features can be very helpful when planning genetic testing: 
• Pancreatic aplasia or hypoplasia accounts for ~5% of PNDM cases. Most 
patients remain genetically undiagnosed, although two rare genetic 
causes have been identified in a few patients: 
− Complete deficiency of the transcription factor IPF1 secondary to 
homozygous or compound heterozygous mutations in the IPF1 gene 
has been described in three probands with pancreatic agenesis 
(Stoffers et al, 1997; Schwitzgebel et al, 2003; Thomas et al, 2009). 
IPF1 is essential to embryonic development of the pancreas, as it 
regulates the differentiation process from mid-gut endodermic stem 
cells. In adults, it also participates in INS transcription. Thus, 
heterozygous mutations of IPF1 are responsible for rare cases of 
familial early-onset diabetes (Stoffers et al, 1997). 
− Homozygous mutations in PTF1A, encoding the pancreas 
transcription factor 1-α, have been identified in three patients with 
pancreatic and cerebellar hypoplasia/agenesis from two unrelated 
consanguineous families (Hoveyda et al, 1999; Sellick et al, 2004). 
All of them died during infancy due to central respiratory failure. 
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• GLIS3 is a widely expressed transcriptional regulator that has recently 
been shown to be involved in the production of a complex syndrome 
including neonatal diabetes, congenital hypothyroidism and dysmorphic 
features (Taha et al, 2003; Senee et al, 2006). Some patients also 
presented with congenital glaucoma, hepatic fibrosis and renal cysts. To 
date, homozygous mutations in the GLIS3 gene have been reported in 4 
probands from 3 unrelated consanguineous families. 
• IPEX (Immune dysregulation, Polyendocrinopathy, Enteropathy, X-
linked) syndrome is a multisystemic disorder that presents in hemizygous 
males with a mutation in the FOXP3 gene (Wildin et al, 2002). The 
protein encoded by this gene is necessary for the proper development 
and function of regulatory T cells (Ochs et al, 2007). Its lack is associated 
with the presence of numerous early-onset autoimmune diseases 
(enteropathy, diabetes, eczematous dermatitis, hypothyroidism, 
cytopenias, etc.) that leads to the patient’s death usually within the first 
years of life. Remarkably, antibodies against β-cell antigens can be 
found, representing an important difference with other causes of PNDM. 
Immunosuppressive drugs and bone marrow transplantation are both 
included in the treatment regimen. Heterozygous carrier females remain 
asymptomatic. 
The remaining subtypes of diabetes associating extrapancreatic features, 
although having been described in a number of patients with PNDM, produce 
diabetes mainly beyond the first 6 months of life and hence will be described 
later. 
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1.6 FAMILIAL DIABETES WITH AUTOSOMAL DOMINANT 
INHERITANCE 
The sometimes confusing term MODY originates from the time when the terms 
juvenile-onset and maturity-onset were used to distinguish between type 1 (insulin-
dependent) and type 2 (non insulin-dependent) diabetes. MODY was used to describe a 
subgroup of autosomal-dominantly inherited diabetes that was initially non insulin-
dependent despite having a young age of onset (at least one family member diagnosed 
before 25 years of age). The different genetic subtypes differ in age of onset, pattern of 
hyperglycemia, response to treatment and associated extrapancreatic manifestations, 
which suggests that it is inappropriate to place them into a single category. 
Four of the 6 classic MODY subtypes (MODY1, 3, 4 and 6) are characterized by 
familial symptomatic diabetes with no extrapancreatic features. All are caused by 
heterozygous mutations in a gene encoding a β-cell transcription factor (HNF4A, HNF1A, 
IPF1, and NEUROD1, respectively) and show an autosomal dominant inheritance (Stride 
et al, 2002). 
 
1.6.1 HNF1A (MODY3) and HNF4A (MODY1) diabetes 
These two subtypes of monogenic diabetes are by far the most common forms of 
monogenic diabetes secondary to a mutation in a transcription factor, although most 
cases are misdiagnosed as type 1 or type 2 and remain unidentified. HNF1A mutations 
are about 10 times more frequent than mutations in HNF4A (Pearson et al, 2005). 
Therefore, HNF1A is the first diagnostic possibility to be considered in families with 
autosomal dominant diabetes.  
The glucose intolerance usually becomes evident during adolescence or early 
adulthood. In the early stages of the disease, fasting blood glucose may be normal but 
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patients tend to show a large increment in blood glucose (>80 mg/dL or 5 mmol/L) after 
meals or at 2 hours during an oral glucose tolerance test (OGTT) (Stride et al, 2002). 
Over time, fasting hyperglycemia and osmotic symptoms (polyuria, polydipsia) present 
but patients rarely develop ketosis because some residual insulin secretion persists for 
many years. Chronic complications of diabetes are frequent and their development is 
related to the degree of metabolic control (Isomaa et al, 1998). The frequency of 
microvascular complications (retinopathy, nephropathy, neuropathy) is similar to that of 
patients with type 1 and type 2 diabetes. However, HNF1A mutations are associated with 
an increased frequency of cardiovascular disease, although patients usually have plasma 
levels of HDL cholesterol higher levels that do not, however, seem to be cardioprotective 
(Pearson et al, 2003; Hattersley, personal communication).  
Mutations in HNF1A show a high penetrance so that 63% of mutation carriers 
develop diabetes before 25 years of age, 79% before age 35 and 96% before 55 years 
(Murphy et al, 2008). The age at diagnosis of diabetes is partly determined by the 
location of the mutation within the gene (Harries et al, 2006; Bellanné-Chantelot et al, 
2008). Patients with mutations affecting the terminal exons (8-10) are diagnosed, on 
average, 8 years later than those with mutations in exons 1 to 6. On the other hand, 
exposure to maternal diabetes in utero (when the mutation is maternally inherited) brings 
forward the age at onset of diabetes by about 12 years (Stride et al, 2002). Diabetes in 
HNF4A mutation carriers tend to appear slightly later than in patients with mutations in 
HNF1A (Hattersley, personal communication). 
There are some differential clinical characteristics between patients with 
mutations in HNF4A and HNF1A that can help decide which gene should be considered 
first in a particular family:  
- Patients with HNF1A mutations typically have a low renal threshold for 
glucose reabsorption due to impaired renal tubular transport of glucose. 
Slightly over half of children and adolescents carrying a mutation have 
postprandial glycosuria before developing significant hyperglycemia (Stride et 
 37
Chapter 1 
al, 2005). A positive urine test for glycosuria after a large unrefined 
carbohydrate meal could, therefore, suggest the need for predictive genetic 
testing in asymptomatic young children from families with HNF1A diabetes. 
- Mutations in HNF4A are associated with relatively low levels of HDL 
cholesterol and high levels of LDL cholesterol. However, the most relevant 
clinical feature is that about 50% of HNF4A mutation carriers are macrosomic 
at birth (weight >4400 g) and 15% have diazoxide-responsive neonatal 
hyperinsulinemic hypoglycemia (Pearson et al, 2007). In this case, 
hyperinsulinism usually remits during infancy and patients develop diabetes 
from adolescence (Kapoor et al, 2008). 
Patients with both HNF1A and HNF4A-diabetes are extremely sensitive to 
sulfonylureas (Pearson et al, 2003) and the glycemic control is usually better than that 
achieved on insulin, especially in children and young adults (Byrne et al, 1996). The initial 
dose should be low (one-quarter of the normal starting dose in adults) to avoid 
hypoglycemia (Hattersley et al, 2009). As long as the patients do not have problems with 
hypoglycemia, they can be maintained on low-dose sulfonylureas (e.g. 20–40 mg 
gliclazide daily) for decades. If there is hypoglycemia despite dose titration of a once or 
twice daily sulfonylurea preparation, a slow release preparation or meal time doses with a 
short-acting agent like nateglinide may be considered (Tuomi et al, 2006). 
 
1.6.2 Other subtypes 
Dominantly acting mutations in other transcription factors [IPF1 - MODY4 
(Stoffers et al, 1997), NEUROD1 - MODY6 (Malecki et al, 1999), KLF11 (Neve et al, 
2005), PAX4 (Plengvidhya et al, 2007) and ISL1 (Shimomura et al, 2000)] have been 
reported in a handful of pedigrees with familial diabetes. They are extremely rare and 
therefore they are not usually considered in children and adolescents with diabetes in a 
clinical setting. 
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1.7 FAMILIAL MILD FASTING HYPERGLYCEMIA 
The incidental finding of mild hyperglycemia (100-145 mg/dL or 5.5-8 mmol/L) in 
asymptomatic children and adolescents raises the possibility that these patients 
subsequently develop type 1 diabetes. In the absence of pancreatic autoimmunity 
markers, that risk is minimal (Lorini et al, 2001). However, a significant proportion will 
have a heterozygous mutation in the GCK gene (MODY2) (Feigerlová et al, 2006; Lorini 
et al, 2009). This is the commonest subtype of monogenic diabetes in the pediatric 
diabetes clinic.  
The phenotype associated with heterozygous GCK mutations is remarkably 
homogeneous. In contrast to other subtypes of monogenic diabetes, GCK-MODY 
patients regulate insulin secretion adequately but around a slightly higher set point than 
normal controls. As a result, they show non-progressive mild hyperglycemia from birth. 
Their hemoglobin A1c is mildly elevated but usually below 7.5%. Despite the mild fasting 
hyperglycemia, there is a small increment in blood glucose during an OGTT (<60 mg/dL 
or <3.5 mmol/L) (Stride at al, 2002). Since the degree of hyperglycemia is not high 
enough to cause osmotic symptoms, most cases are usually diagnosed incidentally when 
blood glucose is measured for any other reason. Very often, the affected parent remains 
undiagnosed or has been misdiagnosed with early-onset type 2 diabetes. 
Since blood glucose does not deteriorate significantly over time, this subtype of 
monogenic diabetes is rarely associated with chronic complications of diabetes (Velho et 
al, 1997) and patients do not generally require any treatment. Of note, the presence of a 
GCK mutation does not protect against the concurrent development of polygenic type 2 
diabetes later in life, which occurs at a similar prevalence than in the general population 
(Murphy et al, 2008). 
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1.8 MULTISYSTEMIC GENETIC SYNDROMES ASSOCIATED WITH 
DIABETES  
A monogenic disorder should be considered in any child with diabetes associated 
with a number of extrapancreatic features. Some of these syndromes cause neonatal 
diabetes and have been described above (Table 1.4). The most common ones causing 
diabetes beyond the first 6 months of life are listed below. 
 
1.8.1 Renal cysts and diabetes (RCAD) syndrome (MODY5) 
HNF1B is a transcription factor expressed during early embryonic development in 
the kidney, pancreas, liver and genital tract. Heterozygous mutations in HNF1B are less 
common than other forms of MODY. Patients rarely present with isolated diabetes 
(Bingham et al, 2004). In contrast, genetic testing should be considered in patients with 
developmental renal abnormalities, even in the absence of diabetes (Ulinski et al, 2006).  
The renal involvement is characterized mainly by renal cysts and renal dysplasia 
although a number of other presentations are possible (Edghill et al, 2006). Genital-tract 
malformations (particularly uterine abnormalities), hyperuricemia and gout can also occur, 
as well as abnormal liver function tests (Bingham et al, 2004). Approximately half of 
HNF1B mutation carriers will develop diabetes during adolescence or early adulthood. 
They are insulin deficient but also have some degree of hepatic insulin resistance 
(Pearson et al, 2004). Furthermore, HNF1B mutations have also been reported in three 
probands with transient neonatal diabetes (Yorifuji et al, 2004; Edghill et al, 2006; 
Haumaitre et al, 2006). The coexisting pancreatic hypoplasia (Bellanné-Chantelot et al, 
2004) and hepatic insulin resistance explain why patients with HNF1B diabetes do not 
respond adequately to sulfonylurea treatment and early insulin therapy is required 
(Murphy et al, 2008). 
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The phenotype of RCAD patients is highly variable even within families sharing 
the same HNF1B mutation. Therefore, this disorder should be considered not only in the 
diabetes clinic but also in other clinics (nephrology, urology and gynecology, at least). 
Importantly, a family history of renal disease or diabetes is not essential to prompt a 
screen for this disorder, as spontaneous mutations and deletions of this gene are 
common (one-third to two-thirds of cases) (Bellanné-Chantelot et al, 2005; Ulinski et al, 
2006). 
 
1.8.2 Wolfram syndrome (Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy 
and Deafness, DIDMOAD) 
The association of diabetes with progressive optic atrophy below 16 years of age 
is diagnostic of this autosomal recessive syndrome (Domenech et al, 2006). Insulin-
deficient diabetes is usually the first manifestation of the disease and presents at a mean 
age of 6 years. Over time, other features such as sensorineural deafness, central 
diabetes insipidus, urinary tract dilatations and neurological symptoms develop. These 
can present in a variable order, even within the same family. Patients with Wolfram 
syndrome die at a median age of 30 years, mainly from neurodegenerative complications.  
At least 90% of patients harbors recessively-acting mutations in the WFS1 gene 
(Khanim et al, 2001). A second variant of the syndrome has recently been described in 
association with mutations in CISD2 (Amr et al, 2007). Patients with this rare variant do 
not develop diabetes insipidus but present with additional symptoms including bleeding 
diathesis and peptic ulcer disease.  
 
1.8.3 Mitochondrial diabetes (maternally inherited diabetes and deafness, MIDD) 
The most common form of mitochondrial diabetes is caused by a m.3243A>G 
mutation in mitochondrial DNA. Since all mitochondria in an individual come from the 
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mother, only females transmit the disease to their offspring (Murphy et al, 2008). 
Diabetes onset is usually insidious but approximately 20% of patients have an acute 
presentation, even in diabetic ketoacidosis (Maassen et al, 2004). Although it typically 
presents in adulthood, some cases have been reported in adolescents with a high degree 
of heteroplasmy (Guillausseau et al, 2004). Mitochondrial diabetes should be suspected 
in all patients presenting with diabetes mellitus and sensorineural hearing loss inherited 
from mother's side. Interestingly, the same m.3243A>G mutation also causes a much 
more severe clinical syndrome known as MELAS (myopathy, encephalopathy, lactic 
acidosis and stroke) (Goto et al, 1990).  
Patients with mitochondrial diabetes may respond initially to diet or oral 
hypoglycemic agents but often require insulin treatment within months or years. 
Metformin should be avoided as it interferes with mitochondrial function and may trigger 
episodes of lactic acidosis.  
The penetrance of diabetes in mutation carriers depends on the age considered, 
but is estimated to be above 85% at 70 years (Maassen et al, 2004). Affected males do 
not transmit the disease to their offspring. In contrast, females transmit the mutation to all 
her children, although some may not develop the disease (Murphy et al, 2008).  
Besides the m.3243A>G mutation, early-onset diabetes (even in infancy) has 
been reported in other less common mitochondrial diseases such as Kearns-Sayre 
syndrome and Pearson syndrome (Laloi-Michelin et al, 2006; Superti-Furga et al, 1993). 
 
1.8.4 Wolcott-Rallison syndrome 
Biallelic mutations in EIF2AK3 cause this rare autosomal recessive syndrome 
characterized by early-onset diabetes mellitus, spondyloepiphyseal dysplasia, and 
recurrent hepatic and/or renal dysfunction (Delepine et al, 2000; Senee et al, 2004). 
EIF2AK3 (eukaryotic translation initiation factor alpha 2-kinase 3) encodes a protein 
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involved in the regulation of the endoplasmic reticulum stress response. This occurs 
when there is an imbalance between protein synthesis and processing so that misfolded 
proteins accumulate in the endoplasmic reticulum. Pancreatic development is rather 
normal in the absence of the functional protein but misfolded proteins accumulate within 
the endoplasmic reticulum after birth and eventually induce β-cell apoptosis. Diabetes 
usually manifests during infancy, but may do so within the first 3-4 years of age. 
 
1.8.5 Roger’s syndrome 
Thiamine-responsive megaloblastic anemia (TRMA) is an autosomal recessive 
disorder characterized by diabetes, megaloblastic anemia, and sensorineural deafness. 
Some patients also present with congenital heart disease, optic atrophy, retinal 
degeneration and stroke. The disease is caused by biallelic mutations in SLC19A2 
(Labay et al, 1999). This gene encodes a widely expressed cell membrane thiamine 
transporter known as THTR1. Insulin-deficient diabetes, like most of the associated 
clinical features, initially responds to the administration of thiamine supplements. 
However, the majority of patients need insulin after puberty (Ricketts et al, 2006). 
Although the disease usually presents in toddlers and preschoolers, some cases have 
been reported from 3 months of age (Mandel et al, 1984). 
 
1.8.6 Fanconi-Bickel syndrome 
Mutations in the SLC2A2 gene, which encodes the glucose transporter of the 
plasma membrane of β-cells (GLUT2), are responsible for a rare autosomal recessive 
syndrome characterized by abnormal metabolism of glucose and galactose, accumulation 
of glycogen in the liver and kidneys, and renal proximal tubular dysfunction (Santer et al, 
1998). Usually patients show fasting hypoglycemia and postprandial hyperglycemia, but a 
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number of cases with neonatal diabetes have been described (Kentrup et al, 1999; Yoo 
et al, 2002). 
 
1.8.7 Diabetes secondary to monogenic diseases of the exocrine pancreas 
Heterozygous mutations in CEL, which encodes a pancreatic lipase, cause an 
autosomal dominant disorder of pancreatic exocrine insufficiency and diabetes (Raeder 
et al, 2006). Other autosomal dominant monogenic diseases affecting mainly the 
exocrine pancreas that can lead to diabetes sooner or later include cystic fibrosis (CFTR) 
(Moran et al, 2003) and hereditary pancreatitis (PRSS1 and SPINK1) (Teich et al, 2008). 
 
 
1.9 MONOGENIC INSULIN RESISTANCE SYNDROMES 
Monogenic diabetes associated with extreme insulin resistance is less common 
than monogenic β-cell failure.  
 
1.9.1 Insulin receptor (INSR) gene mutations 
Biallelic INSR mutations cause a number or very rare recessive syndromes 
characterized by severe insulin resistance and greatly increased insulin and C-peptide 
levels. There is a strong genotype-phenotype correlation (Longo et al, 2002; Musso et al, 
2004): 
- Nonsense mutations or mutations in the extracellular domain of the receptor 
produce the most severe syndrome, referred to as Donohue syndrome or 
leprechaunism. It is characterized by intrauterine growth retardation, 
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abnormal glucose metabolism and dysmorphic features (low-set ears, thick 
lips, flat nose root, thick skin, lack of subcutaneous fat, hypertrichosis and 
macrogenitalism). Most patients die during infancy. 
- Less severe mutations in the insulin-binding domain or in the intracellular 
domain of the receptor lead to Rabson–Mendenhall syndrome. Affected 
patients present with dysplastic teeth and gums, thickened nails and 
hirsutism. Recently, an association with medullary sponge kidney has been 
described. Most patients die before adolescence.  
In both cases, patients initially have fasting hypoglycemia and postprandial 
hyperglycemia, but eventually develop persistent hyperglycemia and 
ketoacidosis. 
- Type A insulin resistance syndrome is characterized by severe insulin 
resistance in the absence of obesity. It is usually diagnosed in non-obese 
female adolescents with severe acanthosis nigricans and hyperandrogenism 
(polycystic ovarian syndrome). Abnormal glucose tolerance develops later 
on. 
Treatment of severe insulin resistance is mostly ineffective. Metabolic control 
remains poor and long-term diabetes complications are frequent. Approaches used 
include the use of the insulin sensitizers, i.e. metformin and/or glitazones, but their impact 
is limited when the insulin resistance is very severe. Insulin is the main stay of treatment, 
but extraordinarily high doses are needed, and 500U insulin and insulin pumps are 
usually required (Hattersley et al, 2009). As an alternative therapeutic method, 
recombinant human insulin-like growth factor-I (rhIGF-I) has been reported to be 
successful in treatment of Donohue syndrome and type A insulin resistance (Kuzuya et 
al, 1993). This treatment is effective in lowering both fasting and postprandial plasma 
glucose concentrations, and in some cases, improvement of acanthosis nigricans was 
also observed; however, the long-term effect is still unsatisfactory (Nakae et al, 1998). 
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1.9.2 Genetic lipodystrophies 
Lipodystrophies are characterized by a selective lack of adipose tissue. This 
results in a decreased adipokines levels and insulin resistance (Garg, 2004). 
- Congenital generalized lipodystrophy (Berardinelli–Seip syndrome) is a 
recessive disorder characterized by an almost complete absence of 
subcutaneous and visceral fat with severe hyperinsulinemia that progresses 
to diabetes in early adolescence. Patients may show acanthosis nigricans, 
extreme hypertriglyceridemia, fatty liver, virilisation and cardiomyopathy. 
Mutations in two genes (AGPAT2 and BSCL) account for approximately 80% 
of cases (Agarwal et al, 2003). Extremely high doses of insulin are needed 
for metabolic control. In contrast, the response of diabetes to recombinant 
leptin can be dramatic but it is only available on a research basis (Beltrand et 
al, 2007). 
- Patients with familial partial lipodystrophy show loss of subcutaneous fat from 
the extremities, lower trunk and the gluteal region. They exhibit a severe 
insulin resistance phenotype with hyperinsulinemia, hypertriglyceridemia and 
decreased HDL cholesterol. Diabetes usually appears in late adolescence or 
early adulthood. Dominantly acting heterozygous mutations in LMNA or 
PPARG account for approximately 50% of cases (Garg, 2004), which 
suggests that additional loci may exist. Mutations in ZMPSTE24, AKT2, and 
CIDEC have been identified in a few cases (Garg et al, 2009; Rubio-Cabezas 
et al, 2009), but many patients still remain undiagnosed. Insulin treatment 
together with metformin is still not sufficient in most cases. Due to their 
PPARγ agonist effect, thiazolidinediones may be of benefit (Arioglu et al, 
2000). 
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1.9.3 Alström syndrome 
This autosomal recessive disorder shares symptoms with Bardet-Biedl syndrome 
(See below), including retinitis pigmentosa, deafness, obesity, and diabetes mellitus. It 
can be distinguished from the latter syndrome by the lack of polydactyly and 
hypogonadism and by the absence of mental impairment (Alström et al, 1959). The 
syndrome is caused by mutations within the ALMS1 gene of unknown function (Hearn et 
al, 2002). Patients with Alström syndrome show many features of the metabolic syndrome 
including hyperlipidemia, hyperuricemia, insulin resistance, hypertension, and diabetes. 
Furthermore, acanthosis nigricans, chronic active hepatitis (possibly based on non-
alcoholic steatohepatitis) and dilated cardiomyopathy have also been reported. 
 
1.9.4 Bardet-Biedl syndrome 
This (in most cases) autosomal recessive disorder is characterized by mental 
retardation, pigmentary retinopathy, polydactyly, obesity, diabetes mellitus, renal 
dysplasia, hepatic fibrosis, and hypogonadism (Beales et al, 1999). Obesity is found in 
almost every patient, while diabetes affects less than 50%. While the syndrome shares 
some similarities with Lawrence-Moon syndrome, these two disorders can be 
distinguished by the presence of paraplegia and the absence of polydactyly, obesity, and 
diabetes mellitus in Lawrence-Moon syndrome. Terms such as Lawrence-Moon-Bardet-
Biedl or Lawrence-Moon-Biedl syndrome should therefore be avoided. Bardet-Biedl 
syndrome has been linked to at least 14 different genetic loci, referred to as BBS1 to 
BBS14 (Stoetzel et al, 2007; Leitch et al, 2008). Heterozygous carriers possibly exhibit an 
increased risk for obesity, hypertension, diabetes mellitus, and renal disease. 
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1.10 RATIONALE  
 The vast majority of diabetic children have type 1 diabetes, while monogenic 
diabetes is responsible for only 1-2% of cases. Despite the recent advances in the 
understanding of the molecular basis of monogenic diabetes outlined above, the 
translation of the new knowledge into changes in daily clinical care usually occurs very 
slowly. As a consequence, many pediatric patients with monogenic diabetes continue to 
be initially misdiagnosed as having type 1 diabetes, especially where pancreatic antibody 
measurement is not routinely performed in the clinical setting. 
Whilst genetic testing confirms or excludes a diagnosis of monogenic diabetes 
with both high sensitivity and high specificity, molecular studies are expensive and some 
criteria must be used to select candidates to genetic testing in order to approach the 
problem in a cost-effective way. 
Age at diabetes onset can be considered one of these cornerstone criteria. Six 
months is a reasonable cut-off as classic polygenic autoimmune type 1 diabetes will 
account for most cases presenting during late infancy (6 to 12 months), childhood or 
adolescence, whereas most infants diagnosed before 6 months will have monogenic 
diabetes. However, some patients diagnosed after 6 months will also have monogenic 
diabetes. Therefore, a different approach for selecting candidates for genetic testing must 
be used. Since the number of genes associated with neonatal and early infancy onset 
diabetes is relatively high, additional selection criteria are also needed in this case.  
The history and physical examination are the best and cheapest tools available 
for this purpose (Barrett, 2007). Specific clinical features associated with a certain genetic 
syndrome can be easily identified and help guide the genetic testing. The existence of 
consanguinity or a history of miscarriages or infant mortality suggests a possible 
autosomal recessive syndrome. A positive family history of diabetes is an important clue, 
especially if the disease follows an autosomal dominant inheritance pattern (familial 
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diabetes or MODY) or is associated with deafness or epilepsy only on the maternal side 
(mitochondrial diabetes).  
Some laboratory tests may also prove useful, especially the measurement of 
autoantibodies to β-cells and plasma levels of insulin and/or C-peptide. In selected 
patients, other tests should be considered including, but not limited to, liver and kidney 
function tests, X-ray bone survey, audiogram, echocardiogram and/or brain MRI.  
In order to identify children with monogenic diabetes accurately, it is therefore 
important to define the most informative clinical and laboratory findings pointing at a 
specific gene. Although pancreatic autoantibodies are considered the diagnostic hallmark 
for type 1 diabetes, their usefulness (when absent) as a selection tool for genetic testing 
in patients with isolated diabetes needs to be further explored.  
New monogenic syndromes are usually described in affected patients showing a 
severe phenotype. However, as soon as the causative gene is identified, it is not 
uncommon that less severe mutations are reported in patients with milder 
oligosymptomatic forms of the disorder. Whether this is also true for some subtypes of 
monogenic diabetes remains to be determined. In addition, a genetic cause can be 
identified in only 60% of PNDM patients indicating there must be other genes to be 
identified. Some of these patients have isolated diabetes whereas others present with 
complex multisystemic syndromes. Considering neonatal diabetes as a developmental 
disorder, genes encoding transcription factors central to pancreatic or ß-cell development 
are especially interesting as potential novel genetic causes. 
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1.11 OBJECTIVES 
The aims of the present work were: 
I. To explore the contribution of common causes of monogenic diabetes to the 
production of idiopathic type 1 diabetes in children. 
II. To investigate the frequency of autoimmune diabetes among patients with 
permanent neonatal diabetes. 
III. To increase the current knowledge on the molecular bases of monogenic 
diabetes in newborns and infants. 
  
 
1.12 OUTLINE OF THE THESIS 
 This doctoral dissertation gives a detailed account of five different studies. 
Chapter 2 describes the genetic screening of four relatively common causes of 
monogenic diabetes (HNF1A, HNF4A, KCNJ11 and INS) in children clinically diagnosed 
as having antibody-negative type 1 diabetes. Chapter 3 describes the relative frequency 
of monogenic autoimmune diabetes secondary to FOXP3 mutations among male patients 
with PNDM from a large international cohort. In addition to the well-known IPEX 
syndrome, a milder phenotype is reported for the first time. Chapter 4 describes in 
detailed a patient with a homozygous nonsense mutation in GCK. Chapter 5 explores the 
contribution of EIF2AK3 mutations to PNDM and the identification of potential candidates 
for genetic testing before the full clinical picture develops by using a novel approach 
based on homozygosity mapping. Chapter 6 reports the identification of recessively 
acting mutations in the INS gene, encoding proinsulin, as a novel cause of neonatal 
diabetes. During this study, a previously uncharacterized region in the INS promoter has 
been identified. Chapter 7 describes a novel genetic subtype of PNDM due to 
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homozygous mutations in NEUROD1, a gene central to pancreatic islet development and 
ß-cell function. Chapter 8 discusses the significance of the presented data in the context 
of the literature, as well as some recommendations for future research. Finally, Chapter 9 
summarizes this dissertation and gives the final conclusions, both in English and 
Spanish. 
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ABSTRACT 
Aims: Monogenic diabetes is frequently misdiagnosed as type 1 diabetes. We aimed to 
screen for undiagnosed monogenic diabetes in a cohort of children who had a clinical 
diagnosis of type 1 diabetes but were pancreatic autoantibody-negative. 
Methods: We studied 252 patients clinically diagnosed with type 1 diabetes between 6 
months and 17 years old. Pancreatic autoantibodies (ICA, GADA and/or IA2A) were 
absent in 25 cases (9.9%). The most frequent genes involved in monogenic diabetes 
[KCNJ11 and INS for neonatal diabetes and HNF1A and HNF4A for maturity-onset 
diabetes of the young (MODY)] were directly sequenced. 
Results: Two of the twenty five (8%) antibody-negative patients had de novo 
heterozygous mutations in INS; c.94G>A (G32S) and c.265C>T (R89C). The two patients 
presented with non-ketotic hyperglycaemia at 8 and 11 months. In contrast, the four 
antibody-positive patients who presented at a similar age (6-12 months) showed a more 
severe metabolic derangement, manifested as ketosis in all four cases, with ketoacidosis 
in two. At age 15 and 5 years both INS mutation patients were prescribed a replacement 
dose of insulin with good glycemic control [glycated hemoglobin (HbA1c) 7.0 and 7.2%]. 
No mutations were found in KCNJ11, HNF1A or HNF4A. 
Conclusions: The identification of patients with monogenic diabetes from children with 
clinically defined type 1 diabetes may be helped by clinical criteria including the absence 
of pancreatic autoantibodies. 
69 

INS mutations in paediatric-onset antibody-negative type 1 diabetes 
INTRODUCTION 
Immune-mediated destruction of the pancreatic β-cells underlies the commonest 
subtype of diabetes mellitus in children, type 1 diabetes (1). Although destruction of β-
cells is considered T-cell mediated, anti-islet autoantibodies are the best characterized 
markers of β-cell autoimmunity. However, some patients do not present with autoimmune 
markers and are classified as having antibody-negative type 1 diabetes, also referred to 
as idiopathic or type 1b diabetes (1). Monogenic diabetes is rare in children and is often 
misdiagnosed as type 1 diabetes (2-7). We hypothesized that it could explain some cases 
of apparent type 1 diabetes in children. The aim of the present study was therefore to 
search for a monogenic cause in selected children with antibody-negative type 1 
diabetes. 
 
PATIENTS AND METHODS 
We retrospectively reviewed the medical records of 280 patients with clinically-
diagnosed type 1 diabetes actively followed in the paediatric diabetes clinic at the 
Hospital Infantil Universitario Niño Jesús, Madrid, Spain. Median age at onset of diabetes 
was 5.9 years [interquartile range (IQR): 3.1 – 9.0], ranging from 0.7 to 16.4 years. 
Information on islet cell antibodies (ICA) within one week of diagnosis was 
available for 224 cases. The presence of ICA was investigated by immunofluorescence 
using human pancreatic tissue and titres ≥5 Juvenile Diabetes Foundation (JDF) units 
were considered to be positive. There were no differences in clinical characteristics 
between patients who had or had not been tested for ICA (data not shown). The 56 
patients without an ICA result and the 47 patients with a negative ICA result (n=103) were 
invited for additional antibody studies and, if these were negative, genetic testing was 
performed. Twenty-eight patients declined to take part in further testing. Thus, we are 
only able to give results on 252 subjects. 
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A random venous blood sample was taken and glutamic acid decarboxylase 
isoform 65 and insulinoma-associated antigen-2 antibodies (GADA and IA2A, 
respectively) were measured by ELISA (DRG Instruments GmbH, Marburg, Germany), at 
a median 5.3 years after diabetes onset (IQR: 3.2-9.2). The cut-offs to define antibody 
status as negative were GADA levels <10 U/mL and IA2A levels <20 U/mL. 
Patients with either positive ICA at diagnosis or positive GADA and/or IA2A 
during follow-up were considered to have autoimmune type 1 diabetes (n = 227). The 
remaining 25 patients were classified as having antibody-negative type 1 diabetes, nine 
of whom had a negative ICA result at diabetes onset.  
Genetic testing was performed on the antibody negative subjects. Genomic DNA 
was extracted from peripheral leukocytes using standard procedures. The coding exons 
and intron-exon boundaries of KCNJ11, INS, HNF1A and HNF4A were amplified by PCR 
(primers and conditions available upon request). Single-strand sequencing was carried 
out using standard methods on an ABI 3730 sequencer (Applied Biosystems, Warrington, 
UK). Sequences were compared with the published reference templates (NM_000525, 
NM_000207, NM_000545.4 and NM_000457.3, respectively) using Mutation Surveyor 
v3.20 (SoftGenetics, State College, PA, USA). Changes in the sequence were checked 
against published polymorphisms and mutations. Gene deletions in the aforementioned 
genes and other rare causes of monogenic diabetes, including ABCC8 and HNF1B 
mutations, have not been addressed in this study. As all the patients presented with 
symptomatic random hyperglycaemia and HbA1c >7.5%, GCK mutations were not 
considered likely and they have not been tested. 
Written informed consent was obtained from all participants or their parents. The 
study was approved by the local Ethics Committee and performed according to the 
Helsinki Declaration, as revised in 2000. 
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RESULTS 
The 25 (9.9%) patients with antibody-negative diabetes were diagnosed at a 
younger age than the 227 patients with diabetes and pancreatic autoantibodies [median 
3.85 (IQR: 1.74–6.45) vs. 6.29 (IQR: 3.16–9.43) years, p=0.01]. GADA and IA2A were 
tested significantly later after diabetes onset in patients with a negative result [median 
7.60 (IQR: 4.02–11.58) vs. 4.95 (IQR: 2.50–7.90) years, p=0.02). 
Two of the twenty five antibody negative patients (8%) had monogenic diabetes. 
These two patients had heterozygous mutations in INS; c.94G>A (G32S) and c.265C> T 
(R89C). These mutations have been previously reported as being pathogenic (8). They 
were not found in unaffected parents, representing de novo mutations, and were not seen 
in 222 UK Caucasian control chromosomes. No mutations were found in KCNJ11, 
HNF1A or HNF4A. 
The patient with the G32S mutation presented with progressive polyuria and 
polydipsia at 11 months of age. Blood tests revealed hyperglycaemia without ketonuria 
and a normal C-peptide level (929 pmol/L) that was still measurable one year after 
diabetes onset (570 pmol/L). She is currently 15 years old and has good metabolic 
control (HbA1c: 7.0%) on a full replacement insulin dose (0.92 U/kg/day).  
The proband with the R89C mutation presented with a persistent nappy rash at 8 
months. Following further investigation, glycosuria was found and the parents recalled 
some degree of polyuria and polydipsia during the previous weeks. The child was 
hyperglycaemic but not ketotic. At 5 years of age, he has acceptable metabolic control 
(HbA1c: 7.2%) on a basal-bolus insulin regimen (0.48 U/kg/day). 
There were four other children in this cohort who were diagnosed before 1 year of 
age but all of them were considered to have autoimmune type 1 diabetes (Table 1). The 
youngest case was diagnosed at the age of 10 months. In contrast to the INS mutation 
carriers, they presented with either ketosis or ketoacidosis. Birth weight did not 
discriminate the two patients with an INS mutation from the remainder of the group.  
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Table 1. Clinical characteristics of patients diagnosed with diabetes before 1 year of age. Standard 
deviation scores (SDS) for birth weights were calculated by comparing to the Child Growth 
Foundation LMS data (9). ICA, islet cell autoantibodies; JDF: Juvenile Diabetes Foundation units. 
 
DISCUSSION 
Approximately 10% of the patients with a clinical diagnosis of type 1 diabetes in 
this study did not have autoantibodies on initial testing or on follow-up. This is in keeping 
with previous reports showing that 5–20% of paediatric patients with newly diagnosed 
type 1 diabetes are autoantibody negative, with the proportion being higher in older 
children and adolescents and in non-Caucasian ethnic groups (10-12). Antibody-negative 
type 1 diabetes in children has a slower disease progression than antibody-positive 
diabetes, with preservation of residual β-cell function, lower insulin requirement, and 
better glycaemic control during the first year after diagnosis (13). Whether antibody-
negative type 1 diabetes arises from a different pathogenic mechanism leading to β–cell 
failure is not currently known. Islet cell autoantibodies may disappear overtime after 
diabetes onset in a significant proportion of children with proven autoimmune diabetes 
(14). It has also been reported that a small proportion of cases might lose autoantibodies 
before diabetes onset (15). Thus, lack of pancreatic autoantibodies does not exclude 
autoimmune diabetes, especially if testing is performed during follow-up. Our study is a 
cross-sectional study and patients with a negative result were tested later after diagnosis 
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than patients with positive antibodies. This might explain that, in contrast to previous 
reports, patients with antibody-negative diabetes were younger at diagnosis than children 
with confirmed autoimmune diabetes in our cohort. 
We hypothesized that a mutation in a gene implicated in monogenic diabetes 
could be responsible for some cases of antibody-negative type 1 diabetes. Following 
sequencing the most common subtypes of monogenic diabetes in 25 children with 
antibody-negative diabetes, we identified two patients with monogenic diabetes (8%). 
This supports that molecular testing in patients with antibody-negative diabetes increases 
the yield for identifying children with monogenic disease. Both patients had an INS 
mutation and were diagnosed with diabetes at 8 and 12 months of age. INS mutations 
are rare in unselected patients with permanent diabetes diagnosed between 6 and 12 
months of age (16). Low birth weight has been associated with INS mutations (16) but it 
did not discriminate between early-onset type 1 diabetes and INS mutation carriers in our 
cohort. Absence of ketosis cannot be used as a clinical marker either, as ketosis has 
been previously reported in patients with an INS mutation (6, 8, 16-18). Therefore, lack of 
pancreatic antibodies might be the best single clinical criterion for genetic testing in 
infants diagnosed between 6 and 12 months (6, 7). 
In addition, while the proband with the G32S mutation in INS has had similar 
glycaemic control over time to the four antibody-positive patients diagnosed at a similar 
age, the child with the R89C mutation has maintained unusually good glycaemic control 
(HbA1c 6-7%) with a slow increase in insulin requirements (0.2-0.4 U/kg/day). This 
pattern is unusual in infancy-onset type 1 diabetes and probably indicates slowly 
progressive β-cell destruction (Figure 1). 
We did not find patients with undiagnosed HNF1A or HNF4A MODY. Making a 
molecular diagnosis is important, as in both forms, oral sulphonylureas are the treatment 
of choice. These patients have previously been shown to be misdiagnosed as type 1 
diabetes and a number of different strategies have been used to identify them, including a 
non high-risk HLA haplotype, positive family history of diabetes and/or persistently 
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measurable C peptide (2-5). Our cohort originated from a paediatric cross-sectional study 
and therefore older children and adolescents are under-represented as those diagnosed 
later in childhood are quickly transferred to adult clinics. HNF1A and HNF4A mutation 
carriers who develop diabetes within the paediatric age range are usually diagnosed 
around adolescence (median age: 14 years, IQR: 12-16 years, n=215 probands 
diagnosed <19 years) (A.T. Hattersley and S. Ellard, unpubl. observ.). The age at 
diabetes onset was significantly younger in our patients, with only two having been 
diagnosed after 11 years. This could explain why we did not find any HNF1A or HNF4A 
mutations in our cohort. 
 
 
Figure 1. Glycated Haemoglobin (HbA1c) (black line) and insulin requirements (dotted line) of the 
patient with the R89C mutation in the INS gene. Apart from the initial metabolic decompensation, 
the patient has maintained HbA1c <7% for several years, requiring only partial replacement insulin 
doses. This is in keeping with the presence of an unusually long partial remission phase and is 
probably because of rather slow progressive destruction of insulin-producing pancreatic β-cells. 
 
In conclusion, monogenic diabetes is uncommon in children with type 1 diabetes. 
However the lack of pancreatic autoantibodies can be used as an indicator for genetic 
testing. At present, most clinics do not routinely screen children with newly developed 
diabetes for autoantibodies. Further prospective studies are needed to show whether 
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autoantibody screening in children and adolescents with diabetes is cost-effective and 
should inform the need for referral for genetic testing. 
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ABSTRACT 
Objective: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome 
is caused by FOXP3 mutations. We aimed to determine the prevalence, genetics and clinical 
phenotype of FOXP3 mutations in a large cohort with permanent neonatal diabetes (PNDM). 
Research Design and Methods: The 11 coding exons and the polyadenylation region of 
FOXP3 were sequenced in 26 male subjects with diabetes diagnosed before 6 months of age 
in whom common genetic causes of PNDM had been excluded. Ten subjects had at least one 
additional immune-related disorder, and the remaining 16 had isolated diabetes. 
Results: We identified four hemizygous FOXP3 mutations in 6 of 10 patients with associated 
immune related disorders and 0 of 16 of those with isolated diabetes (p=0.002). Three patients 
with two novel mutations (R337Q and P339A) and the previously reported L76QfsX53 
developed classical IPEX syndrome and died within the first 13 months. The novel mutation 
V408M was found in three cases from two unrelated families and had a mild phenotype with 
hypothyroidism and autoimmune enteropathy (n=2) or nephrotic syndrome (n=1) and survival to 
12–15 years. 
Conclusions: FOXP3 mutations result in ~4% of cases of males with permanent diabetes 
diagnosed before 6 months. Patients not only have classic IPEX syndrome but, unexpectedly, 
may have a more benign phenotype. FOXP3 sequencing should be performed in any male 
patient diagnosed with diabetes in the first 6 months who develops other possible autoimmune-
associated conditions, even in the absence of full IPEX syndrome. 
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INTRODUCTION 
Type 1 diabetes is the leading cause of diabetes among children except for those 
in whom diabetes is diagnosed before the age of 6 months. HLA studies have shown that 
patients diagnosed with diabetes within the first six months of life (permanent neonatal 
diabetes mellitus, [PNDM]) do not harbor high-risk HLA haplotypes and hence are very 
unlikely to have classic type 1 diabetes (1,2). These patients should be tested for 
monogenic causes of neonatal diabetes. 
Mutations in FOXP3 have been associated with a severe, early-onset, male-
limited autoimmunity syndrome known as IPEX (Immune dysregulation, 
Polyendocrinopathy, Enteropathy, X-linked; OMIM [Online Mendelian Inheritance in Man] 
304930) (3-5). The gene maps to chromosome Xp11.23 and encodes a 431-amino acid 
protein, also named scurfin, required for the generation and functioning of CD4+CD25+ 
regulatory T lymphocytes. FOXP3-expressing CD4+ T cells are potent suppressors of 
self-reactive T-cell activation and proliferation, presumably via direct cell-cell interaction. 
Thus, lack of these cells results in an uncontrolled autoimmune reactivity in male patients 
with hemizygous FOXP3 mutations (6). In keeping with an X-linked recessive mode of 
inheritance, heterozygous carrier females remain completely asymptomatic, but each son 
has a 50% risk of being affected with IPEX syndrome. One patient with IPEX syndrome 
due to recessive inheritance of CD25 mutations has recently been reported (7). 
Most IPEX patients described to date have developed symptoms shortly after 
birth or during the first 3–4 months of life. The most common findings have been 
enteropathy (nearly 100% of patients), diabetes (~70%), skin disease (~65%), failure to 
thrive (~50%), thyroiditis (~30%), and recurrent infections (~20%). Less common 
additional features include autoimmune cytopenias, pneumonitis, nephritis, hepatitis, 
vasculitis, arthritis, myositis, and alopecia as well as lymphadenopathy and 
splenomegaly. These disorders often appear sequentially rather than simultaneously, and 
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the affected organ spectrum varies substantially from patient to patient (8). The life 
expectancy of patients with IPEX syndrome rarely extends beyond infancy. 
However, a milder phenotype has been reported in a number of patients who can 
live longer, sometimes into adulthood. Enteropathy was present in virtually all of them, 
although diabetes was frequently absent (9-11). 
To our knowledge, FOXP3 has never been systematically studied before in 
patients with early-onset diabetes. Hence, we aimed to explore the prevalence of FOXP3 
mutations in the largest worldwide cohort of PNDM. 
 
RESEARCH DESIGN AND METHODS 
This study was conducted in accordance with the Declaration of Helsinki, as 
revised in 2000. Informed consent was obtained from all patients, with parental consent 
given on behalf of children. 
The study population originated from the International Society of Pediatric and 
Adolescent Diabetes (ISPAD) Rare Diabetes Study. In total, 296 patients (154 boys) with 
diabetes diagnosed in the first 6 months of life who were receiving insulin treatment at the 
time of referral were studied. A genetic cause for the disease had previously been 
identified in 171 subjects: KCNJ11 in 85 patients, INS in 37, ABCC8 in 28, GCK in 8, 
EIF2AK3 in 8, PTF1A in 2 and IPF1 in 1 patient (12-14; S.E. and A.T.H.,  unpublished 
data). The most common causes of PNDM had been excluded by direct sequencing in 
the remaining 125 patients, 70 of whom were male. Specifically, mutations in KCNJ11 
had been excluded in 68 patients, ABCC8 mutations had been excluded in 63 patients, 
INS mutations had been excluded in 63 patients, and GCK mutations had been excluded 
in 31 patients. 
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Among the 70 male patients without a molecular diagnosis, we sequenced 
FOXP3 in 10 subjects from 9 unrelated families on the basis of the presence of PNDM 
and any other immune-mediated disease. As a comparison, we also sequenced FOXP3 
in 16 further male patients with PNDM but without any associated immune disease. 
DNA samples were collected in Exeter. Clinical information was obtained from 
hospital records with assistance from the referring clinicians. Pancreatic autoantibodies 
were measured locally according to the standard clinical practice. Sequence variants 
were tested for their presence in family members whenever a DNA sample was available. 
Molecular genetic analysis 
Genomic DNA was extracted from peripheral leukocytes using standard 
procedures. The 11 coding exons, minimal promoter, and the 3’-untranslated region of 
the FOXP3 gene including the polyadenylation signal were amplified by PCR; primers 
and conditions are available upon request. Sequence-specific primers for each amplicon 
were tagged with 5’ M13 tails to allow sequencing to be performed with a “universal” M13 
primer. 
Single strand sequencing was carried out using standard methods on an ABI 
3730 sequencer (Applied Biosystems, Warrington, UK). Sequences were compared to 
the published sequence (NM_014009.3) using Mutation Surveyor (version 3.10). Any 
changes in the sequence were checked against published polymorphisms and mutations 
and for conservation across species. 
We used a panel of microsatellites for chromosome 20q to confirm family 
relationships in those families where the mutation seemed to have arisen de novo. 
Patients with PNDM and other autoimmune disease in whom no FOXP3 mutation was 
identified were also investigated for the presence of CD25 mutations by sequencing of 
the coding region. 
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Molecular models 
Predicted three-dimensional structures for the forkhead DNA-binding domain  
(DBD) (residues 335-423) of normal and variant FOXP3 proteins were generated using 
SWISS-MODEL (http://swissmodel.expasy.org/), an Internet-based tool for automated 
comparative protein modeling (15). Structures were visualized and images generated 
using either MDL Chime (Symyx Technologies) or DeepView (Swiss Pdb-Viewer) 
programs (16). 
 
RESULTS 
Molecular genetics 
We identified four different mutations in FOXP3 in six male subjects with PNDM 
from five unrelated families, all of whom presented with an associated immune-mediated 
disease (see below). None of the 16 patients with isolated PNDM had a variant in the 
FOXP3 sequence (Fisher’s exact test; p=0.002). No CD25 mutations were identified in 
probands lacking FOXP3 mutations. 
There were 3 novel FOXP3 missense mutations: R337Q (c.1010G>A; 
p.Arg337Gln), P339A (c.1015C>G; p.Pro339Ala) and V408M (c.1222G>A; p.Val408Met), 
the latter being present in 3 patients (including monozygotic twins) from two unrelated 
pedigrees (Figure 1). The affected amino acid residues were conserved among species 
as well as in several other members of the forkhead transcription factor superfamily (data 
not shown). None of them was found in 510 European Caucasian or in 147 Turkish 
control X chromosomes. Only one of the mutations had previously been reported 
(c.227delT; p.Leu76GlnfsX53). It introduces a frameshift and generates a premature stop 
codon (17, 18). The inheritance within families of the mutations is in keeping with an X-
linked inheritance as shown in Figure 1. 
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Figure 1. Pedigrees for families with individuals harboring a FOXP3 mutation. Filled symbols 
represent patients with early-onset diabetes; black dots represent asymptomatic female carriers. 
The genotype is shown underneath each symbol; M and N denote mutant and wild-type alleles, 
respectively. An arrow indicates the proband. 
 
Clinical features 
The clinical information from patients bearing a FOXP3 mutation is shown in 
Table 1. There were no significant clinical differences (including age at diabetes onset, 
birth weight, or type of associated autoimmune disease) between those who were 
positive and negative for FOXP3 mutations (data not shown). Classic IPEX syndrome 
was present in three of the six patients, all of whom died by 13 months. In contrast, all 
three patients with the V408M mutation had a milder phenotype as well as prolonged 
survival (still alive at age 12–15 years). 
Diabetes was the presenting feature in all subjects. Age at diagnosis varied from 
the first day of life to 3.5 months and did not correlate with the outcome of the disease. 
Birth weight was a feature of disease severity as it was markedly reduced only in the two 
patients who died early in infancy. Antibodies against β-cell antigens were reported to be 
unequivocally present just in one patient; in this patient results were negative at the time 
diabetes was diagnosed and became positive only during follow-up. 
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Table 1. Clinical characteristics of the patients with a FOXP3 mutation. 
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Gastrointestinal symptoms developed in five of six patients, although both the 
timing and the clinical severity varied widely. Interestingly, one of the most severely 
affected infants (Table 1, proband V) had diarrhea with a low fecal elastase and a 
magnetic resonance imaging (MRI) scan performed at 4 months showed only a tiny 
remnant of pancreatic tissue (Figure 2). Thyroid disease was also found in five of six 
patients, but again it ranged between very mildly elevated thyroid-stimulating hormone 
levels without any detectable thyroid antibodies to severe autoimmune hypothyroidism. 
Proband I (hemizygous for V408M) did not suffer from any gastrointestinal problem and 
only had a steroid-sensitive nephrotic syndrome that was considered to represent 
minimal change disease by the attending nephrologist. 
 
 
Figure 2. Abdominal MRI scan showing the absence of recognizable pancreatic tissue in one of the 
patients with classic IPEX syndrome (c.227delT, p.Leu74GlnfsX53 mutation). White arrowheads 
point to the pancreas in a control subject. 
 
Molecular models 
Inspection of the predicted structures of the DBD of FOXP3 suggested that all 
three novel missense FOXP3 mutations are likely to have deleterious effects on protein 
function and therefore be pathogenic, although to varying degrees. In normal FOXP3, the 
side chain of arginine 337 is predicted to make close contact with the DNA backbone 
(Figure 3A, top panel). The presence of a strong basic residue at this position is 
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conserved in all forkhead transcription factors, and it contributes to DNA binding through 
both hydrogen bonding and electrostatic interactions. The R337Q substitution destroys 
this close contact with the DNA backbone (Figure 3A, bottom panel) and is predicted to 
cause a significant loss of positive charge at the DNA-binding surface of FOXP3 (Figure 
3B). Taken together, the data strongly suggest that the R337Q mutation will result in a 
significant loss of DNA binding affinity. 
 
 
Figure 3. Predicted structures of the DBD of normal and R337Q FOXP3. A: Predicted interaction of 
FOXP3 with DNA. FOXP3 is represented in ribbon form, colored blue (NH2-terminal) to red (COOH-
terminal), except for residue 337 (labeled) that shows the van der Waals radii of backbone and side 
chain atoms as dotted surfaces (white, carbon; blue, nitrogen; red, oxygen). Other features referred 
to in the text (helix 1 and the wing region) are labeled; the main DNA recognition helix (helix 3, 
green) lies in the major groove of the DNA. The DNA strand predicted to contact FOXP3 R337 is 
represented as a space-filling model, showing the van der Waals radii of the backbone atoms 
(white, carbon; red, oxygen; yellow, phosphorus). For clarity, each of the second DNA strands is 
shown only as a stick model of the backbone (blue). B: Molecular surface of FOXP3, showing areas 
of positive (blue) or negative (red) electrostatic potential. The structure shown in A has been rotated 
upward to look toward the DNA-binding surface; the position of residue 337 is indicated by the 
purple oval, and the DNA strands have been omitted for clarity. Structures were visualised and 
molecular surfaces calculated using DeepView (A) or MDL Chime (B) programs. 
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Proline 339 lies in a gamma-turn between Arg337 and helix 1 of the DBD. 
Substitution of this residue by alanine (as in the P339A mutation) is likely to affect the 
topology of Arg337 and/or helix 1 relative to the DNA and so would also be expected to 
have a deleterious effect on DNA binding affinity. 
Valine 408 lies in a β-turn at the COOH-terminal of wing 1; in the predicted 
structure of FOXP3 its side chain points away from the DNA-binding surface and towards 
the side chain of arginine 347 in helix 1 (data not shown), although there is no apparent 
contact between the two side chains. Interestingly, replacing Val408 with the longer 
methionine is predicted to allow van der Waals contact between the two side chains (data 
not shown). This increased interaction between wing 1 and helix 1 is likely to have some 
effect on protein flexibility within the DBD, and it is reasonable to suspect that reduced 
flexibility in the DBD of FOXP3 will have an impact on DNA binding affinity. However, 
given the weak nature of van der Waals interactions, such effects are likely to be 
relatively modest, and the V408M substitution has no apparent effect either on the 
predicted hydrogen bond between the nearby residue Tyr406 and the DNA backbone or on 
surface charge distribution (data not shown). Therefore, the effects of the V408M 
substitution on protein structure are milder than the other mutations which is consistent 
with the mild phenotype observed among subjects with this mutation. 
 
CONCLUSIONS 
Our systematic search for FOXP3 mutations in a large cohort of male probands 
with PNDM in whom the common causes had been excluded has shown that mutations 
are common in males who subsequently develop possible immune-mediated disorders (6 
of 10 [60%]) but are absent or very rare in those who have isolated diabetes (0 of 16 
[0%]). We show that there is clinical heterogeneity with three of the six mutation carriers 
having a severe phenotype and dying by 13 months, whereas the other three are still 
alive at 12–15 years. 
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We report on four different mutations, including three novel mutations. The 
previously reported single base pair deletion at position 227 generates a frameshift and 
introduces a premature stop codon. If the mutant mRNA evades nonsense mediated 
decay, the resulting protein would lack the forkhead as well as the zinc finger and the 
leucine zipper domains and is predicted to be completely inactive. Consistent with this 
null mutation, the patient presented with classic IPEX syndrome and died within the first 
year of life. The likely pathogenicity of the three novel missense mutations was explored 
by using molecular modeling software. All of them are located within the forkhead domain 
of FOXP3; their predicted structural effects are likely to alter function of the protein and 
can be broadly correlated with the observed phenotype. The pathogenicity of R337Q is 
further supported as a different substitution at position 337 (R337P) has previously been 
described in a patient with IPEX syndrome (19). A substitution of asparagine for aspartic 
acid at position 409 of FOXP3 (adjacent to the site of the V408M mutation) also produces 
IPEX syndrome (20). Thus, we believe that the three novel mutations are likely to be 
responsible for the observed phenotypes. 
Permanent diabetes was the presenting feature in the six patients with a FOXP3 
mutation, although age at diagnosis varied. There was no correlation between the age at 
presentation and the clinical outcome of the patients; however, there was a suggestion 
that low birth weight, a reflection of intrauterine insulin secretion, was a prognostic 
marker: two of the three patients who died within the first thirteen months of life as a 
result of a severe IPEX syndrome were born with severe intrauterine growth retardation. 
Low birth weight might be a marker of poor prognosis among patients with FOXP3 
mutations. 
Autoantibodies against β-cell antigens were only persistently found in one of our 
six affected children, and in this child they were not present at diagnosis, suggesting that 
the main pathogenic mechanism leading to β-cell destruction is mediated by activated T 
lymphocytes. A systematic investigation of all possible beta-cell autoantibodies was not 
performed in these children, and serum was not available for a retrospective analysis in a 
central laboratory. Therefore the complete lack of antibodies cannot definitely be 
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confirmed. However, our results show that antibodies against β-cell proteins as they are 
used in routine clinical practice may be absent in patients with proven FOXP3 mutations. 
Thus, the absence of pancreatic autoantibodies should not be taken as a screening test 
to exclude the possibility of a FOXP3 mutation. 
One patient with a classic IPEX syndrome only had a small remnant of pancreatic 
tissue seen on an abdominal MRI scan and had evidence of evolving exocrine pancreatic 
dysfunction, suggesting the development of pancreatic atrophy. Although both mild 
pancreatic exocrine insufficiency and a reduced pancreas volume are relatively common 
findings in long-standing classic type 1 diabetes they are not as severe as in this patient. 
It is possible that a massive autoimmune response against the pancreas might be 
responsible for both PNDM and pancreatic atrophy in this patient as seen in maternal 
enteroviral infection (21). 
There was considerable clinical heterogeneity among the patients with FOXP3 
mutations. Three patients with classic IPEX syndrome died during the first 13 months of 
life despite the use of immunosuppressive therapy. However, the phenotypic spectrum is 
extended from that previously described in the three patients with the V408M mutation. 
Permanent neonatal diabetes was the only clinical feature in two twin brothers from one 
of the pedigrees with this mutation until the age of 1 year, when autoimmune 
hypothyroidism was diagnosed in both of them. Subsequently, they both developed 
recurrent diarrhea, and autoimmune enteropathy was diagnosed on the basis of positive 
antienterocyte antibodies in both twins. They had multiple antibodies indicating 
gastrointestinal autoimmunity (Table 1). Twin IIa had a jejunal intestinal biopsy showing 
villous atrophy, but the second twin (IIb) had a normal jejunal biopsy. Interestingly, they 
both developed very well on a gluten-free diet. These patients are now 12 years old, and 
no other significant problems have been detected except that both have intellectual 
impairment (IQ of 74 and 80, respectively). The other patient with a V408M mutation has 
the mildest phenotype associated with a FOXP3 mutation to date. Although diabetes was 
diagnosed 2 days after birth, no other evidence of immune dysfunction has been detected 
apart from an episode of nephrotic proteinuria at 6 years. Clinical remission was achieved 
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on steroid treatment, and the disease has not relapsed. The patient is currently 15 years, 
and no other autoimmune problems have arisen since then. Nephrotic syndrome and 
classic type 1 diabetes can be associated, indicating a shared immunological basis for 
both disorders (22, 23), and nephrotic syndrome has previously been described in a 
patient with classic IPEX syndrome (24). We therefore believe there may be a causal link 
between both diabetes and nephrotic syndrome and the presence of the V408M mutation 
in our patient. 
IPEX syndrome is thought to be an extremely rare condition with only 
approximately 50 cases reported in the literature. As with any other X-linked recessive 
disorder with reduced survival, IPEX frequently presents as a single case either caused 
by de novo or maternally inherited mutations. Patients with a mild presentation are likely 
to have been under-reported, so the true incidence of the disease might actually be 
higher than is currently perceived. A clinical diagnosis of IPEX syndrome was made in 
only one of our patients prior to the genetic analysis, whereas the others were referred for 
genetic testing because of their PNDM. The varied clinical spectrum resulting from 
mutations in FOXP3 emphasizes the need of be aware of this possibility in male patients 
with PNDM who develop any other immune-mediated disorder later in life. 
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ABSTRACT 
Glucokinase deficiency is an unfrequent cause of permanent neonatal diabetes 
(PND), as only seven patients have been reported, either homozygous for a missense or 
frameshift mutation or compound heterozygous for both of them. We report here the first 
known case caused by a homozygous nonsense mutation (Y61X) in the glucokinase 
gene (GCK) that introduces a premature stop codon, generating a truncated protein that 
is predicted to be completely inactive as it lacks both the glucose- and the adenosine 
triphosphate-binding sites. The proband, born to consanguineous parents, was a full-
term, intrauterine growth-retarded male newborn who presented with a glycaemia of 129 
mg/dL (7.16 mmol/L) on his second day of life, increasing thereafter up to 288 mg/dL 
(15.98 mmol/L) and 530 mg/dL (29.41 mmol/L) over the next 24 h, in the face of low 
serum insulin (<3 mIU/mL; <20.83 pmol/L). He was put on insulin on the third day of life. 
Insulin has never been discontinued since then. The patient was tested negative for 
antiinsulin and islet cell antibodies at age 5 months. His father had nonprogressive, 
impaired fasting glucose for several years. The mother was found to be mildly 
hyperglycaemic only when her glucose was checked after the child was diagnosed. In 
conclusion, biallelic GCK loss should be considered as a potential cause of PND in 
children born to consanguineous parents, even if they are not known to be diabetic at the 
time of PND presentation. 
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INTRODUCTION 
There is increasing evidence indicating that most cases of insulin-requiring 
hyperglycaemia diagnosed in infants less than 6 months old must be considered as the 
consequence of underlying monogenic disorders until proven otherwise (1–4). The 
incidence of this condition, for which the term _monogenic diabetes of the infant’ has 
been proposed, seems to be higher than previously thought affecting approximately 1 in 
100,000 live births (4).  
The outcome of this condition is varied as some infants require insulin treatment 
for life (permanent neonatal diabetes, PND), whereas others present a remission 
(transient neonatal diabetes, TND) that may be either transient with subsequent 
recurrence around puberty or apparently permanent (5). TND is associated with 
imprinting abnormalities in chromosome 6 and, to a lesser extent, with mild activating 
mutations in either of the two genes encoding the adenosine triphosphate (ATP)-sensitive 
potassium channel of the beta cell, namely ABCC8 (encoding the SUR1 subunit) or 
KCNJ11 (encoding the Kir6.2 subunit) (2, 3). In contrast, PND is mainly produced by 
severe activating KCNJ11 mutations, although insulin gene mutations have been also 
recently reported as an important cause of PND (6), and ABCC8 mutations have been 
involved in a few cases (7). In addition, a number of other less frequent causes have 
been also described (8).  
It is well known that the glucose-sensing enzyme glucokinase (GCK, hexokinase 
4; E.C.2.7.1.2), encoded by glucokinase gene (GCK) (7p15.3–p15.1), plays a central role 
in glucose homeostasis. Activating heterozygous GCK mutations have been identified in 
several patients with persistent hyperinsulinemic hypoglycaemia of infancy, whereas 
inactivating heterozygous GCK mutations cause the mildest form of maturity-onset 
diabetes of the young, type 2 (MODY2) (9). In contrast, homozygous or compound 
heterozygous inactivating GCK mutations have been described in a few cases of PND 
(10–12).  
105 
Chapter 4 
We report a new case of PND caused by a complete GCK deficiency secondary 
to a homozygous GCK mutation and compare the patient’s clinical phenotype with those 
previously published. 
 
PATIENT REPORT 
A male newborn was admitted to the neonatal intensive care unit (NICU) because 
of respiratory distress and intrauterine growth restriction (IUGR). He was born at 41-wk 
gestation to an 18-yr-old primigravida woman by spontaneous vaginal delivery after an 
uncomplicated pregnancy. Thick meconium was noted during labour. Nevertheless, his 
Apgar scores were 8 and 9 at 1 and 5 min, respectively, and no resuscitation was 
necessary. Birth weight (BW) was 1800 g [-3.80 standard deviation scores (SDS)], length 
46 cm (-2.17 SDS) and head circumference 33 cm (-1.92 SDS). The infant developed 
mild respiratory distress, otherwise the physical examination shortly after birth was 
completely normal. 
On admission to the NICU, serum glucose concentration was low (37 mg/dL; 2.05 
mmol/L), and the infant was given 10% dextrose at a rate of 80 mL/kg/d (10 mg/kg/min). 
Respiratory distress improved spontaneously within the next few hours, and transient 
tachypnoea was considered to be the most likely diagnosis. By the second day of life, the 
glycaemia was 129 mg/dL (7.16 mmol/L). Subsequent glucose concentrations over the 
next 24 h increased to 288 mg/dL (15.98 mmol/L) and 530 mg/dL (29.41 mmol/L), and 
glycosuria without ketonuria was noted. Serum insulin concentration was low (<3 
mU/mL). At this time, the dextrose infusion rate was 12.5 mg/kg/min. The intravenous (IV) 
solution was changed to 5% dextrose, but the glycaemia remained high, and IV insulin 
was started on the third day of life (initial rate: 0.1 U/kg/h). By that time, the infant had 
passed several hypocholic stools and was noted to be mildly jaundiced. Serum 
conjugated bilirubin concentration was elevated (4.5 mg/dL, accounting for 85% of total 
serum bilirubin), and liver function tests were consistent with a cholestatic syndrome 
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(aspartate aminotransferase: 43 U/L, alanine aminotransferase: 44 U/L and g-glutamil 
transpeptidase: 216 U/L). He underwent several specific investigations (urine cultures, 
abdominal and brain ultrasound, ophthalmologic examination, skeletal X-ray survey, 
serologic tests for perinatal infections, metabolic and endocrine screening, serum a1-
antitrypsin and immunoreactive trypsinogen level, and serum total cholesterol), but none 
of them was informative, and the usual causes of neonatal cholestasis were ruled out. He 
was fed with an elementary formula and received treatment with phenobarbital for 7 d, 
after which cholestasis resolved. By age 23 d, the patient developed high temperature, 
poor feeding and poor reactivity and hyperglycaemia worsened. He received broad-
spectrum antibiotic treatment for 10 d as blood cultures turned positive for Escherichia 
coli infection. 
At the age of 1 month, the patient was transferred to subcutaneous insulin. Since 
then, the treatment was never discontinued. Fasting C-peptide level was 0.1 ng/mL at 3 
months of age (normal range: 0.3–5.4 ng/mL). By that time, the infant had experienced a 
significant catch-up growth [weight: 5,000 g (-1.87 SDS), length 57 cm (-1.62 SDS) and 
head circumference 39.5 cm (-1.05 SDS)]. Anti-insulin and islet cell antibodies were 
negative at age 5 months. An abdominal computerized tomography (CT) scanning 
performed at 8 months revealed a normal pancreas, thus excluding pancreatic agenesis 
as the cause of his PND. Basal (0.1 ng/mL, 1 month; 0.9 ng/mL, 9 months) and glucagon-
stimulated (0 min, 0.3 ng/mL; 6 min, 0.1 ng/mL; 22 months) C-peptide levels determined 
during the first 2 yr of life confirmed very low basal and stimulated endogenous insulin 
secretion. Because of poor family support and psychosocial difficulties, the infant was 
managed on an inpatient basis until he was 11.5 month old, when he was discharged on 
a twice-daily insulin regimen (0.8 U/kg/d). His weight was 8.815 g (-0.98 SDS), his length 
72.5 cm (-0.55 SDS) and his head circumference 45 cm (-1.65 SDS). Psychomotor 
development was considered completely normal. During admission, he suffered a 
number of infections as follows: otitis, bronchiolitis and pneumonia at 5 months; urinary 
tract infection at 6 months; parotitis at 8 months and gastroenteritis at 11 months. A 
voiding cystourethrogram was normal, and vesicoureteral reflux was excluded. His 
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postnatal growth and pubertal development and progress were normal: Tanner II at age 
12.2 yr; height 147 cm (-0.08 SDS), BW 37.6 kg (-0.26 SD); Tanner IV at age 16.8 yr; 
height 167 cm (-1.09 SDS) and BW 62 kg (-0.33 SDS). The patient is currently 17 yr old. 
Excluding diabetes, he is otherwise a healthy adolescent with no chronic complications 
related to diabetes. Optimal metabolic control has never been achieved, mainly because 
of poor compliance with diet and insulin treatment, but it improved after glargine 
introduction when the child was 13 yr old (mean HbA1c ± SDS: 9.6 ± 1.3% vs. 7.9 ± 0.5% 
before and after glargine, respectively). He has presented to the emergency room on 
several occasions with moderate to severe hypoglycaemia. Neither hepatic dysfunction 
nor frequent infections have been present since the first hospital discharge. Current 
insulin dose is 1.26 U/kg/d (40% as glargine at bedtime and 60% as aspart analogue 
before meals). No alternative or simultaneous treatment with sulfonylureas has been 
attempted. 
The family tree reveals parental consanguinity (paternal and maternal great 
grandmothers were siblings; Figure 1). Several relatives on both sides have mild fasting 
hyperglycaemia that does not need any treatment (Figure 1), resembling a MODY2 
phenotype. 
 
Figure 1. Family pedigree showing co-segregation of hyperglycaemia and Y61X mutation in GCK. 
Mutation status is denoted by M for mutant allele and n for normal allele. 
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Figure 2. (A) Denaturing high performance liquid chromatography analysis of the GCK exon 2-
including amplicon of all family members and a control showing the specific chromatographic 
profiles for the wild-type allele (control) and the homozygous and  heterozygous carriers of the 
c.183C>A mutation at 62.8ºC. (B) Direct sequencing of GCK exon 2 showing the homozygous and 
heterozygous nonsense mutation TAC>TAA resulting in the premature stop codon Y61X. 
 
The coexistence in this patient of PND, parental consanguinity and a family 
history of mild hyperglycaemia prompted us to look for mutations in GCK. The study was 
approved by the local Ethics Committee. After obtaining written informed consent from 
the affected subject(s) and/or parents, DNA was extracted from peripheral lymphocytes 
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from the patient and several relatives, as previously described (13). The coding 
sequences, intron–exon boundaries and known regulatory regions of GCK were amplified 
by PCR using specific primers and screened for mutations by denaturing high 
performance liquid chromatography (DHPLC) (Transgenomic Wave 3500HT, 
Transgenomic Inc, Omaha, NE, USA), and subsequent sequencing of any identified 
heteroduplex or homoduplex variant was performed using the BigDye Terminator V3.1 kit 
(Applied Biosystems, Foster City, CA, USA) on a ABI 3100 Genetic analyzer. Further 
information on primer sequences and DHPLC conditions is available upon request. The 
proband was found to be homozygous for a nonsense GCK mutation located in exon 2, 
c.183C>A (TAC>TAA; Y61X), which introduces a premature stop codon at position 61 
(Figure 2). Both parents and several hyperglycaemic relatives from whom DNA was 
available were heterozygous for the mutation, thus showing that the mutation co-
segregated with mild hyperglycaemia in the heterozygous status (Figures 1 and 2). 
 
DISCUSSION 
Here, we describe a patient with PND caused by a homozygous nonsense Y61X 
mutation in GCK. The mutation introduces a premature stop codon at position 61, 
generating a truncated protein that is predicted to be completely inactive as it lacks both 
the glucose- and the ATP-binding sites. The mutation affects both the hepatic and the 
neuroendocrine isoforms of the enzyme for which the patient must be considered as 
having a complete GCK deficiency. The same mutation has been recently reported in a 
Spanish MODY2 family in the heterozygous state. The mutation co-segregated with the 
phenotype and was not present in 200 control chromosomes (14). 
Since its first description in 2001 (10), complete GCK deficiency has been 
previously described in only seven patients (Table 1). Although, early-onset neonatal 
diabetes and IUGR were present in all of them, our patient showed some unique and 
interesting features. First, hypoglycaemia developed shortly after birth. This could be 
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explained by the fact that both insulin and hepatic GCK (lacking in our patient) are 
necessary for prenatal glycogen accumulation in the liver. It is well accepted that hepatic 
glycogenolysis is the main source of glucose for the newborn immediately after birth, 
before oral feeding is successfully established (15). In accordance with this, there is a 
significant reduction in liver glycogen stores in GCK-deficient knockout mouse (16). 
Moreover, meconium-stained amniotic fluid indicates some foetal distress, which is 
considered a further risk factor for early neonatal hypoglycaemia (17). 
 
 
Table 1. Reported patients with permanent neonatal diabetes caused by complete glucokinase 
deficiency. GA: gestational age; BW: birth weight. 
 
Second, our patient developed transient unexplained cholestasis. Although PND 
and biliary tract malformations can coexist (18), this seems not to be the case as 
abdominal ultrasound and CT scans did not detect any abnormality. However, perinatal 
asphyxia has been associated with TND (19). Recurrent hypoglycaemia and unexplained 
neonatal cholestasis can be also found in patients with hypopituitarism (20). However, the 
patient’s postnatal growth and pubertal development were normal, which excludes this 
possibility. 
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Whether GCK deficiency in tissues other than pancreas and liver has any 
functional relevance in these patient remains to be explored. Hypothalamic and pituitary 
GCK activity is especially interesting in this respect. Counter-regulatory hormonal 
response to hypoglycaemia is activated at a higher plasma glucose concentration in 
MODY2 patients (21), which could provide a relative protection against the development 
of severe hypoglycaemia. This has not yet been studied in detail in humans with 
complete GCK deficiency in whom the set point for hypoglycaemia counterregulation may 
be even higher. However, serum glucagons levels have been reported to be either in the 
upper normal or above the normal range in the face of hyperglycaemia in three of the 
studied patients, which indicates an excessive production of this hormone by GCK-
expressing pancreatic α-cells. Although attempts to selectively abolish hypothalamic GCK 
activity in mice have failed, it has been shown that GCK haploinsufficiency does affect 
reproductive function and energy metabolism in mice (22). Our patient has presented with 
severe hypoglycaemia several times, and his pubertal development has been completely 
normal. Unfortunately, our patient’s lack of interest in participating in further clinical 
studies impeded us to perform a more in-depth evaluation of this case. 
As GCK is considered a key element of the glucose-stimulated insulin release, 
patients with PND caused by biallelic GCK loss have been thought to need insulin 
injections for life. Nevertheless, although no sulfonylurea treatment could be attempted in 
our patient, high dose glibenclamide treatment has been recently shown to stimulate 
endogenous basal insulin secretion and to improve metabolic control in a patient with 
PND caused by a homozygous GCK mutation, though the need for insulin persisted (23). 
Furthermore, Bakri et al. recently reported the case of a patient presenting with 
compound heterozygous GCK mutations, in whom one of the alleles probably retains 
certain enzymatic activity, who was successfully transferred to repaglinide (24). Also, the 
therapeutic use of GCK activators is being studied for use in patients with type 2 diabetes 
(25), and might offer some benefit for selected patients with GKC-related PND and 
complete although dysfunctional GCK proteins. 
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In summary, we present a new case of PND associated to a complete GCK 
deficiency caused by a homozygous nonsense mutation in GCK. Although biallelic GCK 
loss accounts only for a small fraction of patients with PND (26, 27), it must be 
considered as a potential cause, especially when both parents have mild hyperglycaemia 
and consanguinity is present. As MODY2 is usually a silent disorder, testing fasting blood 
glucose in the parents of every infant with neonatal diabetes should be a must, even if 
there is not a family history of known diabetes (12). 
 
ACKNOWLEDGMENTS 
The authors would like to thank all the participants in this study. This work was 
supported by grants from the “Fondo de Investigación Sanitaria” (PI021663; PI0690459 
to A. C.-B) and “Fundación Endocrinología y Nutrición”. O. R.-C is a recipient of a “Ayuda 
para contratos post Formación Sanitaria Especializada” from the Instituto de Salud 
Carlos III (FIS CM06/00013). A. C.-B was supported by an investigator award from the 
“Fondo de Investigación Sanitaria’ (FIS 00/3145). 
 
113 
Chapter 4 
REFERENCES 
1. Hattersley A, Bruining J, Shield J, Njølstad P, Donaghue K; International Society for Pediatric 
and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2006–2007. The 
diagnosis and management of monogenic diabetes in children. Pediatr Diabetes. 2006; 7: 352–
360 (Erratum in: Pediatr Diabetes. 2007; 8: 49). 
2. Flanagan SE, Patch AM, Mackay DJ, Edghill EL, Gloyn AL, Robinson D, Shield JP, Temple K, 
Ellard S, Hattersley AT. Mutations in KATP channel genes cause transient neonatal diabetes 
and permanent diabetes in childhood and adulthood. Diabetes. 2007; 56: 1930–1937. 
3. Vaxillaire M, Dechaume A, Busiah K, Cavé H, Pereira S, Scharfmann R, de Nanclares GP, 
Castano L, Froguel P, Polak M; SUR1-Neonatal Diabetes Study Group. New ABCC8 mutations 
in relapsing neonatal diabetes and clinical features. Diabetes. 2007; 56: 1737–1741. 
4. Sperling MA. ATP-sensitive potassium channels – neonatal diabetes mellitus and beyond. N 
Engl J Med. 2006; 355: 507–510. 
5. von Muhlendahl KE, Herkenhoff H. Long-term course of neonatal diabetes. N Engl J Med. 
1995; 333: 704–708. 
6. Støy J, Edghill EL, Flanagan SE, Ye H, Paz VP, Pluzhnikov A, Below JE, Hayes MG, Cox NJ, 
Lipkind GM, Lipton RB, Greeley SA, Patch AM, Ellard S, Steiner DF, Hattersley AT, Philipson 
LH, Bell GI; Neonatal Diabetes International Collaborative Group. Insulin gene mutations as a 
cause of permanent neonatal diabetes. Proc Natl Acad Sci U S A. 2007; 104: 15040–15044. 
7. Stanik J, Gasperikova D, Paskova M, Barak L, Javorkova J, Jancova E, Ciljakova M, Hlava P, 
Michalek J, Flanagan SE, Pearson E, Hattersley AT, Ellard S, Klimes I. Prevalence of 
permanent neonatal diabetes in Slovakia and successful replacement of insulin with 
sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers. J Clin Endocrinol Metab. 2007; 
92: 1276–1282. 
8. Shield JP. Neonatal diabetes: how research unravelling the genetic puzzle has both widened 
our understanding of pancreatic development whilst improving children’s quality of life. Horm 
Res. 2007; 67: 77–83. 
9. Gloyn AL. Glucokinase (GCK) mutations in hyperand hypoglycemia: maturity-onset diabetes of 
the young, permanent neonatal diabetes, and hyperinsulinemia of infancy. Hum Mutat. 2003; 
22: 353–362. 
114 
Homozygous nonsense GCK mutation in permanent neonatal diabetes 
10. Njølstad PR, Søvik O, Cuesta-Muñoz A, Bjørkhaug L, Massa O, Barbetti F, Undlien DE, Shiota 
C, Magnuson MA, Molven A, Matschinsky FM, Bell GI. Neonatal diabetes mellitus due to 
complete glucokinase deficiency. N Engl J Med. 2001; 344: 1588–1592. 
11. Njølstad PR, Sagen JV, Bjørkhaug L, Odili S, Shehadeh N, Bakry D, Sarici SU, Alpay F, 
Molnes J, Molven A, Søvik O, Matschinsky FM. Permanent neonatal diabetes caused by 
glucokinase deficiency: inborn error of the glucose-insulin signaling pathway. Diabetes. 2003; 
52: 2854–2860. 
12. Porter JR, Shaw NJ, Barrett TG, Hattersley AT, Ellard S, Gloyn AL. Permanent neonatal 
diabetes in an Asian infant. J Pediatr. 2005; 146: 131–133. 
13. Nicolaides NC, Stoeckert CJ Jr. A simple, efficient method for the separate isolation of RNA 
and DNA from the same cells. Biotechniques. 1990; 8: 154–156. 
14. Estalella I, Rica I, Perez de Nanclares G, Bilbao JR, Vazquez JA, San Pedro JI, Busturia MA, 
Castaño L; Spanish MODY Group. Mutations in GCK and HNF-1alpha explain the majority of 
cases with clinical diagnosis of MODY in Spain. Clin Endocrinol. 2007; 67: 538–546. 
15. Cowett RM, Farrag HM. Selected principles of perinatal-neonatal glucose metabolism. Semin 
Neonatol. 2004; 9: 37–47. 
16. Grupe A, Hultgren B, Ryan A, Ma YH, Bauer M, Stewart TA.Transgenic knockouts reveal a 
critical requirement for pancreatic beta cell glucokinase in maintaining glucose homeostasis. 
Cell. 1995; 83: 69–78. 
17. Cowett RM, Loughead JL. Neonatal glucose metabolism: differential diagnoses, evaluation, 
and treatment of hypoglycemia. Neonatal Netw. 2002; 21: 9–19. 
18. Mitchell J, Punthakee Z, Lo B, Bernard C, Chong K, Newman C, Cartier L, Desilets V, Cutz E, 
Hansen IL, Riley P, Polychronakos C. Neonatal diabetes, with hypoplastic pancreas, intestinal 
atresia and gall bladder hypoplasia: search  or the aetiology of a new autosomal recessive 
syndrome. Diabetologia. 2004; 47: 2160–2167. 
19. Vajro P, Paludetto R, Decurtis M. Transient neonatal cholestasis and perinatal asphyxia. J 
Pediatr. 1999; 134: 795. 
20. Choo-Kang LR, Sun CC, Counts DR. Cholestasis and hypoglycemia: manifestations of 
congenital anterior hypopituitarism. J Clin Endocrinol Metab. 1996; 81: 2786–2789. 
21. Guenat E, Seematter G, Philippe J, Temler E, Jequier E, Tappy L. Counterregulatory 
responses to hypoglycemia in patients with glucokinase gene mutations. Diabetes Metab. 
2000; 26: 377–384. 
115 
Chapter 4 
22. Yang XJ, Mastaitis J, Mizuno T, Mobbs CV. Glucokinase regulates reproductive function, 
glucocorticoid secretion, food intake, and hypothalamic gene expression. Endocrinology. 2007; 
148: 1928–1932. 
23. Turkkahraman D, Bircan I, Tribble ND, Akçurin S, Ellard S, Gloyn AL. Permanent neonatal 
diabetes caused by a novel glucokinase gene mutation, and initial response to oral 
sulfonylurea therapy. Horm Res. 2007; 68 (Suppl.1): 42. 
24. Bakri D, Gershoni-Baruch R, Shehadeh N. Permanent neonatal diabetes. Isr Med Assoc J. 
2004; 6: 290–291. 
25. Matschinsky FM, Magnuson MA, Zelent D, Jetton TL, Doliba N, Han Y, Taub R, Grimsby J. 
The network of glucokinase-expressing cells in glucose homeostasis and the potential of 
glucokinase activators for diabetes therapy. Diabetes. 2006; 55: 1–12. 
26. Gloyn AL, Ellard S, Shield JP, Temple IK, Mackay DJ, Polak M, Barrett T, Hattersley AT. 
Complete glucokinase deficiency is not a common cause of permanent neonatal diabetes. 
Diabetologia. 2002; 45: 290. 
27. Vaxillaire M, Samson C, Cavé H, Metz C, Froguel P, Polak M. Glucokinase gene mutations are 
not a common cause of permanent neonatal diabetes in France. Diabetologia. 2002; 45: 454–
455. 
 
116 
 CHAPTER 5 
Wolcott-Rallison syndrome is the most common 
genetic cause of permanent neonatal diabetes in 
consanguineous families 
 
 
Rubio-Cabezas O1,2, Patch A-M1, Minton JAL1, Flanagan SE1, Edghill EL1, 
Hussain K3, Balafrej A4, Deeb A5, Buchanan CR6, Jefferson IG7, Mutair A8, 
the Neonatal Diabetes International Collaborative Group9, Hattersley AT1, 
Ellard S1. 
 
1 Institute of Biomedical and Clinical Science, Peninsula Medical School, Exeter, UK 
2 Department of Endocrinology, Hospital Infantil Universitario Niño Jesus, Madrid, Spain 
3 Department of Endocrinology, Great Ormond Street Hospital for Children, London, UK 
4 Pediatric Diabetes Clinic, Children's Hospital, Rabat, Morocco 
5 Imperial College London Diabetes Centre, Abu Dhabi, UAE 
6 Child Health, King's College Hospital NHS Trust, London, United Kingdom 
7 Department of Pediatrics, Sheikh Khalifa Medical City, Abu Dhabi, UAE 
8 Department of Pediatrics, King Abdulaziz Medical City, Riyadh, Kingdom of Saudi 
Arabia 
 
# Members of the Neonatal Diabetes International Collaborative Group (in alphabetical 
order): Mohammed A. Albalwi, Jamal Aljubeh, Abdulrahman Alswaid, Ibrahim 
Alwan, Hisham Arabi, Christopher Bennett, Ruveyde Bundak, Laura Davis-
Keppen, Ilse Engelsberger, Betul Ersoy, Tulay Guran, Abdelhadi Habeb, Sujatha 
Jagadeesh, Jackie Jones, Iwar Klimes, Ahmed Massoud, Anne Millward, 
117 
Chapter 5 
Nadezda Misovicova, Bayram Özhan, Katja Schaaf, Seema Thakur, Doga 
Turkkahrman, Ishwar C. Verma, Marja Wessels. 
 
Accepted for publication in the Journal of Clinical Endocrinology and 
Metabolism. 
118 
EIF2AK3 mutations in permanent neonatal diabetes 
Author contributions: S.E., and A.T.H. designed research; O.R-C., A-M.P., J.A.L.M., 
S.E.F., E.L.E., K.H., A.B., A.D., C.R.B., I.G.J., A.M., and the Neonatal Diabetes 
International Collaborative Group performed research; O. R-C. A-M:P., and S.E. analyzed 
data; and O.R-C, S.E., and A.T.H. wrote the paper. 
119 

EIF2AK3 mutations in permanent neonatal diabetes 
ABSTRACT 
Context and Objective: Mutations in EIF2AK3 cause Wolcott-Rallison syndrome (WRS), 
a rare recessive disorder characterized by early-onset diabetes, skeletal abnormalities 
and liver dysfunction. Although early diagnosis is important for clinical management, 
genetic testing is generally performed after the full clinical picture develops. We aimed to 
identify patients with WRS before any other abnormalities apart from diabetes are present 
and to study the overall frequency of WRS among patients with permanent neonatal 
diabetes. 
Research Design and Methods: The coding regions of EIF2AK3 were sequenced in 34 
probands with infancy-onset diabetes with a clinical phenotype suggestive of WRS (n=28) 
or homozygosity at the WRS locus (n=6).  
Results: 25 probands (73.5%) were homozygous or compound heterozygous for 
mutations in EIF2AK3. Twenty of the 26 mutations identified were novel. Whilst a 
diagnosis of WRS was suspected before genetic testing in 22 probands, three patients 
with apparently isolated diabetes were diagnosed after identifying a large homozygous 
region encompassing EIF2AK3. In contrast to non-consanguineous pedigrees, mutations 
in EIF2AK3 are the most common known genetic cause of diabetes among patients born 
to consanguineous parents (24% vs. <2%). Age at diabetes onset and birth weight might 
be used to prioritize genetic testing in the latter group. 
Conclusions: WRS is the commonest cause of PNDM in consanguineous pedigrees. 
Besides testing patients with a definite clinical diagnosis, EIF2AK3 should be tested in 
patients with isolated neonatal diabetes diagnosed after 3 weeks of age from known 
consanguineous families, isolated populations or countries where inbreeding is frequent. 
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INTRODUCTION 
Wolcott-Rallison syndrome (WRS, OMIM #226980) is a rare autosomal recessive 
multi-systemic disorder due to biallelic mutations in EIF2AK3, the gene encoding the 
eukaryotic translation initiation factor 2-α kinase 3 (1). This transmembrane enzyme, also 
known as PERK or PEK, localizes exclusively in the endoplasmic reticulum (ER) and it is 
activated by the accumulation of unfolded proteins in the ER lumen during stress, 
resulting in phosphorylation of the α-subunit of the eukaryotic initiation factor 2 (eIF2α) at 
residue Ser51 and down-regulation of protein synthesis (2). Lack of PERK activity leads 
to cell death by apoptosis in a number of different tissues, as clearly shown in two 
independent knockout mice (3, 4). The high level expression of EIF2AK3 in both beta 
cells and bone tissue (4) explains the development of early-onset diabetes mellitus and 
skeletal abnormalities in virtually all patients with WRS, and hence their association is 
considered a cornerstone for diagnosing this rare clinical entity (5-7). However, the gene 
is expressed at lower levels in several other tissues which determines a number of other 
inconsistently present features (8, 9). Importantly, most patients develop chronic or 
intermittent acute liver dysfunction sometimes leading to hepatic failure. Genetic testing 
for this condition is usually delayed until the full clinical picture is evident and a clinical 
diagnosis of WRS made (9). 
Permanent diabetes mellitus diagnosed within the first 6 months of life 
(permanent neonatal diabetes, PNDM) is a rare disorder likely to be monogenic rather 
than autoimmune (10, 11). It is estimated to affect approximately 1 in 215,000 live births 
(12). Most patients have heterozygous activating mutations in the KCNJ11 and ABCC8 
genes encoding potassium ATP channel subunits Kir6.2 (13) and SUR1 (14, 15) or 
heterozygous mutations in the preproinsulin (INS) gene (16-17). In addition, a number of 
rare recessive causes of PNDM have been described, including INS (18), ABCC8 (19), 
GCK (20), IPF1 (21), PTF1A (22), GLIS3 (23), SLC2A2 (24), and SLC19A2 (25). 
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Homozygosity mapping, performed by total genome scan with polymorphic 
markers in individuals whose parents are related, has been extensively used to identify 
the gene responsible for a recessive disorder. It assumes that a homozygous mutation in 
a recessive disease gene segregates twice to the affected child from a common ancestor 
through both the maternal and the paternal lines and is hence “identical by descent 
(IBD)”. The homozygous mutation will be embedded in a chromosomal segment which 
has not undergone recombination. Therefore SNP (single nucleotide polymorphism) 
markers in that segment will also be homozygous by descent (26). This short segment of 
homozygosity by descent can be easily detected and will harbor the disease gene. 
Taking into account that WRS is a recessive disorder in which diabetes is generally the 
first manifestation to occur, we hypothesized that homozygosity mapping could be a 
powerful genetic tool to identify candidates for EIF2AK3 sequencing among infants with 
isolated permanent neonatal diabetes (PNDM) and reported parental consanguinity. 
We report the successful use of homozygosity mapping for early molecular 
diagnosis of WRS. In addition, we describe the clinical and genetic findings in the largest 
international cohort of WRS cases assembled to date. 
 
MATERIALS AND METHODS 
This study was conducted in accordance with the Declaration of Helsinki and 
informed consent was obtained from all patients, with parental consent given on behalf of 
children. 
Study population 
All patients were referred to the Exeter Molecular Genetics Laboratory (UK) for 
testing. Clinical information was obtained using a standardized questionnaire from 
hospital records. Parental consanguinity was defined as parents being 2nd cousins or 
closer. A total of 34 probands were tested for EIF2AK3 mutations. These included 28 
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probands with a suspected diagnosis of WRS on the basis of early-onset diabetes (within 
the first 15 months of age) and either skeletal dysplasia and/or unexplained liver 
dysfunction, and six consanguineous probands with isolated PNDM at referral in whom 
the most common genetic causes of diabetes had been previously excluded (including 
KCNJ11 and ABCC8 in all of them, INS in 5, and GCK in 4) and a large (9.22–67.64 Mb) 
region of homozygosity encompassing the EIF2AK3 gene on chromosome 2  had been 
identified (see below). 
Homozygosity mapping 
Genotyping was carried out on the Affymetrix human 10K Xba and 50K Hind 
mapping SNP chips by Medical Solutions Nottingham (formerly GeneService), UK, or the 
Affymetrix 5.0 mapping chip by ALMAC Diagnostics Carigavon, Northern Ireland. 
Processing of genomic DNA was performed as per the Affymetrix protocol and the mean 
SNP call rate was 98.7%. In house Perl scripts were developed to automatically identify 
genomic homozygous segments for the 10K chip, defined by at least 20 consecutive 
homozygous SNPs marking a region that exceeded 3 cM (27). These thresholds were 
empirically extended to the larger chips identifying any region >3 Mb delimited by 
consecutive homozygous SNP calls, allowing for a maximum of 2 heterozygous SNPs per 
100 calls. All regions for each case were assigned a rank, in descending size order.  
EIF2AK3 gene analysis 
Genomic DNA was extracted from peripheral leukocytes using standard 
procedures. The coding exons and the intron-exon boundaries of the EIF2AK3 gene were 
PCR-amplified; primers and conditions are available upon request. Sequence specific 
primers for each amplicon were tagged with 5’ M13 tails to allow sequencing to be 
performed with a “universal” M13 primer. Single strand sequencing was carried out using 
standard methods on an ABI 3730 (Applied Biosystems, Warrington, UK). Sequences 
were compared to the published template (accession number AF110146.1) using 
Mutation Surveyor v3.20 (SoftGenetics, PA, USA). Any changes in the sequence were 
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checked against published polymorphisms and mutations and for conservation across 
species. Sequence variants were tested for their presence in family members whenever a 
DNA sample was available. 
Further molecular testing in probands with EIF2AK3 mutations  
In case of proband 3021-1, we used a panel of microsatellites for chromosome 20 
(D20S482, D20S851, D20S477, D20S107, D20S481, D20S171) to confirm family 
relationships. An alternate set of exon 11 primers were also designed to amplify across 
the original set of exon 11 specific primers, to exclude allelic drop out. We then designed 
a Multiplex Ligation-dependent Probe Amplification (MLPA) assay to quantify the number 
of copies of EIF2AK3. We used synthetic oligonucleotide probes for EIF2AK3 exons 10-
12 with HNF1A and HNF4A as control probes (method previously described by Ellard et 
al. (28)). To investigate uniparental isodisomy, a panel of microsatellite markers flanking 
EIF2AK3 on chromosome 2p11.2-q11.2 (D2S2368, D2S139, D2S2333, D2S388, 
D2S2216, D2S2181, D2S2154, D2S113 and D2S2264) was used. The same set of 
microsatellite markers was also used to explore relatedness between probands 3377-1 
and 3750-1. 
Other genetic testing in patients from consanguineous pedigrees 
The common genetic causes of PNDM were tested in 591 patients diagnosed 
with diabetes within the first 6 months after birth. KCNJ11 (NM_000525), ABCC8 
(NM_000352.2), and INS (NM_000207) were screened in all of the patients. GCK 
(NM_000162.2) testing was limited to those patients born to consanguineous parents in 
whom a homozygous region encompassing the gene on chromosome 7 had been 
identified using the mapping chips (see above). Genetic analysis was performed as 
described above for EIF2AK3. 
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Statistical analysis 
Clinical numeric data is given as median and interquartile range (IQR). Standard 
deviation scores (SDS) for birth weights were calculated by comparing to the Child 
Growth Foundation LMS data (29). The clinical features of the patients were analyzed 
using Kruskal-Wallis and Mann Whitney-U tests, and Spearman correlation coefficient in 
the statistical package SPSS version 15.0 (Chicago, USA). χ2 test was used to compare 
the frequencies of the different genetic subtypes of PNDM in consanguineous and non-
consanguineous pedigrees. 
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RESULTS 
Molecular genetic findings 
We identified 26 different EIF2AK3 mutations in 25 probands (Table 1). Figure 1 
displays the pedigrees of the 5 families with more than one affected individual. Twenty-
three probands had a homozygous mutation and two were heterozygous for two different 
mutations. Six mutations had previously been described and 20 mutations were novel, 
including nonsense (n=8), frameshift (n=7), missense (n=4), and splicing (n=1) mutations. 
Twenty-three probands had private mutations. The same homozygous mutation (R587X) 
was present in two probands from Turkey and the possibility of a founder effect could not 
be excluded by a combination of intragenic SNP and microsatellite analysis. 
 
 
Figure 1. Pedigrees for families with more than one affected individual. Solid black filled shapes 
represent patients with Wolcott-Rallison syndrome. An arrow indicates the proband. The genotype 
is shown underneath each symbol; M and N denote mutant and normal alleles, respectively. ID: 
family identification number. 
128 
 EIF2AK3 mutations in permanent neonatal diabetes 
 
Table 1. Mutation data. 
 
The predicted effect of the different mutations on the EIF2AK3 protein is shown in 
Figure 2. The nonsense and frameshift mutations were distributed throughout the gene. 
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They are predicted to result in truncated proteins missing all or part of the catalytic 
domain and hence expected to lead to a complete loss of function. Pathogenicity of the 4 
novel missense variants (F592L, R632W, I650T and G985R) was suggested by a) 
homozygosity or compound heterozygosity for the variant in affected individuals within 
families, b) no unaffected family members were homozygous or compound heterozygotes 
for the variant(s), c) location in one of the two serine/threonine protein kinase domains, 
and d) conservation of the amino-acid residues involved across species (including 
chimpanzee, rat, mouse, dog, chicken, Tetraodon, fruitfly, and C. elegans). One patient 
was homozygous for an intronic variant that changes the splice donor site of exon 14 
from GTGAG to GGTGAG and is likely to be pathogenic, either by a direct effect on 
splicing leading to exon skipping or retention or by incorporating an extra base in exon 14 
that would result in a frameshift mutation. 
DNA was available from the parents of 16 probands. All unaffected parents were 
heterozygous carriers except for the father of 3021-1. The unaffected mother was 
heterozygous for the F592L mutation. Microsatellite marker analysis confirmed family 
relationships (results not shown). To determine the genetic mechanism of disease we 
excluded allelic-drop out (due to a SNP under the original primers) by re-sequencing 
exon 11 with an alternate set of specific primers. A paternally-inherited heterozygous 
deletion was also excluded by MLPA (data not shown). Further analysis using 
microsatellites flanking EIF2AK3 (chr2p13.3-2q11.2) showed segmental maternal 
uniparental isodisomy for a minimal ~446Kb region encompassing the EIF2AK3 gene 
(Figure 3). 
No mutations in EIF2AK3 were identified in six patients with a suggestive 
phenotype (3 with early-onset diabetes and skeletal dysplasia, and 3 with diabetes and 
liver dysfunction; none of them from consanguineous descent) and in further 3 
consanguineous probands with isolated PNDM. 
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Figure 2. Summary of the effect of all the mutations identified to date on the EIF2AK3 protein 
(modified from reference 9). The structure of the EIF2AK3 protein is illustrated in the upper part of 
the chart, with the regulatory (dotted bar) and the two conserved serine/threonine protein kinase 
subdomains (squared bars) in the catalytic domain indicated. Novel mutations identified in this 
study are depicted in italics. Missense mutations are grouped directly under the region involved. 
The bars in the lower part of the chart indicate the extent of the EIF2AK3 mutant proteins, with the 
black portion representing abnormal amino acid sequence secondary to frameshift mutations. 
Further three other EIF2AK3 mutations have been identified, including two splicing mutations 
(c.2981+1G>A and c.2981+1dupG, the latter in the present study) and a 184-bp deletion in 
exon15/intron 15. 
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Figure 3. Microsatellite markers analysis in family 3021. The solid black filled circle 
represents the proband with Wolcott-Rallison syndrome. The genotype is shown underneath 
each symbol; M and N denote mutant and normal alleles, respectively. The table shows 
genotype analyses of family members using 9 microsatellite markers around EIF2AK3 on 
chromosome 2; the disease-relevant mutation is shown in italics. Apparent homozygosity 
for the informative marker D2S2216 in the proband indicated maternal segmental isodisomy 
for chromosome 2 (bold). 
 
Clinical features 
Twenty-two of the 25 probands with biallelic mutations in EIF2AK3 were selected 
for genetic testing because of a clinical phenotype suggesting WRS. The remaining 3 
were tested following the identification of a large homozygous region in chromosome 2 
encompassing the EIF2AK3 gene (Table 2, Supplementary Table 1). At the time of this 
study, three probands had died aged between 7 and 14 months (a further affected 
relative wasdeceased at 4 years of age due to an unrelated condition, Supplementary 
Table 1). The median age of the remaining ones was 4.95 years (range: 1.2 - 32.3). The 
phenotype of the parents and heterozygous siblings was unremarkable. 
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Table 2. Clinical features at time of referral for patients with a proven genetic diagnosis. Data is 
generally given as median (IQR). Age at death is given as full range. 
 
All probands first presented with permanent diabetes mellitus, at a median age of 
10.5 weeks (IQR: 6.0 - 19.3). The earliest presentation was at 3 weeks and all patients 
but one were diagnosed within or slightly after the first 6 months of life. The only patient 
diagnosed after 1 year of age (14 months) is homozygous for a missense I650T mutation. 
There are no differences in age at diabetes onset among the different types of mutation 
(p=0.46). Although patients with WRS have a reduced birth weight (median: –1.4 SDS, 
IQR: –2.1 to –0.6), intrauterine growth retardation defined as a birth weight at or below –2 
SDS was present only in 7 of 20 patients for whom that information was available. There 
was no significant correlation between birth weight and age at diagnosis of diabetes 
(ρ=0.33, p=0.16). All patients are currently on full-replacement insulin doses, suggesting 
endogenous insulin secretion is negligible. 
In addition to diabetes, skeletal abnormalities (mostly spondyloepiphyseal 
dysplasia) were initially reported by the referring clinician in probands from 13 families 
making the clinical diagnosis of WRS likely. Probands with skeletal abnormalities at 
referral did not differ from patients without in terms of either birth weight (p=0.73) or age 
at diabetes onset (p=0.87). However, they were significantly older at molecular testing 
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[median age: 6.6 years (IQR: 4.0-10.8) vs. 1.4 years (IQR: 0.9-1.8), p=0.02]. Nine further 
probands were tested because of the association of early-onset diabetes and liver 
dysfunction ranging from mild hypertransaminasemia to acute liver failure requiring a 
transplant. Although none of them presented clinically evident skeletal abnormalities at 
referral, they have become evident after molecular diagnosis in at least 2 cases. Major 
hepatic dysfunction was often accompanied by acute multiorgan failure (encephalopathy, 
renal failure, bone marrow failure) and sometimes resulted in the patient’s death. Hepatic 
and renal functions usually returned to normal in patients who survived. Residual 
cerebellar signs (ataxia, dysarthria) were found in two patients after recovery from an 
acute encephalopathic episode. The oldest patient in the series, currently aged 32 years, 
is the only one having chronic renal failure and erythropoietin-dependent anemia; the 
remaining patients are currently 15 years old or younger. Pancreatic exocrine 
insufficiency requiring supplemental enzymes was present in two patients, with severe 
pancreatic hypoplasia reported in one of them. 
Three consanguineous patients with isolated PNDM received a molecular 
diagnosis between 0.8 and 1.6 years following the identification of a large homozygous 
region encompassing EIF2AK3. One of them, currently aged 1.6 years, has not 
presented any other features of WRS as yet. Another one was found to have 
hepatomegaly and irregular fragmented epiphyses shortly after the molecular diagnosis 
was made at 1.2 years. The third one has developed the full clinical picture of WRS by 
the age of 3 years, including liver dysfunction identified at 1 year and skeletal 
abnormalities at 2 years. Interestingly, he was also diagnosed with primary 
hypothyroidism at 1.4 years but this may not be related to the EIF2AK3 mutation. 
Known parental consanguinity was reported in 17 of the 25 families; affected 
individuals from all of them have a homozygous EIF2AK3 mutation. Two probands were 
compound heterozygotes for two different mutations and a third was homozygous for an 
EIF2AK3 mutation as a result of segmental uniparental isodisomy of chromosome 2. The 
remaining 5 probands were homozygous for an EIF2AK3 mutation. Three originate from 
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countries with high rates of consanguinity (Turkey and Saudi Arabia) (32) and the other 
two are from relatively isolated populations (Kosovo and South Dakota, USA). 
Prevalence of Wolcott-Rallison syndrome among patients with PNDM  
Mutations in EIF2AK3 account for 15 of 63 (23.8%) consanguineous probands 
with PNDM tested in the Exeter laboratory. WRS is the most common known genetic 
cause of PNDM in consanguineous pedigrees, followed by recessive mutations in INS 
(12.7%), GCK (11.1%), and ABCC8 (6.3%). This is in contrast to non-consanguineous 
families, where WRS accounts for only 8 of 583 cases (1.4%, p=7 x 10-20). Heterozygous 
mutations in KCNJ11, ABCC8 and INS, the most common genetic causes of PNDM in 
non-consanguineous pedigrees (36.9%), are responsible for only 4.8% of PNDM cases in 
consanguineous families (p=3 x 10-7). 
 
 
Figure 4. Age at diabetes onset (panel A) and adjusted birth weight (panel B) in the four most 
common recessive genetic causes of PNDM. There is no significant difference in age at 
presentation between EIF2AK3 and ABCC8 (p=0.60). However, patients with EIF2AK3 mutations 
are diagnosed with diabetes later than those with INS or GCK mutations (p=0.001 and p=0.009, 
respectively). Similarly, birth weight in EIF2AK3 mutation carriers was slightly reduced and 
comparable to that of patients with a mutation in ABCC8 (p=0.63) but significantly higher than birth 
weight of patients with recessive INS and GCK mutations (p=0.001 and p=0.001, respectively). 
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We compared the age at diagnosis of diabetes and birth weight of the 29 patients 
with EIF2AK3 mutations with the three other most frequent forms of recessive PNDM 
from the Exeter cohort, including 18 patients with ABCC8 mutations, 14 with INS 
mutations, and 8 with GCK mutations (Figure 4). There was a strong association of the 
genotype with both age at diagnosis of diabetes (p=0.000005) and birth weight adjusted 
by gestational age (p=0.000001). Patients with EIF2AK3 mutations were not different 
from patients with recessive ABCC8 mutations either in terms of age at diabetes onset or 
birth weight. However, they showed less severe intrauterine growth retardation and were 
diagnosed later than patients with recessive INS or GCK mutations. 
 
DISCUSSION 
We report the largest series of WRS assembled to date. Overall, a molecular 
diagnosis of WRS has been confirmed in 25 families. Twenty of the 26 mutations (77%) 
identified are novel. Most cases were selected for genetic testing following diagnosis of 
skeletal dysplasia and/or unexplained liver dysfunction in a patient with a previous 
diagnosis of neonatal or infancy-onset diabetes. However, a homozygosity mapping 
approach allowed the identification of three patients before any other abnormalities apart 
from diabetes became evident. 
Genetic testing for mutations in EIF2AK3 is usually delayed until the full clinical 
picture of Wolcott-Rallison syndrome is evident (9). As each intercurrent illness can 
potentially be complicated by acute liver and/or renal failure, this diagnostic delay might 
be responsible for the poor outcome of some patients who develop unexplained acute 
multi-organ failure during minor intercurrent illnesses and may explain that WRS 
syndrome may go unnoticed when the evolution is rapidly fatal before the skeletal 
involvement is evident (6, 33). Early diagnosis of WRS is important because it allows the 
anticipation of potential complications during concomitant situations such as acute illness, 
trauma, or major surgery (34). For this purpose, radiological screening for epiphyseal 
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abnormalities in any infant with diabetes has been recommended (34). However, this 
approach would lead to a high number of unnecessary X-ray surveys in infants with 
diabetes, among whom WRS is still a relatively rare condition. Moreover, in most 
spondyloephiphyseal or multiple epiphyseal dysplasias the bone lesions are discovered 
only after the first year of life, and sometimes even later (6), which argues against the 
potential benefit of a radiological screening method for WRS. Homozygosity mapping has 
been previously used for positional cloning of unknown genes producing a recessive 
disorder, but this is the first time it has been used for early diagnosis of a recessive 
disease before the full clinical picture is present. 
In contrast to nonsense and frameshift mutations spread throughout the gene, 
missense mutations have only been identified within or nearby each of the two Ser/Thr 
protein kinase domains of the catalytic domain. This underscores the important functional 
role of these domains. Missense variants in other parts of the gene might be either very 
well tolerated or contribute to a less severe phenotype with later onset diabetes or milder 
skeletal abnormalities. In keeping with this possibility, Senée et al. (9) reported a patient 
with a homozygous N655K mutation in EIF2AK3 who presented with diabetes at a 
relatively late age (2.5 yr). Functional studies showed that the mutation is hypomorphic so 
that the mutated protein still had some residual kinase activity. We identified a proband 
homozygous for an I650T mutation who also had a late onset of diabetes at 14 months. 
However, this patient developed acute liver failure requiring liver transplantation at 2 
years, so a later onset of diabetes clearly does not predict a milder phenotype of the 
disease. Furthermore, skeletal abnormalities are not evident in our patient with the F592L 
mutation even though she is 32 years old and has developed many of the acute 
complications of WRS. The severity of the different clinical manifestations of WRS is 
largely independent of the genotype. 
The majority of probands (88%) were homozygous for EIF2AK3 mutations and 
were from known consanguineous pedigrees, isolated populations or countries where 
consanguinity is frequent (32). We report the first case of uniparental isodisomy for an 
EIF2AK3 mutation in a patient who inherited the mutation only from her mother. This 
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emphasizes the importance of testing parents of patients with recessive disorders in 
order to offer an accurate genetic counseling as the risk of recurrence is almost negligible 
in this case. However, lack of reported consanguinity should not be used as an exclusion 
criterion for EIF2AK3 testing in the presence of a typical clinical presentation as genetic 
mechanisms other than homozygosity may be encountered in patients with WRS. 
We have shown that birth weight and age at diabetes onset can discriminate 
between EIF2AK3 and other genetic subtypes of neonatal diabetes in consanguineous 
probands. Whilst patients with WRS usually have a normal or mildly reduced birth weight 
and are diagnosed with diabetes after the first 3 weeks of life, patients born with severe 
intrauterine growth retardation (birth weight below –2 SDS for gestational age) or 
diagnosed with diabetes within the first 3 weeks of life are more likely to have biallelic INS 
or GCK mutations. 
In summary, EIF2AK3 mutations are the most common cause of PNDM in 
consanguineous pedigrees. Besides testing patients with a definite clinical diagnosis of 
Wolcott-Rallison syndrome, we recommend that analysis of the EIF2AK3 gene is 
considered in patients with isolated neonatal diabetes diagnosed after 3 weeks of age 
from known consanguineous pedigrees, isolated populations or countries where 
inbreeding is frequent. 
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ABSTRACT 
Heterozygous coding mutations in the INS gene that encodes preproinsulin were 
recently shown to be an important cause of permanent neonatal diabetes. These 
dominantly acting mutations prevent normal folding of proinsulin which leads to β-cell 
death through ER stress and apoptosis. We now report 10 different recessive INS 
mutations in 15 probands with neonatal diabetes. Functional studies showed that 
recessive mutations resulted in diabetes due to decreased insulin biosynthesis through 
distinct mechanisms including gene deletion, lack of the translation initiation signal, and 
altered mRNA stability due to the disruption of a polyadenylation signal. A subset of 
recessive mutations caused abnormal INS transcription, including the deletion of the C1 
and E1 cis regulatory elements, or 3 different single base-pair substitutions in a CC 
dinucleotide sequence which was so far not known to be essential for INS promoter 
activity. In keeping with an earlier and more severe β-cell defect, patients with recessive 
INS mutations had a lower birth weight (-3.2 SDS vs. -2.0 SDS) and were diagnosed 
earlier (median 1 week vs. 10 weeks) compared to those with dominant INS mutations. 
Mutations in the insulin gene can therefore result in neonatal diabetes as a result of two 
contrasting pathogenic mechanisms. Moreover the recessively inherited mutations 
provide a genetic demonstration of the essential role of multiple elements that regulate 
the biosynthesis of insulin in man. 
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INTRODUCTION 
Neonatal diabetes is diagnosed within the first 6 months of life (1, 2) and there 
are two main clinical subtypes: the persistent, permanent neonatal diabetes (PNDM) and 
the remitting and frequently relapsing, transient neonatal diabetes (TNDM). Recently 
there have been considerable advances in the understanding of the genetics of neonatal 
diabetes (3). Most patients with PNDM have activating mutations in KCNJ11 or ABCC8, 
the genes encoding the potassium ATP-sensitive (KATP) channel subunits Kir6.2 (4) and 
SUR1 (5-7), or heterozygous mutations in the preproinsulin (INS) gene (8-12). In 
contrast, abnormalities in chromosome 6q24 are the most common cause of TNDM (13), 
followed by mutations in the KCNJ11 and ABCC8 genes (14). Despite these advances 
the etiology of neonatal diabetes is still not known in at least 30% of patients with PNDM, 
suggesting other genetic causes are still to be found (9). 
Insulin is secreted from islet beta cells of the pancreas. Insulin biosynthesis and 
secretion are tightly regulated to maintain blood glucose levels within a narrow 
physiological range. Insufficient secretion of insulin results in hyperglycemia and 
diabetes, whereas excessive secretion results in hypoglycemia. The synthesis of insulin 
is tightly regulated. Extensive studies have dissected an array of cis sequence elements 
in the INS promoter region and their cognate DNA binding factors, which together ensure 
the cellular specificity and rate of INS transcription (15-22). In addition, insulin 
biosynthesis is strongly dependent on posttranscriptional regulatory mechanisms, 
including the modulation of translation and mRNA stability (23-25). The latter is largely 
mediated through sequences located in the untranslated regions of INS transcripts (26-
28). 
Heterozygous missense mutations in the coding region of the INS gene have 
recently been described as a cause of neonatal diabetes (8-12). Most of the reported 
mutations are predicted to disrupt the folding of the proinsulin molecule. The resulting 
misfolded protein accumulates in the endoplasmic reticulum (ER), resulting in ER stress 
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and beta cell apoptosis (29, 30). An alternative potential genetic mechanism would be 
reduced insulin secretion due to a disruption of the INS coding sequence, as seen in the 
double Ins1 and Ins2 knockout mouse (31), or of the sequences that regulate insulin 
biosynthesis. However, this has so far not been demonstrated in humans. 
We report, for the first time, recessively acting mutations within the INS gene in a 
series of patients with neonatal diabetes. In contrast to the previously described dominant 
mutations, these mutations reduce insulin synthesis and thus represent a novel 
pathogenic mechanism for human diabetes. These mutations also provide genetic 
evidence for the essential role of distinct nucleotide sequences in the regulation of the 
human preproinsulin gene. 
 
MATERIAL AND METHODS 
Cohort characteristics 
We studied an international cohort of 122 unrelated patients (69 males) with 
diabetes diagnosed before 6 months (median age 4 weeks) and without a known genetic 
etiology, which were referred to the Exeter (n=110) or Bilbao laboratories (n=12). Thirteen 
patients were offspring of consanguineous parents (2nd degree relatives or closer). In the 
101 probands with PNDM we excluded mutations in KCNJ11, ABCC8, GCK and 
previously described heterozygous coding mutations in INS (9). In the 21 patients with 
TNDM we excluded 6q24 anomalies, KCNJ11 and ABBC8 mutations. Babies born before 
33 weeks of gestation were excluded in order to avoid hyperglycemia of prematurity. 
Studies were approved by local ethics committees. Informed consent was obtained from 
all patients or their parents and the studies were conducted in line with the Declaration of 
Helsinki. Clinical data was obtained from the patients’ clinical records. We calculated 
standard deviation scores (SDS) for birth weight (32). 
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Molecular genetic analysis 
Genomic DNA was extracted from peripheral leukocytes using standard 
procedures. Regulatory elements up to 450 bp upstream of the transcriptional start site 
and exons 1-3 of the INS gene (Figure 1) were amplified by the polymerase chain 
reaction (PCR) in three amplicons (primers and conditions available on request). 
Unidirectional sequencing was carried out on an ABI3730 (Applied Biosystems, 
Warrington, UK) and analyzed using Mutation Surveyor v3.20. Sequences were 
compared to the published sequence (Ensembl sequence ENSG00000129965) and 
published polymorphisms. The genomic reference sequence nucleotide 1 is the 
transcriptional start site (g.1A or c.-238A) whilst the translational start site is located at 
g.238 (c.1). Mutation nomenclature is shown in compliance with HGVS, where nucleotide 
1 represents the A of the translational start site codon ATG (c.1). Suspected mutations 
were tested for conservation across species and co-segregation within families. Putative 
gene deletions were investigated using Multiplex Ligation dependent Probe Amplification 
(MLPA) assay oligonucleotide probes specific for the three exons of INS (see 
Supplementary Methods). 
 
Figure 1. A schematic of the INS gene showing the 10 mutations identified in 15 families. Positions 
of point mutations are indicated below the exons, whilst deletions are shown above the gene. The 
blue shaded regions are non-coding, the red text indicates a deletion, the blue text are non-coding 
mutations and the green are coding mutations. The precise breakpoints of the multiexonic deletion 
are not known; the solid line represents the minimal deleted region. Mutation nomenclature is 
based on the coding sequence where nucleotide 1 represents translational start site. 
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Functional studies 
Investigating the effect of INS promoter mutations on transcriptional activity 
To determine the functional impact of the c.-331(C>G, C>A) and c.-332C>G 
mutations we performed site-directed mutagenesis of an INS promoter firefly luciferase 
reporter construct (251hINS-Luc), and compared the activity of control and mutated 
promoters in MIN6 β-cells and control cell lines, using a Renilla luciferase minimal 
promoter (pGL4.75) (see Supplementary Methods). 
Investigating the effect of the translation initiation mutations (c.3G>T and c.3G>A) 
To determine the effect of these mutations on insulin production we transfected 
HeLa cells, which do not express insulin, with wild type or mutant INS and analysed 
intracellular insulin content using radio-immunoassay (see Supplementary Methods). 
Investigating the effect of the c.*59A>G mutation on mRNA stability 
We determined the effect of the c.*59A>G mutation on insulin mRNA stability 
using real time-PCR to measure the relative levels of the INS mRNA transcripts in a 
heterozygous lymphoblastoid cell line derived from the proband’s mother. We used a 
heterozygous SNP, rs3842753, to identify the mutation bearing allele (see 
Supplementary Methods). 
Statistical analysis 
Clinical numeric data is given as median (interquartile range). Functional data is 
given as mean (standard error). The clinical features of patients were compared using 
Kruskal Wallis, χ2 (Fisher´s exact) or Mann Whitney-U tests in the statistical package 
SPSS version 13 (Chicago, USA). Student’s t-test or analysis of variance was used for 
expression studies. 
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RESULTS 
Recessive INS mutations cause neonatal diabetes 
We sequenced 122 unrelated probands with diabetes diagnosed before 6 months 
(13 offspring of consanguineous parents) in whom the known common genetic causes 
had been excluded. We identified 10 different INS recessive mutations in 15 unrelated 
families (Figures 1 and 2). Nine of the 15 pedigrees are known to be consanguineous as 
parents were second cousins or closer. Four homozygous mutations affected the coding 
region: c.184C>T (p.Q62X), c.3G>T (p.0?), c.3G>A (p.0?), and a large deletion that 
removes a segment of the promoter, exon 1 and coding exon 2 of INS (c.-370-
?_186+?del). Five homozygous mutations were found in regulatory regions: c.-331C>A (2 
families), c.-331C>G (5 families), c.-218A>C, and a 24 base pair deletion (c.-366_-
343del) are located in the promoter region, whereas c.*59A>G is within the 3’ 
untranslated region. One proband was a compound heterozygote for two regulatory 
region mutations, c.-331C>G and c.-332C>G. 
The mutations were inherited in a recessive manner either homozygous or 
compound heterozygous with heterozygous carrier parents being unaffected (Figure 2). 
In keeping with the recessive inheritance, 9 of the 15 probands are born to 
consanguineous parents. Pathogenicity of mutations was suggested by conservation 
across species and absence of variants in controls (see Supplementary results). 
Recessive INS mutations uncover essential regulatory sequences in man 
Further support for the pathogenicity of mutations came from known function of 
mutated residues and functional studies (Figure 3, Figure 4 and Supplementary results). 
Multiple mutation mechanisms were involved in the recessive INS mutations which are 
described briefly below: 
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Figure 2. Partial pedigrees of the 15 families with recessive INS mutations. (N=Normal allele, M= 
Mutation, Del=Deletion). Solid black filled shapes represent patients with permanent neonatal 
diabetes, gray filled shapes represent patients with transient neonatal diabetes and shapes filled 
with diagonal lines represent those patients diagnosed with diabetes after 6 months of age. Age at 
diagnosis and remission (where applicable) is shown below the symbols. 
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Figure 3. Functional evidence for the pathogenicity of recessive promoter INS mutations. (a) 
Schematic of the genomic sequence of the INS promoter structure with major cis regulatory 
elements, and the sequence context of mutated elements in several mammalian species that do not 
exhibit major divergence in these regions. Mutated bases are highlighted in red. The numbering of 
promoter landmarks is relative to the transcription start site (genomic numbering, where g.1 is 
equivalent to c.-238) consistent with the convention used in previous studies. Mutations are 
described according to HGVS guidelines (http://www.hgvs.org/mutnomen/) (cDNA numbering 
according to the translational start site where c.1 is equivalent to g.238), and distance to the 
transcription start site is shown in parenthesis. (b) Evidence for loss-of-function of the c.-331(C>G, 
C>A) and c.-332C>G mutations. Firefly luciferase expression is compared in constructs containing 
the wild type (WT) INS promoter sequence (INS WT), or c.-331 C>G, c.-331 C>A, c.-332 C>G 
mutations, after transfection in MIN6 β-cells. Data shown are means (+SE) from three independent 
constructs for each mutation, each performed in triplicate. Results are corrected for transfection 
efficiency using a vector that constitutively expresses Renilla luciferase, and expressed relative to 
the INS WT results. The asterisks denote P<0.001 in ANOVA for the difference between INS WT 
and mutant constructs. 
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Figure 4. Functional evidence for the pathogenicity of recessive INS mutations affecting translation 
and mRNA stability. (a) Homozygous mutations in the translation initiation codon of the INS gene 
result in reduced insulin content of transfected HeLa cells. The insulin content of HeLa cells was 
measured by radioimmunoassay after transfection with wild type insulin (INS WT) or either of two 
INS mutant constructs, as shown. Both nucleotide changes were identified in patients with 
permanent neonatal diabetes. Non-specific values obtained with HeLa cells transfected with empty 
vector were subtracted from all samples and those data are presented as mean +/- SE (n=3 
replicates). (b) Allele-specific quantitative real-time PCR of c.*59A>G and normal transcripts. The 
graph shows the relative abundance of the wild type and mutant RNA transcripts in mutant and 
normal cell lines. The rs3842753 A allele tags the c.*59A (wild type, shown in green), whilst the 
c.*59G (mutant) was tagged by rs3842753 C allele (blue). The graph shows the level of transcripts 
in the control sample heterozygous only for rs3842753 and in the maternal sample (family DM1165) 
which is heterozygous for both rs3842753 and c.*59A/G. The level of the mutant transcript is 
reduced to less than 3 x 10-4 per cent compared to the normal transcript in the heterozygous 
c.*59A>G cell line. Experimental error as calculated from the standard deviation (SD) of the 
replicate experiments is indicated. The SD for the quantification of the c.*59G allele in the maternal 
sample is 3x10-6, and thus the experimental error is not visible in the figure. 
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• Truncated proteins: The nonsense mutation (p.Q62X) is predicted to give rise 
to a mutant protein that is truncated within the C peptide region and will lack 
the insulin A chain. 
• Promoter mutations: The (c.-366_-343del) 24 base pair deletion abolishes 
the INS promoter evolutionary conserved C1 and E1 elements, where MAFA 
and NEUROD1 bind, respectively (16, 20, 33) (Figure 3A). The c.-218A>C 
mutation disrupts the CRE3 site that interacts with multiple DNA binding 
proteins in vitro (22) (Figure 3A). All of these elements have been previously 
shown to be critically important for the INS promoter activity in transient 
transfection studies (15, 18, 34-36). The c.-331(C>G, C>A) and c.-332C>G 
mutations were located in a more poorly characterized segment of the INS 
promoter situated between the E1 and A1 elements (Figure 3A). This 
sequence is conserved amongst a subset of mammalian species (Figure 3A). 
No interacting protein complex has been reported in binding studies that 
examined this region (17, 37), although a 3 base pair mutation that includes 
the 3’ cytosine of this dinucleotide and two other nucleotides located further 
3‘ partially impairs insulin promoter activity (37). We constructed insulin 
promoter fragments carrying the c.-331(C>G, C>A) and c.-332C>G mutations 
and showed up to 90% reduction in transcriptional activity (Figure 3B) in 
pancreatic beta-cell lines. Thus, the CC dinucleotide that is mutated in 8 
unrelated probands with neonatal diabetes forms part of a positive cis 
regulatory sequence of the INS promoter. 
• Mutated or absent translational start site: The two point mutations (c.3G>A 
and c.3G>T) at the first methionine residue (p.Met1) abolish the native 
translation initiation site for the preproinsulin protein. Quantification of total 
INS mRNA levels by real-time PCR revealed no differences in mRNA 
abundance for c.3G>A or c.3G>T mutations compared with the wild type. The 
insulin content of HeLa cells transfected with these mutations was reduced 
by 86% and 79% for c.3G>A and c.3G>T, respectively, compared to cells 
transfected with the wild type sequence (Figure 4A and Supplementary 
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results). The multi-exon deletion (exons 1 and 2) removes over half the 
coding region including the translational start site and is expected to be a null 
mutation. 
• Altered mRNA stability through a mutation in the 3’ untranslated region: The 
c.*59A>G mutation is located in the polyadenylation signal of the 3’ 
untranslated region and potentially impairs mRNA stability. In a heterozygous 
lymphoblastoid cell line generated from the proband’s mother the mutant 
mRNA transcript was present at a very low level compared to the wild type 
allele. This is consistent with reduced mRNA stability (see Figure 4B and 
Supplementary results). 
Clinical phenotype of patients with recessive INS mutations 
The clinical characteristics of patients with recessive INS mutations are shown in 
Table 1 (and Supplementary results). In keeping with the known actions of insulin before 
and after birth, the phenotype was limited to markedly reduced fetal growth and diabetes. 
 
Table 1. Comparison of clinical characteristics in patients with isolated neonatal diabetes with 
recessive and dominant INS mutations. Data are median (interquartile range). NA: not applicable. 
 
The diabetes phenotype within the families is shown in Figure 2. Nineteen 
patients had neonatal diabetes (15 probands and 4 family members); 14 had PNDM and 
were treated with insulin from diagnosis, whilst 5 patients had TNDM having gone into 
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remission at a median age of 12 weeks (IQR 11, 22). Birth weight was markedly reduced 
in all patients with neonatal diabetes resulting from recessive mutations [median birth 
weight 1680 g (1420, 2050) which is -3.2 SDS (-4.1, -2.6)]. In keeping with more severe 
insulin deficiency, patients with PNDM had a more severe intrauterine growth retardation 
[median SDS for birth weight -3.9 (-4.4, -2.8) vs. -1.8 (-3.4, -0.9) in TNDM, p=0.03] and 
diabetes was diagnosed earlier [2 days (1, 9.5) vs. 24 days (5, 62), p=0.04] 
(Supplementary results). All patients with mutations that altered the coding region or 
mRNA stability had PNDM. The noncoding promoter mutations were associated with both 
PNDM and TNDM. 
Differences in the clinical phenotype with recessive and dominant INS mutations 
To identify if the different mutation mechanisms in the same gene resulted in 
phenotypic differences we compared the clinical characteristics of patients with neonatal 
diabetes due to recessive INS mutations with patients with the previously identified 
dominant mutations in INS (Table 1). Patients with neonatal diabetes resulting from 
recessive INS mutations had a markedly different phenotype with lower birth weight 
[median SDS score -3.2 (IQR -4.1, -2.6) vs. -2.0 (-2.5, -1.0), p <0.001] and an earlier age 
of diagnosis [median age in weeks 1 (0, 3) vs. 10 (5, 22), p<0.001]. TNDM is only seen in 
patients with recessive mutations (26 vs. 0%, p=0.001). 
 
DISCUSSION 
We have shown that recessively acting mutations in the preproinsulin gene (INS) 
are a novel cause of neonatal diabetes. They act by reducing synthesis of the 
preproinsulin peptide due to a truncated protein, abnormal transcription, reduced mRNA 
stability or disrupted translation. These mutations usually cause PNDM but may manifest 
as TNDM or diabetes outside the neonatal period. In keeping with the recessive 
inheritance, many probands (60%) were the offspring of consanguineous parents. 
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The clinical manifestations of recessive INS mutations reflect the consequences 
of insulin deficiency in humans during pre- and postnatal life. The birth weight was 
markedly reduced [median SDS score -3.2 (-4.1, -2.6)], consistent with the major role of 
insulin in fetal growth. The early onset of neonatal diabetes (median 1 week) reflects 
severe insulin deficiency postnatally. In contrast to many other subtypes of neonatal 
diabetes, there are no extrapancreatic features. 
Differences in the underlying pathophysiology explain why patients with recessive 
INS mutations are diagnosed earlier and have a lower birth weight than patients with 
heterozygous INS mutations (8-12). The disrupted insulin synthesis seen with recessive 
mutations occurs as soon as the fetal beta cell starts to secrete insulin. In contrast insulin 
secretion is required before beta cell dysfunction develops in patients with heterozygous 
mutations which result in misfolding of the preproinsulin peptide, accumulation of the 
misfolded protein in the endoplasmic reticulum (ER) and hence the destruction of the 
beta-cell through ER stress. These two distinct disease mechanisms are supported by 
phenotypic studies in mouse models, where reduced insulin secretion at birth or 
progressive ER stress and cell death have been described in mice carrying analogous 
recessive or dominant mutations, respectively (30, 31, 38). 
The majority of the patients with neonatal diabetes have PNDM, but 26% (5/19) 
have TNDM. TNDM is only found in patients with non-coding mutations and they have a 
higher birth weight and are diagnosed later. This is consistent with TNDM resulting from a 
less severe insulin deficiency, and is comparable to the situation with mutations in the 
Kir6.2 subunit of the KATP mutations (39) where TNDM mutations have less severe 
functional consequences. The mechanism of remission in recessive INS mutation carriers 
is not understood but is likely to reflect a variation in demand or the ability of the beta-cell 
to meet this demand as a similar timing of remission is seen in some patients with less 
severe mutations resulting in channelopathies (14, 39) and pancreatic developmental 
defects (40, 41). 
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The mutations identified in this study illustrate multiple mechanisms by which 
insulin biosynthesis can be disrupted. These include absent/altered translation due to 
coding sequence deletions or mutations, reduced transcription due to mutations of the 
promoter, or abnormal mRNA stability. Our functional studies established that the 3’ UTR 
mutation that abolishes the polyadenylation signal results in severe RNA instability and 
that the initiation codon mutations result in reduced transcription of the preproinsulin 
gene. The promoter mutations are highly informative because they provide human 
genetic evidence that discrete INS cis regulatory elements are essential. Numerous 
studies have demonstrated that multiple cis elements are required for the activity of 
episomal INS reporter constructs in cultured cells (15, 17-19, 21, 22). However, it is not 
known if each of those cis elements is truly necessary in vivo, because such studies can 
only partially predict their function in the integrated chromatin environment of true 
differentiated cells. Studies in other selected genes have addressed this by targeted 
deletion of transcriptional regulatory elements in mice (42). We have now established for 
the first time that the C1/E1, CC, and CRE3 elements are essential for INS gene 
transcription in humans. The discovery of 3 separate mutations that target the CC 
dinucleotide sequence is particularly significant. One earlier study reported that an 
artificial 3 base pair mutation that disrupts one C nucleotide of this element leads to a 
partial decrease of INS promoter activity (37). However, the CC element or its 
surrounding sequence have not been thoroughly characterized, and it is not recognized 
as an essential regulatory element of the INS promoter (21, 22) The importance of the 
CC and CRE3 cis elements for insulin biosynthesis warrant the need to identify the DNA 
binding factors that act through these elements. 
In conclusion we have shown that homozygous INS mutations are a novel cause 
of neonatal diabetes. The mutations result in reduced synthesis of the insulin peptide 
through a variety of mechanisms and may yield further insights into the regulation of 
insulin biosynthesis. 
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SUPPLEMENTARY INFORMATION 
Supplementary Methods 
Gene dosage analysis using Multiplex Ligation dependent Probe Amplification (MLPA)  
We designed MLPA assay oligonucleotide probes (supplementary table 1) to 
measure the number of copies of INS exons 1-3 using probes for HNF1A and HNF4A as 
controls (method previously described by (1). 
Methodology for the investigation of the effect of promoter mutations on insulin gene 
promoter activity  
A plasmid containing nucleotides -489 to -228 of the human insulin gene 
promoter linked to the firefly luciferase gene (Dr Roland Stein, Vanderbilt University) was 
used to perform site-directed mutagenesis with the QuickChange kit (Stratagene, Texas). 
This plasmid is named -251hINS-Luc plasmid because it includes nucleotides -251 to +10 
according to a previous reference sequence (2). Three independent mutations were 
created for each base substitution. They were verified by direct sequencing, and assayed 
in transient transfection assays in triplicate on two separate occasions as described (3). 
Mouse 10T/2 fibroblasts and MIN6 β cells were trypsinized 14 hours before transfection, 
distributed into 12-well plates (3×104 cells/well) and maintained in DMEM supplemented 
with 15% FBS. Cells were transfected with promoter-luciferase or empty vector plasmid 
DNA (300 ng) using Lipofectamine 2000 (Invitrogen). pGL4.75[hRluc/CMV] (10 ng) was 
added to control for transfection efficiency. Firefly and Renilla luciferase were assayed 
with the Dual-Luciferase Reporter Assay System (Promega), and the ratios were 
expressed relative to the wild type insulin promoter values.  
 
Methodology for investigating the effect of the translation initiation codon mutations 
(c.3G>T and c.3G>A)  
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DNA encoding wild-type INS and both mutant forms of INS-p.0?,c.3G>T and 
c.3G>A, were cloned into pcDNA 3.1/myc-His A. Correct insertion was verified by 
sequencing of the plasmids. 4x106 HeLa cells were cotransfected with 8μg pcDNA 3.1 
and 8 μg pMAX GFP using Nucleofector technology (Amaxa/Lonza) according to the 
manufacturer’s instructions. GFP expression was examined by fluorescence microscopy 
to monitor transfection efficiency. Control cells were transfected with empty pcDNA3.1 
vector. 
Non insulin expressing HeLa cells were cultured in DMEM Glutamax medium 
(Gibco Life Technologies, Paisley, UK) supplemented with 5% FBS, 100 units/ml 
penicillin and 100μg/ml streptomycin at 37°C in a fully humidified atmosphere of 5% CO2. 
To rule out an effect of these mutations on mRNA stability, we quantified the 
amount of INS mRNA relative to the Beta-2-microglobulin (B2M) gene in transfected cells. 
Total RNA was extracted from approximately 1X106 EBV-transformed lymphoblastoid 
cells) using the Perfect RNA Mini RNA kit (Eppendorf, Hamburg, Germany). 4.5 μg mRNA 
was treated with 1u of RNAse-free DNAse (TURBO DNAse kit, Ambion, UK) 30 minutes 
at 37ºC followed by 85ºC for 5 minutes for nuclease inactivation. Complementary DNA 
(cDNA) was synthesized from mRNA using the Thermoscript RT-PCR system (Life 
Technologies, Paisley, UK) with an incubation temperature of 50°C and a random 
hexamer primer. PCR products were detected by the use of a probe situated across the 
boundary of exons 2 and 3 to ensure amplification from cDNA rather than genomic DNA 
(forward primer; CGGGAGGCAGAGGACCT, reverse primer; AGGCTGCCTGCACCAG, 
probe; 6FAM- ACCTGCCCCACCTGC-MGB). Reactions contained 5 μl TaqMan Fast 
Universal PCR Master Mix, no AmpErase™, 0.9 μM each primer and 0.25 μM probe in a 
total volume of 10 μl on the ABI prism 7900HT platform (Applied Biosystems, Warrington, 
UK). Amplification conditions were a single cycle of 95ºC for 20 seconds followed by 60 
cycles of 95ºC for 1 second and 60ºC for 20 seconds. The results given are an average 
of quantifications from three replicate amplifications. 
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Expression levels of the mutant and wild type transcripts were measured by 
comparing the number of cycles at which the INS and B2M PCR products cross a specific 
threshold. The relative abundance is defined by the difference in number of cycles to 
achieve the same quantity of product and calculated using the equation 2-ΔΔCt, where 
ΔΔCt is the difference between the crossing points ΔCttest) in a test sample normalised to 
a reference sample (ΔCtref) (Applied Biosystems, Foster City, USA (4)). Differences in the 
mRNA abundance for wild-type and mutant transcripts were examined for statistical 
significance by Kruskal Wallis test. 
The insulin content of transfected HeLa cells was determined 24 hours post-
transfection by radioimmunoassay. Briefly, cells were lysed in 200μl of acidified ethanol 
(0.8M HCl:98% ethanol mixed in a ratio of 1:3) for 2 hours at -20°C and samples then 
neutralized by addition of NaOH.  In triplicate, 50μl of each experimental sample or 
crystalline recombinant human insulin standard was mixed with 50μl of 125I insulin (Linco; 
diluted to yield approximately 2000 cpm/50µl) and 50μl Guinea Pig anti-bovine insulin 
antibody (ICN) diluted 1:20000 in insulin assay buffer (IAB; 150mM NaCl, 30mM 
Na2HPO4, 10mM KH2PO4, 10mM EDTA, 5mg/ml bovine serum albumin, pH 7.4). Tubes 
were incubated at 4°C overnight before addition of 50 μl of donkey anti-Guinea Pig 
coated cellulose beads (IDS Ltd, Tyne and Wear, UK) (diluted 1:1 with IAB). After 
incubation for 1h, 2ml dH2O was added and tubes centrifuged for 5 minutes at 1000g. 
The supernatant was aspirated under vacuum and the radioactivity retained in each pellet 
measured on a WALLAC gamma counter. The insulin content of each sample was then 
calculated by reference to a standard curve constructed with recombinant human insulin. 
Methodology for investigating the effect of the c.*59A>G mutation on mRNA stability  
Cell lines were established from peripheral blood lymphocytes derived from the 
proband’s heterozygous mother (DM1165) and an unaffected control by EBV 
transformation. Cell lines were maintained in 1X RPMI-1640 (Gibco Life Technologies, 
Paisley, UK), supplemented with 10% fetal calf serum (Gibco Life Technologies, Paisley, 
UK). 
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Total RNA was extracted from approximately 1 X 106 EBV-transformed 
lymphoblastoid cells) using the Perfect RNA Mini RNA kit (Eppendorf, Hamburg, 
Germany). 4.5g mRNA was treated with 1u of RNAse-free DNAse (TURBO DNAse kit, 
Ambion, UK) 30 minutes at 37ºC followed by 85ºC for 5 minutes for nuclease inactivation. 
Complementary DNA (cDNA) was synthesized from mRNA using the Thermoscript RT-
PCR system (Life Technologies, Paisley, UK) with an incubation temperature of 50°C and 
a random hexamer primer. 
Ectopic mRNA transcripts were amplified from lymphoblastoid cells using a single 
tube TaqMan™ approach. It was not possible to design probes for the c.*59A>G mutation 
due to its location at the extreme 3’ end of the transcript. Instead we utilized a 
heterozygous single nucleotide polymorphism (rs3842753) located 37 nucleotides 
upstream of the poly-A tail to differentiate the mutation-bearing and normal transcripts. 
Probe and primer sequences were designed to this variant and validated by standard 
curve analysis [Forward – 5’ ggagaactactgcaactagac 3’, Reverse – 5’ 
catctctctcggtgcaggag 3’, Probe (WT) – VIC-cagccccAcacccg-MGB, Probe (MT) – 6-FAM-
agccccCcacccg-MGB]. 
2l cDNA from the proband’s mother (heterozygous for c.*59A>G and rs3842753) was 
used for real-time PCR quantification and cDNA from a normal cell line (heterozygous for 
rs3842753 only). PCR products were detected by the use of mutation-specific probes 
which were identical except for the site of the mutation. Reactions contained 5 μl TaqMan 
Fast Universal PCR Master Mix, no AmpErase™, 0.36 μM each primer and 0.08 μM each 
probe in a total volume of 10 μl on the ABI prism 7900HT platform (Applied Biosystems, 
Warrington, UK). Amplification conditions were a single cycle of 95ºC for 20 seconds 
followed by 60 cycles of 95ºC for 1 second and 60ºC for 20 seconds. The results given 
are an average of quantifications from three triplicate amplifications derived from two 
separate RNA extractions.  
To validate the real time assay we conducted standard curve analysis which 
indicated that the assay was accurate and quantitative over seven serial 1:2 dilutions. 
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The efficiency of amplification as assessed by the gradient of the standard curves for 
mutant and wild-type probes were -3.1 and -3.0 respectively. The correlation between 
crossing point and input template (r2) was 0.95 and 0.92 for the mutant and wild-type 
probes respectively. The A and C allele transcripts of rs3842753 are present in 
approximately equal amounts in the normal heterozygous cell line, indicating that the 
presence of this SNP does not adversely affect the stability of either allele. 
 Expression levels of the mutant and wild type transcripts were measured using 
the allele specific assays by comparing the number of cycles at which the two different 
PCR products cross a specific threshold. The relative abundance is defined by the 
difference in number of cycles to achieve the same quantity of product and calculated 
using the equation 2-ΔΔCt, where ΔΔCt is the difference between the crossing points 
(ΔCttest) in a test sample normalized to the difference between mutant and normal 
crossing points in a 50:50 mixture (ΔCt50%) (Applied Biosystems, Foster City, USA (4)). 
 
Supplementary Results 
Large deletion detected by MLPA 
A large deletion encompassing the promoter region, the non-coding exon 1 and 
coding exon 2 of INS (c.-370-?_186+?del) was identified in a large consanguineous 
Lebanese family (ISPAD 182). The deletion was identified following failure of PCR 
amplification of INS exons 1 and 2. The MLPA assay showed that the parents had a 50% 
reduction in dosage for exons 1 and 2 but two copies of exon 3. Testing the proband and 
affected cousin showed that INS exon 1 and 2 MLPA probes did not bind to the target 
DNA (suggestive of a homozygous deletion). 
The effect of the translation initiation codon mutations on insulin content 
The homozygous mutations c.3G>T and c.3G>A were identified in two unrelated 
probands with permanent diabetes diagnosed on the first day of life. Both are non-
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synonymous changes affecting the first methionine residue (p.Met1) and abolishing the 
translation initiation site for the preproinsulin protein. A second methionine residue is 
located at codon 5 (p.Met5), but the surrounding sequence does not conform to the 
Kozak consensus for translation since a thymine base is present at position -3 to the ATG 
codon rather than the required adenine (5). We would therefore predict that translation 
from the mutated initiator codon would be compromised but without experimental 
evidence we could not rule out a possible effect on mRNA stability. 
To investigate the possibility that these p.0? mutations (c.3G>T and c.3G>A ) 
could affect mRNA stability, we quantified the amount of INS mRNA in HeLa cells 
expressing wild-type or mutation bearing plasmids by real-time PCR. There were no 
differences in the amount of INS mRNA expressed in cells transfected with either 
mutation compared with cells transfected with wild-type plasmids (INS wild-type: INS 
c.3G>T and INS wild-type: INS: c.3G>A ratios were 1:0.99 (SD=0.19) and 1:0.95 
(SD=0.15) respectively; p=0.875).  
In order to investigate the possibility of low levels of translation from p.Met5, we 
used an in-vitro radio-immuno assay to measured insulin content in cells expressing the 
mutations compared to cells expressing wild type (WT) INS. The cells expressing INS 
(WT) contained 56 pg of insulin per million cells whilst the insulin content was reduced by 
at least 79% in the cells expressing INS c.3G>T and c.3G>A (11.9 and 7.6 pg of insulin 
per million cells respectively) (Figure 3C). This data shows that p.Met5 is unlikely to 
reinitiate translation of preproinsulin in the presence of the c.3G>T or c.3G>A mutations. 
The effect of the c.*59A>G mutation on RNA stability 
To investigate the effect of the c.*59A>G mutation on RNA stability we used real 
time PCR to quantify the level of INS mRNA transcripts in a heterozygous lymphoblastoid 
cell line generated from the proband’s mother (DM1165). We were unable to discriminate 
between the transcripts directly via the c.*59A/G alleles, as the mutation was located at 
the far 3’ end of the transcript.  Instead we used a SNP (rs3842753) to tag the mutation, 
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with the mutation (c.*59G) on the same haplotype as the C allele of the SNP. The 
mutation-bearing transcript was not detectable in the heterozygous mother (Figure 3D) 
and in the homozygous state we predict that the affected child will not express the INS 
gene.  
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Supplementary Table 1. Synthetic probes designed for INS MLPA assay. Text in lower case italics 
are PCR primers, text underlined are ‘stuffer fragments’ non sequence specific probes, text in 
capitals are sequence specific for the INS gene. 
 
 
 
 
 
 
Supplementary Table 2. Assessment of pathogenicity of non-coding genetic variants giving data 
on the conservation of the nucleotides and the number of control chromosome sequences tested. 
The variants were not detected in any of the control chromosomes. 
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Supplementary Table 3. Clinical characteristics of the 21 patients with recessive INS mutations. 
GA Gestational age. NA: not applicable/available. All mutations are recessive except for DM1265 
which is compound heterozygous for the 2 mutations (inherited in trans).  
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Supplementary Table 4. Comparison of clinical characteristics in patients with permanent or 
transient neonatal diabetes due to an INS mutation. Data are median (interquartile range). NA: not 
applicable. 
 
 
 
 
 
Supplementary Table 5. Comparison of clinical characteristics in patients with recessive coding, 
recessive non coding or dominant INS mutations. Data are median (interquartile range). NA: not 
applicable. 
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ABSTRACT 
Objective: NEUROD1 is expressed in both the developing and the mature beta cells. 
Studies in mice suggest this basic helix–loop–helix transcription factor is critical in the 
development of endocrine cell lineage. Heterozygous mutations have previously been 
identified as a rare cause of maturity-onset diabetes of the young (MODY). We aimed to 
explore the potential contribution of NEUROD1 mutations in patients with permanent 
neonatal diabetes. 
Research Design and Methods: We sequenced the NEUROD1 gene in 44 unrelated 
patients with permanent neonatal diabetes of unknown genetic etiology. 
Results: Two homozygous mutations in NEUROD1 (c.427_428del and c.364dupG) were 
identified in two patients. Both mutations introduced a frameshift which would be 
predicted to generate a truncated protein completely lacking the activating domain. Both 
patients had permanent diabetes diagnosed in the first 2 months of life with no evidence 
of exocrine pancreatic dysfunction and a morphologically normal pancreas on abdominal 
imaging. In addition to diabetes, they had learning difficulties, severe cerebellar 
hypoplasia, profound sensorineural deafness, and visual impairment due to severe 
myopia and retinal dystrophy. 
Conclusions: We describe a novel clinical syndrome that results from homozygous loss 
of function mutations in NEUROD1. It is characterized by permanent neonatal diabetes 
and a consistent pattern of neurological abnormalities including cerebellar hypoplasia, 
sensorineural deafness, and visual impairment. This syndrome highlights the critical role 
of NEUROD1 in the development of the endocrine pancreas and central nervous system 
in humans. 
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INTRODUCTION 
Monogenic permanent neonatal diabetes (PNDM) is typically diagnosed within 
the first six months after birth in contrast to polygenic autoimmune type 1 diabetes which 
is usually  diagnosed later in childhood or in young adults  (1, 2). PNDM is both 
phenotypically and genetically heterogeneous. Most patients present with isolated 
diabetes, but in some cases diabetes appears in the context of a more complex multi-
systemic syndrome. Dominant mutations in three genes (KCNJ11, ABCC8 and INS) are 
the cause of PNDM in more than 50% of cases and in the majority diabetes is an isolated 
finding (3, 4). Recessive mutations, autosomal or X-linked, have been described in 10 
genes (ABCC8, GCK, EIF2AK3, FOXP3, IPF1, PTF1A, GLIS3, SLC2A2, SCL19A2, and 
WFS1). These are rare and often result in extra-pancreatic features in addition to 
neonatal diabetes (3). The genetic cause remains unknown in approximately 40% of 
patients with PNDM (Hattersley & Ellard, unpublished data). 
From a pathogenetic perspective, a number of different mechanisms can lead to 
PNDM. Firstly, beta cells may be present but not functional as in patients with activating 
mutations in KCNJ11 and ABCC8, the genes encoding the two subunits of the ATP-
sensitive potassium channel genes (Kir6.2 and SUR1, respectively). Secondly, the 
number of beta cells may be reduced due to an increased destruction, either by apoptosis 
(INS, EIF2AK3) or as a consequence of an autoimmune insult (FOXP3). Finally there 
may be a reduced number of beta cells as a result of impaired pancreatic development, 
affecting either the whole pancreas (IPF1, PTF1A) or specifically beta cells (GLIS3) (3). 
Pancreatic development is coordinated by a complex interplay of signaling 
pathways and transcription factors that determine early pancreatic specification as well as 
the later differentiation of exocrine and endocrine lineages (5, 6). The basic helix–loop–
helix (bHLH) transcription factor NEUROD1 (also known as BETA2) plays an important 
role in the development of the endocrine pancreas. NEUROD1 expression, along with 
NEUROG3 and INSM1, specifies the endocrine lineage (7). Neurod1 −/− mice fail to 
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develop mature islets, leading to ketosis-prone diabetes and death within the first few 
days of life (8). 
Heterozygous loss-of-function mutations in NEUROD1 have previously been 
identified as a very rare cause of maturity-onset diabetes of the young (MODY) and late-
onset diabetes in humans, with only 5 families reported to date (9-12). We assessed the 
role of NEUROD1 in PNDM and describe two unrelated probands with homozygous 
truncating NEUROD1 mutations who have PNDM and similar neurological abnormalities.  
 
RESEARCH DESIGN AND METHODS 
This study was conducted in accordance with the Declaration of Helsinki. The 
study protocol was approved by the local Ethics Committee and written informed consent 
was obtained from the parents/guardians of each patient. 
Study population 
We studied 44 probands with PNDM diagnosed before 6 months of age, who had 
been referred to the Molecular Genetics Laboratory at the Peninsula Medical School in 
Exeter, UK. Mutations in KCNJ11, ABCC8, INS, and GCK had been excluded. The 
relevant clinical information was obtained from the medical records.  
NEUROD1 gene analysis 
Genomic DNA was extracted from peripheral leukocytes using standard 
procedures. The single coding exon of NEUROD1 was PCR-amplified in three 
overlapping fragments using specific primers for each amplicon tagged with 5’ M13 tails 
to allow sequencing to be performed with a “universal” M13 primer (primers and 
conditions are available upon request). Single strand sequencing was carried out using 
standard methods on an ABI 3730 sequencer (Applied Biosystems, Warrington, UK). 
Sequences were compared to the published template (accession number NM_002500) 
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using Mutation Surveyor v3.20 (SoftGenetics, PA, USA). Sequence variants were tested 
for their presence in family members whenever DNA was available. 
Homozygosity mapping 
High-density single nucleotide polymorphism (SNP) genotyping was carried out 
on the Affymetrix human 10K Xba chip by Medical Solutions Nottingham (formerly 
GeneService), UK. Processing of genomic DNA was performed as per the Affymetrix 
protocol. In house Perl scripts were developed to automatically identify genomic 
homozygous segments, defined by at least 20 consecutive homozygous SNPs marking a 
region that exceeded 3 cM (13). 
 
RESULTS 
Molecular genetics 
Two novel homozygous mutations in NEUROD1, a single base pair duplication 
(c.364dupG) and a 2-base pair CT deletion (c.427_428del), were identified in 2 unrelated 
probands. Both mutations result in a frameshift and a premature truncation of the C 
terminus of the expressed protein (p.Asp122Glyfs*12 and p.Leu143Alafs*55, 
respectively), leading to mutated proteins completely lacking the transactivation domain 
(Figure 1). These mutations had not been previously documented and were not present 
in 200 alleles from healthy unrelated individuals. No mutations were identified in the 
remaining 42 patients. 
The two homozygous probands inherited the mutation from their heterozygous 
parents (Figure 2). In family A with the c.364dupG mutation, parents were known to be 
first cousins and, consistent with parental consanguinity, SNP genotyping analysis of the 
proband revealed a total genomic homozygosity value of 6.0% (13). The mutation-
containing homozygous segment was the largest homozygous segment (46.6-Mb long) 
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and spanned 2q31.1-2q36.1 delimited by the SNPs rs726032 to rs724149. In contrast, in 
family B, the parents of the patient with the homozygous c.427_428del mutation were not 
known to be related and, in keeping with this, total genomic homozygosity value was very 
low (0.3%). However, the mutation in both parents was inherited on an extended 
haplotype of 10.4 Mb between positions Chr2q31.1-32.1 (SNPs: rs2884471-rs722385) 
suggesting that the mutation arose from a single common ancestor. 
 
 
Figure 1. Schematic organization of NEUROD1 protein and effect of the two mutations on its 
structure. Numbers refer to the amino acids bordering the functional domains. Both mutations result 
in the generation of a truncated protein lacking the transactivation domain. The abnormal protein 
sequence between the frameshift and the termination codon is colored in grey. 
 
Clinical features 
The two probands were diagnosed with permanent diabetes within the first two 
months of life and had presented with intrauterine growth retardation (birth weights 1490 
and 2230 g at 34 and 38 weeks of gestation, respectively) reflecting reduced insulin 
secretion in utero. They had no evidence of pancreatic exocrine dysfunction and normal 
pancreatic size on abdominal scanning. In addition to diabetes, they presented with a 
similar pattern of neurological abnormalities including moderate to severe developmental 
delay, profound sensorineural deafness, and visual impairment due to myopia and diffuse 
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retinal dystrophy. Brain MRI scans showed severe cerebellar hypoplasia with no other 
major intracranial abnormalities (Figure 3). A more detailed clinical description is given in 
Table 1. 
 
 
Figure 2. Extended pedigrees of the two families showing inheritance of NEUROD1 mutations. 
Squares represent male family members, and circles represent female subjects. Black filled 
symbols denote patients with neonatal diabetes and grey filled symbols represent patients with later 
onset diabetes. Subjects who were genotyped were tested for diabetes.  Genotype is shown 
underneath each symbol; M and N denote mutant and wild-type alleles, respectively. Directly below 
the genotype is the age of the individual at testing or the age at diagnosis of diabetes if diabetic, 
followed by the most recent treatment for diabetes. OHA means oral hypoglycemic agents. A dash 
denotes information not applicable or not available. An arrow denotes the proband in each family. 
 
There was limited availability of other family members for genetic and clinical 
testing. The diabetes status, age of diagnosis, treatment and genetic testing result of 
family members is shown in Figure 2. We assessed glucose tolerance in the four parents 
of the two probands who were proven heterozygous carriers of the mutations. In family A 
(c.364dupG mutation), the mother had been diagnosed with type 2 diabetes at 33 years, 
            191
Chapter 7 
despite having a normal BMI, and was treated with glicazide. In contrast, the father (also 
aged 33) had normal fasting (4-6 mmol/l) and postprandial (5-7 mmol/l) blood glucose 
levels on several occasions. In family B (c.427_428del mutation), the mother and father 
underwent standard oral glucose tolerance tests (aged 33 and 37 years) that confirmed 
normal glucose tolerance (6.2 and 4.8 mmol/L at 2 hours, respectively). No heterozygous 
family members in either family had any developmental delay or neurological features on 
clinical examination. 
 
 
Figure 3. MRI of the brain in proband from Family A demonstrating the typical neuroimaging 
findings of NEUROD1-PNDM (Panel A: Sagittal T1-weighted  image. Panel B: Coronal T2-
weighted image). There is significant cerebellar hypoplasia particularly of cerebellar vermis 
inferiorly. Unusually the posterior fossa is well formed. Supratentorial midline structures and 
myelination are normal. 
 
CONCLUSIONS 
We report the first two cases of PNDM caused by homozygous mutations in 
NEUROD1. The patients with this novel autosomal recessive syndrome not only had 
early-onset permanent diabetes but also presented with developmental delay, cerebellar 
hypoplasia, and hearing and visual impairment. This is the 13th gene in which mutations 
have been  described in patients with permanent neonatal diabetes. 
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Table 1. Clinical features of the two patients with homozygous NEUROD1 mutations. 
 
NEUROD1, a tissue-specific member of the basic helix-loop-helix (bHLH) family 
of transcription factors, is expressed in the developing pancreatic islets as well as in 
mature beta cells. It forms a heterodimer with the ubiquitous bHLH transcription factor 
E47 that binds to specific E-box motifs on specific target genes, including INS, GCK, and 
ABCC8, to regulate their expression (14-16). The two homozygous NEUROD1 mutations 
both introduce a frameshift that result in truncated proteins lacking the transactivation 
domain which has been shown to be important for the interaction of NEUROD1 with its 
main coactivator, p300 (17). These are likely to have no biological activity as shown 
previously for a different frameshift mutation (c.616dupC, p.His206Profs*38) identified in 
a patient with NEUROD1-MODY (9).  
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Further evidence for the homozygous mutations in NEUROD1 being etiological is 
that both unrelated patients have remarkably consistent, complex genetic syndrome 
whose clinical features are in keeping with the known expression and biology of this 
transcription factor (Table 1). Both unrelated patients have a remarkably consistent 
phenotype, with clinical features in keeping with the known expression and biology of this 
transcription factor and this provides further evidence for the homozygous mutations in 
NEUROD1 being causative.  
Both patients have neonatal diabetes but a normal pancreas on scanning and no 
evidence of an exocrine dysfunction. This is consistent with the central role of NEUROD1 
in islet development. Mice lacking Neurod1 die shortly after birth from severe diabetic 
ketoacidosis (8). Histological examination of the Neurod1-deficient pancreas shows an 
impaired islet morphogenesis with a reduction in the number of endocrine cells, 
especially beta cells (8).  
In addition to diabetes, our two patients presented with a similar pattern of 
neurological features, including developmental delay, cerebellar hypoplasia and visual 
and hearing impairment. This is in keeping with the abundant expression of NEUROD1 in 
the developing and mature nervous system. Interestingly the initial Neurod1-null mice that 
rapidly died from diabetes had no obvious anatomic and histologic abnormalities of the 
brain (8). However it is possible to explore the role of Neurod1 in the nervous system  by 
rescuing Neurod1-null mice either by expressing a transgene encoding the mouse 
Neurod1 gene under the insulin promoter (18) or by crossing the null mutation into a 
different genetic background to reduce the severity of the diabetes (19). The rescued 
Neurod1-null mice show a similar neuronal phenotype consisting of impaired balance, 
ataxic gait, circling, and swaying head movement as a result of impaired cerebellum 
development (18-20).  Furthermore, rescued Neurod1-deficient mice have abnormal 
hearing and vision as a result of severe sensory neuronal defects in the inner ear and 
neural retina, respectively (20-22). The main feature seen in the mouse which was not 
present in our patients was epilepsy (19). The remarkable similarity between the 
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NEUROD1 deficient patients and the Neurod1 deficient mice (Table 2) strongly supports 
a similar biological role of this transcription factor across species.  
 
 
Table 2. Comparison of the major features seen in Neurod1 deficient mice (8, 18-22) and 
NEUROD1 deficient patients with homozygous NEUROD1 mutations. 
 
Homozygous mutations in PTF1A, which encodes another bHLH transcription 
factor, also cause a syndrome of neonatal diabetes and cerebellar hypoplasia/agenesis 
(23). However, in this condition the pancreatic phenotype is not limited to the islets as 
affected patients have pancreatic hypoplasia/aplasia. In keeping with the islets 
representing less than 1% of the endocrine pancreas, the size of the pancreas was found 
to be normal in our two patients with homozygous NEUROD1 mutations. This suggests 
that shared developmental pathways are important during development in the pancreas 
and the cerebellum. 
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Although heterozygous loss-of-function mutations in NEUROD1 have been 
previously identified as a very rare cause of diabetes in humans (9-12), diabetes was 
present in only one of four heterozygous mutation carrying parents. Their age at the time 
of the study ranged from 33 to 39 years, and does not exclude the possibility of 
developing diabetes later in life. In addition, incomplete penetrance has been described in 
some of the families with NEUROD1-diabetes (9). Homozygous mutations in other known 
MODY genes, namely GCK and IPF1, have been previously associated with isolated 
PNDM and isolated pancreatic agenesis, respectively (24, 25). We have shown that 
homozygous mutations in another MODY gene are also associated with a more severe 
phenotype, of neonatal diabetes.  
In conclusion, homozygous mutations in NEUROD1 constitute a rare novel 
autosomal recessive cause of neonatal diabetes with severe neurological abnormalities. 
This confirms the important role that NEUROD1 plays in the development of both the 
pancreas and the nervous system in humans. 
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General discussion 
This doctoral dissertation describes in detail various collaborative studies 
undertaken to increase the current knowledge on the aetiology of diabetes mellitus in 
infants and young children. The following discussion seeks integration between the 
various findings as such and in the context of the data available in the international 
literature. As a result, recommendations for future research are suggested. 
  
8.1 UNRAVELING THE INTERCONNECTIONS BETWEEN 
MONOGENIC AND AUTOIMMUNE DIABETES IN PEDIATRICS 
Insulin-dependent diabetes is a common disease in the paediatric setting. The 
vast majority of cases in western countries correspond to autoimmune type 1 diabetes. It 
is estimated to affect one in 500-1,000 children and adolescents, although its annual 
incidence rate varies widely between different countries, within countries, and between 
different ethnic populations (Craig et al, 2009). Monogenic diabetes is responsible for 
only 1-2% of diabetes cases and is often initially misdiagnosed as type 1 diabetes when 
isulin therapy is required. Identification of children with monogenic diabetes usually 
improves clinical care not only for themselves but also for their families. Genetic testing 
confirms the diagnosis, allows a definite classification of the specific subtype of 
monogenic diabetes, predicts the likely clinical course of the disease, defines risk for 
relatives, and may even determine the treatment of choice (Hattersley et al, 2009). 
Differential diagnosis between type 1 diabetes and monogenic diabetes is 
relatively easy when patients present with additional extrapancreatic features suggesting 
a specific multisystemic disorder (Chapters 5 and 7 show a couple of examples). 
However, the distinction may become much more complicated when diabetes is the only 
clinical manifestation. Isolated insulin-deficient pediatric diabetes has been associated to 
a number of monogenic defects impairing β-cell function. They include heterozygous 
mutations in some of the classic MODY genes (mainly HNF1A, and to a lesser extent, 
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HNF4A) and several subtypes of neonatal and infancy-onset diabetes (mutations in 
KCNJ11, ABCC8, INS and GCK). 
In recent years, different approaches to identify children with monogenic diabetes 
have been proposed, all of them based on the current knowledge of the natural history of 
type 1 diabetes. Type 1 diabetes is due to the autoimmune destruction of pancreatic 
insulin-producing β-cells as evidenced by a number of consistent findings, including the 
presence of circulating autoantibodies and activated T cells against target β-cell antigens 
in most patients (Knip et al, 2008; Arif et al, 2004), the positive clinical response to 
immune suppression (Bougnères et al, 1990; Herold et al, 2002), and the frequent 
coexistence of other autoimmune diseases (Anderson, 2002). Type 1 diabetes is a T-cell 
mediated organ-specific autoimmune disease so that circulating autoantibodies are 
considered to be just serological markers of the underlying pathologic process. They are 
present in over 90% of patients when hyperglycemia is first detected and a positive result 
at diabetes onset or shortly thereafter supports the diagnosis of autoimmune diabetes. 
Since proven autoimmune diabetes has been reported in patients without any pancreatic 
antibodies (Martin et al, 2001; Imagawa et al, 2001), a negative result, in contrast, does 
not exclude type 1 diabetes. Familial aggregation has been described in about 10% of 
cases of type 1 diabetes, although there is no recognizable pattern of inheritance 
(Hemminki et al, 2009). Inherited polygenic susceptibility to develop autoimmune type 1 
diabetes is determined by at least 40 different genes (Barrett et al, 2009), with HLA genes 
showing the strongest association and accounting for up to 60% of the genetic 
susceptibility. Thus, 95% of patients with polygenic autoimmune type 1 diabetes have 
high-risk HLA haplotypes. However, these high-risk haplotypes are also found in ~40% of 
the general population even though most people will not develop the disease ever. 
Therefore, although the absence of a high-risk HLA genotype makes type 1 diabetes 
unlikely, its presence does not confirm the autoimmune aetiology on an individual basis 
(Marcovecchio et al, 2007).  
 
204 
General discussion 
8.1.1 Monogenic diabetes in late childhood and adolescence 
In keeping with the aforementioned facts, mutations in HNF1A have been 
previously identified in adolescents and young adults initially thought to have type 1 
diabetes. Most cases were selected for genetic testing on the basis of having a low-risk 
HLA haplotype, a strong family history of diabetes affecting at least 3 generations, or 
absent pancreatic antibodies (Yamada et al, 1997; Møller et al, 1998, Lambert et al, 
2003; Kawasaki et al, 2000). Independently of the selection criterion used, a mutation in 
HNF1A was identified in 5-10% of probands tested. Similar studies for HNF4A have not 
been reported in the literature to date. We did not identify mutations in either gene in our 
study of 25 children with antibody-negative insulin-dependent diabetes (Chapter 2). 
However, this is not surprising since both HNF1A and HNF4A diabetes usually present at 
or after puberty and only two of our patients had been diagnosed with diabetes after 11 
years of age. In order to better define the contribution of HNF1A and HNF4A mutations to 
diabetes presenting in peripubertal children and adolescents, prospective studies are 
needed. In this regard, the SEARCH study will provide valuable information in the near 
future (The SEARCH Writing Group, 2004). So far, a mutation in HNF1A or HNF4A has 
been found in about 5% of children with antibody-negative diabetes participating in the 
study (Gilliam et al, 2007; Hattersley & Ellard, unpublished data). 
 
8.1.2 Monogenic diabetes in infants and young children 
A well documented rise in the incidence of type 1 diabetes has been recently 
noted in many countries worldwide, especially in children under 5 years of age (Patterson 
CC et al, 2009). Since this diagnosis is often not considered by parents or health-care 
providers, such youngsters frequently present after several days or weeks of symptoms 
that were missed (Neu et al, 2003). Even though the diagnosis of diabetes is fairly rare 
among very young children, the clinical presentation of type 1 diabetes before 2 years of 
age is associated with severe metabolic decompensation, poorly preserved residual β-
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cell function, strong humoral autoimmunity against islet cells and insulin, and strong HLA-
defined disease susceptibility (Komulainen et al, 1999).  
A large prospective population-based study on permanent diabetes diagnosed 
within the first year of life revealed the existence of two groups of patients based on age 
at onset, with a clear cut-off at around 180 days, and suggested that infants diagnosed 
before 6 months were unlikely to have classic autoimmune type 1 diabetes (Iafusco et al, 
2002). In addition, low birthweight was more common in those patients, raising the 
possibility that the reduced insulin secretion was already present in utero. These findings 
were later confirmed by a second study, where 41% of patients diagnosed under 6 
months had type 1 diabetes-associated high-risk HLA genotypes in contrast to 93% of 
infants diagnosed between 6 and 24 months (Edghill et al, 2006). Based on the fact that 
the prevalence of high-risk HLA was slightly lower in those diagnosed between 6 and 12 
months of age (89%) compared with those presenting between 12 and 24 months of age 
(94%), it was hypothesized that there may be a few patients with non-autoimmune 
diabetes in the 6- to 12-month age range. On the other hand, persistent β-cell 
autoimmunity may appear slightly before the age of 6 months both in the offspring of 
mothers with type 1 diabetes (Martikainen et al, 1996) and in genetically susceptible 
individuals identified in the general population (Kimpimäki et al, 2001), suggesting that 
type 1 diabetes may very rarely manifest before 6 months of age. Hence, it is difficult to 
be certain of an absolute cut-off at 6 months between early-onset type 1 diabetes and 
monogenic diabetes of infancy. Most probably, genetic testing should be individually 
considered in patients diagnosed around that age (see below). 
There are currently four known monogenic causes of isolated neonatal and 
infancy-onset diabetes. Recessively-acting mutations in GCK are uncommon and present 
within the first few weeks of life in newborns with severe intrauterine growth retardation 
(Chapter 4; Rubio-Cabezas & Hattersley, unpublished data). In contrast, mutations in the 
KATP channel genes (KCNJ11 and ABCC8) and the proinsulin gene (INS) account for 
~50% of cases of diabetes diagnosed under 6 months (Edghill et al, 2008). Heterozygous 
mutations in the INS gene have been reported in a few patients with diabetes presenting 
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beyond the first 6 months of life, most of whom were diagnosed before the age of 5 years 
(Støy et al, 2007; Edghill et al, 2008; Polak et al, 2008; Molven et al, 2008; Colombo et al, 
2008; Støy et al, 2008; Bonfanti et al, 2009). In addition, KCNJ11 mutations can also 
rarely present after 6 months (Mohamadi et al, 2009; Flanagan, Ellard & Hattersley, 
unpublished data). Both INS and KCNJ11 mutations are rare in unselected patients with 
permanent diabetes diagnosed between 6 and 12 months of age, where they account for 
2-3% of diabetes cases (Edghill et al, 2008; Støy et al, 2008; Flanagan, Ellard & 
Hattersley, unpublished data). Mutations in these two genes frequently appear de novo 
so family history of diabetes is often lacking. Moreover, ketosis or even ketoacidosis is 
frequent at diagnosis. Therefore, these patients cannot be clearly distinguished from 
those with early-onset type 1 diabetes just on clinical grounds. Our results (Chapter 2) 
have suggested that limiting genetic testing after the age of 6 months to patients with 
antibody-negative diabetes may increase the yield for identifying children with monogenic 
disease. To prove this hypothesis, a larger study looking at KCNJ11, ABCC8 and INS in 
diabetic infants diagnosed between 6 and 12 months is currently ongoing in Exeter.  
 
8.1.3 Monogenic autoimmune diabetes among diabetic children diagnosed within 
the first six months of life 
As previously stated, polygenic type 1a diabetes accounts for the vast majority of 
autoimmune diabetes cases. It may or may not be associated to other autoimmune 
disorders, especially thyroiditis and celiac disease. In any case, the genetic predisposition 
is given by the combined effect of by many genes, each having a small effect individually 
(Concannon  et al, 2009). The more risk alleles an individual has, the higher the risk of 
developing the disease. However, not all individuals with a high-risk genetic profile will 
present with diabetes. It is generally accepted that exposure to unknown environmental 
factors is also essential in the pathogenic process (Peng et al, 2006).  
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In addition to polygenic autoimmune diabetes, two rare monogenic autoimmunity 
syndromes including diabetes have been described (Ulmanen et al, 2005): 
- Autoimmune polyglandular syndrome type 1 (APS1; also called autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy [APECED]) is an 
autosomal recessive disorder secondary to mutations in the AIRE gene, 
encoding an autoimmune regulator protein. The patients develop multiple 
organ-specific autoimmune diseases, often starting in childhood or during 
teenage years (Ahonen et al, 1990). Hallmark symptoms include chronic 
Candida infection followed by autoimmune hypoparathyroidism and 
Addison’s disease. At least two of the three aforementioned components 
should be present for diagnosis (Husebye et al, 2009), although many other 
associated immune-mediated disorders have been described. Diabetes is 
found in less than 20% of APECED patients and becomes prevalent toward 
middle age (Perheentupa et al, 2006).  
- Mutations in FOXP3 cause a monogenic X-linked recessive disorder known 
as immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) 
syndrome (Torgerson et al, 2007). Diabetes is the commonest endocrine 
manifestation, affecting ~70% of patients, and presents within the first months 
of life. The outcome is very severe and usually results in early death. 
However, a few patients with a prolonged survival in whom diabetes was 
absent and the phenotype limited to autoimmune enteropathy have been 
reported (Powell et al, 1982; De Benedetti et al, 2006; Bacchetta et al, 2006).  
IPEX syndrome is the only monogenic disorder known to produce autoimmune 
permanent neonatal diabetes. We have shown that the V408M mutation in FOXP3 is 
associated with a relatively mild phenotype where very-early onset diabetes is the main 
clinical feature (Chapter 3). As a result, we have recommended that FOXP3 should be 
sequenced in male patients with undiagnosed permanent neonatal diabetes who develop 
any further autoimmune disorders. Further research is needed to clarify the impact of 
FOXP3 mutations in later onset autoimmune diabetes.  
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8.2 DISSECTING THE GENETIC ETIOLOGY OF PERMANENT 
NEONATAL DIABETES  
 Permanent neonatal diabetes is both clinically and genetically heterogeneous. 
Although it is meant to be a monogenic disorder in most patients, the underlying genetic 
defect remains unknown in ~40% of cases (Edghill et al, 2008), suggesting that other 
genetic causes are still to be identified. Among those patients with a known mutation, 
three genes (KCNJ11, ABCC8 and INS) account for the majority of cases. All mutations 
reported to date in KCNJ11 and INS, and most mutations in ABCC8 are heterozygous 
and, hence, dominantly-acting. In contrast, some mutations in ABCC8 and all mutations 
in GCK and other genes less frequently involved in PNDM are homozygous or compound 
heterozygous, indicating a recessive inheritance for the latter. The risk of developing one 
of these recessive subtypes of PNDM is therefore increased when parental consanguinity 
is present. 
 
8.2.1 Parental consanguinity strongly influences the genetic aetiology in 
permanent neonatal diabetes 
In order to assess whether known parental consanguinity actually influences the 
genetic aetiology in permanent neonatal diabetes, we studied a consecutive international 
series of 448 patients referred to Exeter for genetic testing (Rubio-Cabezas et al, 2009). 
Parental consanguinity was reported for 66 probands (15%). The three most common 
causes of PNDM (KCNJ11, ABCC8 and INS) were sequenced in all patients. Further 
genetic investigation depended on the reported phenotype: in those patients with isolated 
PNDM, GCK was sequenced, whereas other genes were selectively tested in patients 
with additional extrapancreatic features. Even tough mutations in KCNJ11, ABCC8 and 
INS were the three most common genetic causes of PNDM in non-consanguineous 
families (33%, 11%, and 10% respectively), parental consanguinity was associated with a 
completely different genetic profile (Figure 1). Biallelic mutations in EIF2AK3, causing 
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Wolcott-Rallison syndrome, were the most common genetic cause of PNDM in our cohort 
(22%), followed by mutations in INS (13%), GCK (11%), and ABCC8 (8%) mutations. Our 
findings on EIF2AK3 and INS during this study have been displayed and discussed in 
detail in Chapters 4 and 5, respectively. Overall, KATP channel mutations (KCNJ11 and 
ABCC8) accounted for 44% of non-consanguineous probands but only 10% of 
consanguineous cases, indicating that the number of patients with PNDM amenable to 
transition from insulin onto oral sulphonylureas is significantly lower when parents are 
related. Interestingly, the relative contribution of INS mutations to PNDM was similar in 
both groups. However, patients born to non-related parents had predominantly 
heterozygous coding mutations whereas patients from consanguineous pedigrees had 
homozygous coding and non-coding mutations.  
 
Figure 1. Influence of parental consanguinity on the genetic aetiology in permanent neonatal 
diabetes. 
 
8.2.2 Novel insights into biology can be derived from human patients 
The finding of recessively-acting mutations in the INS gene (Chapter 5) has had 
two main practical implications. On one side, it is the first time that different mutations in 
the same human gene produce the same disorder through two different mechanisms, 
namely β-cell apoptosis in heterozygous coding mutations and reduced or absent insulin 
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production in homozygous mutations. This is in keeping with the previous knowledge 
obtained from three different mouse models (Duvillié et al, 1997; Wang et al, 1999; 
Herbach et al, 2007). On the other hand, and maybe more importantly, we have identified 
a novel cis regulatory region within the INS promoter. Characterization of the unknown 
transcriptor factor(s) binding to this region to influence INS transcription level is currently 
ongoing. 
 
8.2.3 Birth weight may be used as a clinical criterion to prioritise genetic testing 
in patients with permanent neonatal diabetes 
Insulin is the main hormonal growth factor during both intrauterine and early 
postnatal life (Gicquel et al, 2006). It has repeatedly been reported that patients 
presenting with diabetes during the first 6 months of life tend to be small for gestational 
age at birth (Iafusco et al, 2002; Slingerland et al, 2006), which suggests that the insulin 
deficiency is already evident in utero. However, the degree of intrauterine growth 
retardation (IUGR) among patients with different subtypes of PNDM varies widely. For 
instance, patients unable to secrete any insulin both prenatally and postnatally due to 
pancreatic agenesis or biallelic mutations in the GCK or the INS genes show the more 
severe IUGR, with birth weights usually below –3 SDS for gestational age (Baumeister et 
al, 2005; Chapters 4 and 6). In contrast, birth weight in patients with heterozygous INS 
mutations or Wolcott-Rallison syndrome, although typically low, is usually above –2 SDS 
for gestational age (Edghill et al, 2008; Chapter 5). This is in keeping with their 
pathogenic mechanism involving progressive apoptosis of normally developed (and 
functioning) β-cells: despite the rapid decrease in insulin secretion postnatally leading to 
neonatal diabetes, prenatal insulin secretion is relatively spared and, therefore, 
intrauterine growth is not so much retarded. Interestingly, mutations in the KATP channel 
genes, although almost completely preventing insulin from being secreted (Pearson et al, 
2006; Babenko et al, 2006), are associated with only slightly reduced birth weights 
(Edghill et al, 2008). There is currently no explanation for this unexpected finding. 
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8.2.4 Neonatal diabetes as a developmental disorder 
Despite extensive research during the last few years, ~40% of permanent 
neonatal diabetes remains undiagnosed. So far, three different mechanisms leading to 
neonatal diabetes have been identified. A defective insulin secretion may be secondary to 
a functional impairment of normally developed β-cells, as in patients with activating 
mutations in KCNJ11 or ABCC8, or homozygous loss-of-function mutations in GCK or 
INS. Alternatively, a progressive destruction of β-cells, either by apoptosis or autoimmune 
mechanisms, may reduce the number of β-cells and eventually cause neonatal diabetes, 
as in patients with heterozygous INS mutations, Wolcott-Rallison syndrome or IPEX 
syndrome. Finally, a reduced number of β-cells may also be the consequence of a 
disturbed pancreatic development. The latter mechanism has been involved in a minority 
of cases of permanent neonatal diabetes to date.  
Pancreas development is coordinated by a complex interplay of signaling 
pathways and transcription factors that determine early pancreatic specification as well as 
the later differentiation of exocrine and endocrine lineages (Bonal et al, 2008; Oliver-
Krasinski et al, 2008). Most of the known pancreatic transcription factors are expressed 
prior to or near the onset of pancreas development. Further, many of these factors 
regulate one another through positive feedback loops; as a result, earlier models of the 
transcriptional hierarchy have evolved into less linear schemes (Figure 2). 
So far, only two of the genes from the list above have been implicated in the 
production of permanent neonatal diabetes in humans. Biallelic loss-of-function mutations 
in PDX1, also named IPF1, have been identified in three probands with isolated 
pancreatic aplasia (Stoffers et al, 1997; Schwitzgebel et al, 2003; Thomas et al, 2009). 
Homozygous PTF1A mutations cause pancreatic and cerebellar agenesis/hypoplasia 
(Sellick et al, 2004; Tutak et al, 2009). In addition, homozygous mutations in GLIS3 were 
recently identified in patients with neonatal diabetes, congenital hypothyroidism and 
polycystic kidney disease (Senée et al, 2006). Although this gene had not been 
previously linked to pancreatic development, a recent study using knockout mice has 
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shown that it encodes a transcription factor required for proper differentiation of 
pancreatic endocrine cells (Watanabe et al, 2009). Somewhat surprisingly, no other 
transcription factor-encoding genes have been associated to permanent neonatal 
diabetes.  
 
 
Figure 2. Transcription factor profile during β-cell formation from endodermal derivatives. Diagram 
indicates transcription factors expressed at each stage of differentiation. Factors initially expressed 
at a particular stage are color-coded as follows: gut endoderm (purple), pancreatic endoderm 
progenitor (blue), early endocrine progenitor (black), endocrine progenitor (orange), β-cell (red). 
[Reproduced from Oliver-Krasinski et al, 2008]. 
 
Based on the fact that heterozygous mutations in GCK and IPF1 cause MODY, 
whereas homozygous or compound heterozygous mutations in the same genes produce 
permanent neonatal diabetes, we screened NEUROD1 as a potential candidate gene for 
the latter. Heterozygous mutations had been previously described in a rare variant of 
MODY (Malecki et al, 1999). In keeping with its central role to pancreatic islet 
development and β-cell function, we have shown that biallelic loss-of-function mutations 
in NEUROD1 cause a novel and rare subtype of neonatal diabetes (Chapter 7). The 
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clinical features of the two patients described strongly resemble the phenotype of the 
NEUROD1 knockout mice.  
Targeted gene disruption in mice has provided enormous insight into the role that 
transcription factors play during embryonic development of the pancreas. As many of 
these transcription factors are not pancreas-specific and also control other developmental 
processes elsewhere, extrapancreatic abnormalities in addition to diabetes have been 
described in most animal models. Therefore, a phenotype-driven approach may be useful 
to identify the genetic cause of undiagnosed permanent neonatal diabetes, especially in 
patients with a multisystemic syndrome. In addition to NEUROD1, we have recently 
identified the first patient with biallelic mutations in NEUROG3 by using this candidate 
gene approach (Rubio-Cabezas et al, 2009; manuscript in preparation). 
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SUMMARY  
Monogenic diabetes is rare cause of diabetes in childhood and adolescence. 
Since most patients with monogenic diabetes presenting beyond the first 6 months of age 
are initially misdiagnosed as having type 1 diabetes, selection criteria are needed to 
identify those patients who may benefit most from genetic testing, especially when 
additional extrapancreatic features are lacking. Absence of pancreatic autoantibodies has 
been shown to increase the yield for identifying children with monogenic disease to the 
same extent than other previously suggested approaches, including the presence of a 
low-risk HLA genotype or strong family history of diabetes. 
Despite recent advances in the understanding of the molecular bases of 
permanent neonatal diabetes, i.e. diabetes diagnosed within the first 6 months of life, 
approximately 40% of patients still remain molecularly undiagnosed. Development of 
autoimmune diabetes during the first 6 months of life is very rare and should raise the 
possibility of a monogenic autoimmunity disorder, especially in males who later present 
with any other immune-mediated condition. Among those patients with non-autoimmune 
permanent neonatal diabetes, the presence and quality of other multisystemic problems 
(for instance, skeletal dysplasia or liver dysfunction) informs the appropiate order in which 
genetic testing should be performed and, in case of previously undescribed syndromic 
combinations, may suggest potential novel candidate genes to test. Other clinical 
information such as birth weight or parental consanguinity is also very informative. 
Therefore, performing a complete and detailed medical history and physical examination 
in every single patient with neonatal diabetes should never be overlooked. 
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RESUMEN 
La diabetes monogénica es una causa poco frecuente de diabetes mellitus 
durante la infancia y la adolescencia. Dado que la inmensa mayoría de los casos de 
diabetes monogénica que se manifiestan clínicamente después de los primeros 6 meses 
de edad son erróneamente diagnosticados como diabetes tipo 1, se necesitan criterios 
de selección para identificar aquellos pacientes que pueden beneficiarse de la 
realización de un estudio genético, sobre todo cuando no existen manifestaciones 
extrapancreáticas acompañantes. La ausencia de autoanticuerpos pancreáticos permite 
identificar a los niños con una posible diabetes monogénica con un rendimiento similar al 
de otros enfoques sugeridos previamente, como la presencia de un genotipo HLA de 
bajo riesgo para diabetes tipo 1 o antecedentes familiares de diabetes.  
A pesar de los recientes avances en la comprensión de las bases moleculares de la 
diabetes neonatal permanente, es decir, la diabetes no transitoria diagnosticada en los 
primeros 6 meses de vida, aproximadamente el 40% de los pacientes permanecen sin 
diagnosticar desde el punto de vista genético. La presentación de diabetes autoinmune 
en los primeros 6 meses de vida es excepcional y debe hacer sospechar la posibilidad 
de un trastorno monogénico de autoinmunidad, especialmente en varones que más tarde 
desarrollan cualquier otra enfermedad autoimune. Entre los pacientes con diabetes 
neonatal permanente no autoinmune, la presencia y el tipo de manifestaciones clínicas  
en otros órganos o sistemas (por ejemplo, displasia esquelética o disfunción hepática), 
ayudan a decidir el orden apropiado en el que se deben realizar los estudios genéticos y, 
en caso de combinaciones sindrómicas no descritas anteriormente, pueden sugerir 
nuevos genes candidatos para ser estudiados. Otros datos clínicos, como el peso al 
nacer o la consanguinidad parental son también muy informativos. Por lo tanto, la 
importancia de realizar una historia clínica y un examen físico completos y detallados en 
todos los pacientes con diabetes neonatal no debe menospreciarse. 
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CONCLUSIONS 
I. Measurement of pancreatic autoantibodies could be a useful strategy to identify 
candidates who may benefit from genetic testing for monogenic diabetes among 
children with insulin-dependent diabetes. 
II. Young children with antibody-negative diabetes should be screened for mutations 
in the INS gene, especially when progression to complete insulin deficiency is 
slow, irrespective of the presence of family history of diabetes. 
III. Mutations in FOXP3 should be excluded in male patients with undiagnosed 
permanent neonatal diabetes who develop another immune-mediated disease 
later in life. 
IV. Presence of parental consanguinity strongly influences the genetic aetiology in 
permanent neonatal diabetes and could be used as a selection criterion to 
prioritise genetic testing. Birth weight may also help in the decision-making 
process. 
V. Biallelic mutations in EIF2AK3, INS and GCK are the three most common genetic 
causes of permanent neonatal diabetes among children born to consanguineous 
parents. In this setting, patients are much less likely to successfully transfer from 
insulin onto oral sulfonylureas. 
VI. A phenotype-driven approach might be used to identify new genetic causes of 
permanent neonatal diabetes, especially in patients with additional 
extrapancreatic features. 
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CONCLUSIONES 
I. La determinación de anticuerpos antipancreáticos podría ser una estrategia útil 
para seleccionar, de entre los niños con diabetes insulino-dependiente, aquellos 
que podrían beneficiarse de la realización de un estudio genético para confirmar 
una posible diabetes monogénica. 
II. Es recomendable descartar la existencia de mutaciones en el gen INS en los 
lactantes y niños pequeños con diabetes mellitus pero sin autoanticuerpos, 
especialmente cuando la progresión a la deficiencia completa de insulina es 
lenta, independientemente de la presencia de antecedentes familiares de 
diabetes. 
III. Se deben excluir mutaciones en FOXP3 en los varones con diabetes neonatal 
permanente que desarrollan posteriormente cualquier otra enfermedad 
potencialmente autoinmune. 
IV. La presencia de consanguinidad parental influye fuertemente sobre la causa 
genética de la diabetes neonatal permanente y puede ser utilizada como criterio 
de selección para priorizar los posibles estudios genéticos. El peso al nacer 
también puede ayudar en este proceso de decisión. 
V. Las mutaciones bialélicas en EIF2AK3, INS y GCK son las tres causas genéticas 
más comunes de diabetes neonatal permanente en los niños con antecedentes 
de consanguinidad. En este contexto, los pacientes tienen a priori menos 
posibilidades de ser tratados con sulfonilureas por vía oral. 
VI. Es posible identificar nuevas causas genéticas de diabetes neonatal permanente 
mediante un enfoque basado en el fenotipo de los pacientes, especialmente en 
aquellos que asocian manifestaciones extrapancreáticas adicionales. 
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